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SUMMARY
This study investigates some interactions of agonists 
with the adrenergic receptor using theoretical and 
computationa1 chemistry methods.
In Chapter 1, the effect of ring fluorination of 
noradrenaline on the specificity for the a and 3 
receptor is considered. Using a simple receptor model, a 
conformationa1 difference is found which can explain the 
experimental observations.
In Chapter 2, various theoretical methods are applied to 
clonidine and a series of similar compounds. The results 
of these calculations are compared with the differing 
affinity and activity of these compounds with the 
adrenergic receptor. Although no correlations are found, 
it is suggested that these molecules may interact via a 
charge-transfer interaction, and thus the energies of 
molecular orbitals such as the HDMD and LUMD may be 
important in determining activity.
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In Chapter 3, several molecular orbital procedures are 
applied to the series of c 1onidine-1ike imidazolidines, 
as well as other series of molecules, to find a method 
best suited to calculating the energies of molecular 
orbitals. It is shown that the ST0-3G molecular orbital 
method can be used to calculate a value of the energy of 
the HOMO which gives a good correlation with the pKa for 
several series of compounds, hence this method is chosen 
to calculate the molecular orbital methods of the 
clonidine series of molecules.
The relationship between the activity of clonidine-1ike 
imidazolidines and molecular orbital energies is studied 
in Chapter 4. Several other parameters are also included 
in the regression equation, but it is shown that the 
activity of these compounds correlates well with the 
energy of the LUMO. This suggests that a charge transfer 
interaction does take place between the adrenergic
receptor and the agonist.
The sequence and some secondary structure information 
for the (3:2- adrenergic receptor is published and, in 
Chapter 5, a possible agonist binding site is 
identified using the information gained from the 
previous chapters. Molecular modelling techniques are 
successfully used to dock noradrenaline into this site.
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INTRODUCTION
i. im i « u u u l  i iuixj
1.1 DRUG-RECEPTOR INTERACTIONS
The idea that many biologically active compounds act via 
a "receptor" comes from observations of the nature of 
biological activity. The fact that a very small amount 
of some substances is sufficient to produce a biological 
response means that the substance cannot, for example, 
be simply covering the surface of a cell to alter its 
usual function. Most biologically active compounds are 
structurally very specific, and often stereo-specific. 
Thus a small change in the structure of a substance can
lead to very much reduced activity, and structures can
be synthesised which are similar to the natural compound 
and have similar, or even greater, biological effects. 
Synthetic compounds can be made which are similar to the 
natural compound, but reduce biological activity by 
blocking the action at the receptor of the natural 
substance.
The concept of a receptor is that of a highly
specialised three dimensional structure which interacts 
with a limited range of compounds. The receptor is 
connected in some way to the tissue it controls. The
specific nature of the drug-receptor interaction 
suggests the receptor is "shaped" so as to be able to 
accommodate an active molecule, and the analogy of the 
receptor as a "lock" and the active compound as the
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"key" has been proposed [1]. The current concept of the 
drug-receptor interaction is that of the receptor and 
the active compound having a degree of flexibility [2- 
4], and the analogy is that of "hand in glove". A 
biologically active compound is thus thought to interact 
with its receptor by binding to a specific part of the 
receptor which has a structure complementary to the 
active compound. The structural complexity and diversity 
of receptors suggests that they are bio-polymers, such 
as proteins or DNA, and this is true of all known
receptors.
The interactions which may contribute to the enthalpy of 
binding of a molecule to the receptor are:
1) Covalent bonding: The binding of a substance to a
receptor is very often rapidly reversible, implying that 
the formation of a covalent bond is very rare.
2) Coulombic interactions: The amino acid nature of the 
receptor means that many atoms will bear partial 
charges, and some may carry formal charges. Similarly, 
the active molecule may carry complimentary partial or 
formal charges, leading to an electrostatic attraction.
3) Hydrogen bonding: A hydrogen bond may be formed
between a hydrogen atom connected to an electro-negative 
atom and another electro-negative atom. This bonding is 
mainly electrostatic, and it should be remembered that a 
hydrogen bond between an active molecule and the
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surrounding solvent may be as favourable as a hydrogen 
bond to the receptor.
4) Van der Waals interactions: These can be thought of
as originating from three sources; dipole-dipole, dipole 
- induced dipole and induced dipole - induced dipole 
interactions. If two bonded atoms have differing 
electro-negativity, then charge will be displaced 
towards the more electro-negative atom. This dipolar 
arrangement of charge can interact with other dipoles, 
or induce a complimentary dipole in a neighbouring 
group. Induced dipole - induced dipole, or London, 
interactions arise from the fluctuations of the electron 
clouds in a group of atoms causing an instantaneous 
dipole moment constantly changing in magnitude and 
direction. This may polarise an instantaneous dipole in 
a nearby group and these two dipoles may fluctuate in a 
complimentary fashion. London forces are weak in 
comparison to other interactions, but the fact that they 
can be caused by any type of atom and that they are 
additive means that they can be significant. Although 
Van der Waals interaction are electrostatic in nature, 
the magnitude of the attractive force falls off with the 
sixth power of distance, c.f. coulombic interactions 
which are inversely proportional to the square of the 
distance between two charges.
The free energy of binding to a receptor also includes 
entropic factors. This is caused by the active molecule
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and the receptor combining to form a single species, 
hence the active molecule loses its rotational and 
translational entropy. The binding to the receptor may 
cause a restriction in internal rotation of both 
species, causing a further loss in entropy. This entropy 
loss is compensated for by the fact that both isolated 
species will be solvated, and binding will cause this 
solvent to be released, causing an increase in entropy.
The understanding of these interactions is very 
important when it comes to the design of a molecule 
which will mimic a naturally occurring active species, 
or will bind to the receptor but not cause a response, 
and block the receptor to the natural agonist.
1.2 QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS
The understanding of how a biologically active molecule 
interacts with a receptor can lead to the design of a 
drug specifically targeted for the receptor. Without the 
understanding of this interaction, the design of a drug 
is largely "hit and miss". The chance discovery of a 
compound with the desired activity, the lead compound, 
and the subsequent synthesis and trial of a large number 
of similar compounds is a great drain on the resources 
of a pharmaceutica1 company. The cost of developing a 
new drug can be of the order of tens of millions of 
pounds.
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There is, therefore, a desire to rationalise the process 
of drug design. If the activity of groups of compounds 
can be related to structure without the need to test 
the substance in vivo or in vitro. or even synthesise 
the compound, then the series of likely compounds can be 
screened and inactive compounds rejected. Alternatively, 
if the receptor is a known structure, novel compounds 
can be specifically designed to fit the receptor binding 
site. If these approaches are successful, then the 
number of compounds requiring synthesis and testing can 
be very much reduced.
One of the first steps in the development of a 
relationship between drug activity and chemical 
structure was the observation that the potency of some 
narcotic compounds was inversely proportional to their 
water solubility [5]. However, differences in solubility 
or, more specifically, the partition between a lipid 
membrane and the surrounding fluid, cannot explain the 
highly specific nature of drug-receptor interactions.
This led to the development of quantitative structure- 
activity relationships based on linear free energy 
relationships [6]. The energy of an interaction is 
related to a set of variables. A set of substituent 
constants can be used to relate the behaviour of a 
series of similar compounds to a "parent" molecule.
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These constants can describe various properties such as 
difference in electronic structure [7], steric 
properties [8] and hydrophobic properties [9]. They have 
been successfully applied to several biological systems 
[10-14].
This type of approach is limited by the fact 
series of compounds under investigation must 
related to the tabulated structures, and da 
available for many types of species.
The parameters which describe size and 1ipophi1icity 
can be very useful. If the interaction with the receptor 
can be quantified by some means, then it is not always 
possible to relate this interaction with experimental 
activity. Although the interaction with the receptor may 
be the limiting factor in determining drug activity, if 
the substance is unable to reach the receptor it cannot 
be active. After, for instance, a substance is injected 
into an animal it may become metabolised and/or 
excreted, be bound to serum proteins and will have to 
cross lipid membranes before it reaches the receptor. If 
a molecule has the correct active substituents but is 
physically too large to bind to a receptor it will not 
interact. Hence parameters which describe 1ipophi1icity 
and molecular size can be very important in describing 
the transport of a drug to a receptor site.
that the 
be closely 
ta are not
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Having described some methods of calculating drug
activity, it is of course important to be able to
quantity the experimental activity. This is done by
means of a dose-response curve, an example of which is
shown in Fig. 1.1. The desired response, for examp1e ,
the contract ion of a muscle or a change in heart rate,
is measured for a series of drug concen trations. A
reference compound, often the natural agonist, is also 
used in this way, to find the maximum response. The 
activities of the various compounds can be compared by 
noting the concentration required to give a fraction, 
usually 50'/., of the maximum response. So, for example, 
the concentration required to give 50*/. of a maximum 
effect can be measured over a series of compounds, and 
is termed the EC-,0 value. Binding to the receptor can be 
similarly quantified by measuring the concentration 
required to displace compounds already bound to the 
receptor. The ECso value is a measure of the equilibrium 
between the bound and isolated species, hence to equate 
this in terms of free energy, the log of the reciprocal 
of this value is calculated.
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Figure I.1 The Dose-Response Curve.
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1.3 COMPUTER AIDED MOLECULAR DESIGN
The last few years have seen an enormous growth in the
power and capacity of computers, coupled with a marked 
decrease in price, so that the hardware necessary to
perform very complex calculations is readily available. 
Alongside this has been the development of sophisticated 
graphics devices and programs which can , be used to 
display representations of molecules and molecular 
properties. These can enable complex operations, for 
example the docking of a molecule into a receptor site, 
to be performed in "real time" [15].
The computationally intensive calculations used to 
calculate molecular properties are often based on 
molecular mechanics and molecular orbital techniques. A 
description of these procedures is given in Appendices 1 
and 2 respectively. For example, the minimum energy 
conformation of a biologically active molecule may be 
different to the conformation required for binding to 
the receptor. The difference in energy between these two 
states may be easily calculated by molecular mechanics 
or molecular orbital methods and, for a series of 
compounds, the energy difference between the two 
conformations may be related to drug activity [16,17]. 
The minimum energy conformation(s ) of a compound may be 
unknown and these methods can be used to scan the 
potential energy surface due to the rotation of one or 
more bonds to find such minima.
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The three-dimensional structures of many enzymes have 
been determined by X-ray'crystallography, and active 
molecules can be designed to fit a known active site 
[18]. The interaction of a "probe" group with a known 
enzyme can be calculated, and a low energy surface can 
be contoured to show favourable binding sites [19].
Chemical reactions involve interactions between the 
electrons of reacting species, thus the use of molecular 
orbital methods to describe these electrons can be
extremely informative. Properties which can be 
calculated by this means include the following:-
Atomic charges: A Mulliken analysis [20] can be used to
calculate partial atomic charges. If electrostatic 
interactions are thought to be important in receptor 
binding the a charge on one or more atoms or the
electrostatic interaction between various atoms may 
correlate with receptor binding. Hydrogen bonding may be 
quantified in this way. Atomic charges can also be used 
to estimate dipole moments.
Electrostatic Potential: An alternative method of
quantifying electrostatic interactions is to consider 
the molecular electrostatic potential. The electrostatic 
potential at a point in space is defined as the energy 
required to bring a unit charge from infinity to this
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point. Thus a positively charged group will be attracted 
to a region of negative electrostatic potential and, 
conversely, a negatively charged group will favour a 
positive region. Electrostatic potential can be 
calculated directly from the the wave-function or 
approximated by considering the net effect of all the 
partial atomic charges. The consideration of 
electrostatic potential rather than atomic charges has 
the advantage that the effect of groups of atoms can be 
considered, and that a value can be given for a point in 
space some distance from a molecule.
Molecular Orbitals: If an interaction involves the
transfer of charge from one species to another, then 
this interaction will involve the highest occupied 
molecular orbital (HOMO) of the donor species and the 
lowest unoccupied molecular orbital (LUMO) of the 
acceptor. Thus the energies of these orbitals may be 
useful in quantifying an interaction of this type with 
the receptor. The frontier electron density can be used 
to determine which atoms may be the target of 
electrophi1ic or nucleophilic attack. The frontier 
electron density, FE (e 1ectrophi1ic) and FN 
(nucleophilic) represent the electron density of a 
particular atom due to the HOMO and LUMO respectively.
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Polarisabi1ity : This can be combined with the excitation 
energy (represented by the difference in energy between 
the HOMO and LUMO) to give an estimation of induced 
dipoles. The polarisabi1ity represents the extent to 
which the proximity of a charged species causes an atom 
to become polarised.
Some early investigations into biological activity using 
calculated indices are described in ref. [21]. Some more 
recent examples include the use of Huckel molecular 
orbital energies to calculate the anti-malarial activity 
of some 1,4-naphthoquinones[22], the use of the CNDO/2 
molecular orbital method (described in Appendix 2) to 
calculate electronic factors which correlate with the 
di-hydrofolate reductase inhibitory potencies of a 
series of substituted quinazolines [23]. This method has 
also been used to correlate electronic factors with the 
ribonuclease di-phosphate reductase inhibitory potency 
of a series of N-formyl iso-quina1ine thiosemicarbazoles 
[24]. The MNDO molecular orbital method has also been 
used to show that the anti-tumour activity of a series 
of triazines correlates well with the energy of the 
lowest unoccupied molecular orbital [25],
The receptor environment can be considered in these 
types of calculations by replacing the receptor atoms by 
point charges [26]. This method can be used to study a 
variety of binding interactions [27] and, for example,
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has been used to calculate the binding potency of some 
N-alkyl boronic acids to chymotrypsin A. This calculated 
binding • energy correlates very well with the 
experimental binding energies [28].
1.4 THE NERVOUS SYSTEM
This study will concentrate on interactions at the 
adrenergic receptor, which is found at the junction 
between the sympathetic nervous system and the organ to 
be controlled. The nature of the receptor will be 
discussed in the next section.
The nerves carry electrical stimuli to and from the
central nervous system which, in vertebrates, consists 
of the brain and spinal cord. These nerves can be 
distinguished by those which carry information to the
central nervous system, called sensory nerves and those 
which carry signals away from it, which are known as the 
motor nerves. »
The motor nervous system can be further classified into 
the voluntary nervous system, which can be operated at 
will, and the autonomic nervous system. The autonomic 
nervous system cannot be controlled at will and is used 
to maintain a constant internal environment by
controlling organs such as the heart and blood vessels.
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These organs are each controlled by two subdivisions of 
the autonomic system, known as the sympathetic and 
parasympathetic systems.
Stimulation of, for example, the heart by the 
sympathetic nervous system causes an increase in heart 
rate and output, whereas the reverse happens when this 
organ is stimulated by the parasympathetic system. The 
overall effect of this subdivision of the autonomic 
nervous system is that stimulation of the sympathetic 
system prepares an animal for flight of fight, hence the 
expenditure of energy, whereas stimulation by the 
parasympathetic system results in the conservation and 
restoration of energy.
The junction between one nerve and another nerve or the 
organ it controls is called a synapse, and a signal is 
transmitted across the synapse by a chemical agent known 
as a neurotransmitter. The neurotransmitter which 
carries the signal from a sympathetic nerve to the organ 
it controls is noradrenaline. Another neurotransmitter, 
acetyl choline, is used to transmit a signal from a 
parasympathetic nerve to the organ.
A diagram of the synapse between, a nerve and the organ 
it controls is shown in Fig. 1.2. The neurotransmitter 
is stored in vesicles in the nerve ending, and a nerve
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impulse causes the release of the neurotransmitter which 
diffuses across the synaptic gap and binds to a receptor 
on the surface of a cell of the organ. The binding of 
the neurotransmitter to the receptor causes some change 
which leads to the response. This will be discussed in 
more detail in the next section.
1.5 THE ADRENERGIC RECEPTOR
It is the interaction of noradrenaline, Fig. I . 3a, R=H, 
and similar compounds with the adrenergic receptor which 
is of interest in this study. Also active at this 
receptor is the hormone adrenalin, Fig. I.3a, R=CH3 , 
which is produced by the adrenal glands and reaches the 
receptor via the bloodstream. Noradrena1ine is though to 
control smooth muscle tone and adjust circulation 
whereas adrenalin is secreted in an emergency to prepare 
an animal for fight or flight.
Noradrena1ine and adrenalin are formed from the amino 
acid tyrosine, Fig. I.3b, and these compounds are 
removed by either O-methylation or oxidation, the 
products being metanephrine, Fig I.3d, and 3,4-dihydroxy 
mandelic acid, Fig. I.3c, respectively.
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Figure 1.3
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The adrenergic receptor can be divided into two 
categories, the a- and (3- adrenergic receptors,
depending on the sensitivity to different agonists, in 
particular noradrenaline, adrenaline and isoproterenol, 
Fig 1.3a, R=CH(CH.3 )=:- The order of activity at the a-
site is:
Noradrenaline >= Adrenaline > Isoproterenol 
Whereas the order at the |3- site is:
Isoproterenol > Adrenaline > Noradrenaline
The (3- receptor is further categorised into two types, 
Pi- and P^-. The Pi- receptors control, for example, 
heart rate and output whereas the P22- receptors control , 
for example, the dilation of bronchioles and blood
vessels. Further examples of organs controlled by a-, 
Px, and P2 receptors are shown in Table 1.1.
The a- receptors have also been subdivided into two 
types, based on the fact that the release of 
noradrenaline into the synaptic gap is controlled by a 
negative feedback mechanism. The binding of 
noradrenaline to a receptor located on the nerve
terminal, known as the pre-synaptic or a=- receptor, 
blocks the further release of noradrena1ine. It has been 
found that these receptors are not identical to the 
post-synaptic, or ax~ receptors located on the organ
surface. receptors are also found in the cerebral
cortex and ganglia.
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Table 1.1 Adrenergic Receptors.
Organ Response Receptor
Heart Increase in rate & output (3 ±
Blood vessels Dilation f3 =
Lung Relaxation of bronchial muscle (3s
Gut Relaxation of smooth muscle (3X
Contraction of Stomach & intestine a
Eye Relaxation of ciliary muscle (3
Contraction of radial muscle a
Skeletal Stimulation of glycolysis
muscle
Adipose Stimulation of lipolysis (3X
tissue
Pancreas Increased insulin production f3 =
1.6 MECHANISM OF ACTION
Activation of the [3- receptor leads to the production of 
a second chemical messenger, cyclic AMP, which is 
produced by the enzyme adenylate cyclase. The a - 
receptor is also involved in the production of cyclic 
AMP by inhibiting adenylate cyclase.
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The control of adenylate cyclase by the adrenergic
receptors involves two other proteins, the guanine 
nucleotide regulatory proteins, known as the G- 
proteins. The whole system is membrane bound and is 
thought to consist of the adenylate cyclase stimulatory 
and inhibitory receptors and their associated G-
proteins, the stimulatory G- protein Gs and the
inhibitory G- protein Gx [29].
Each G- protein consists of two subunits one of which, 
the (3- subunit, is common to both. The a- subunit of Gs , 
Gs,*, is responsible for the activation of adenylate 
cyclase. Inactivation of adenylate cyclase is caused by 
the (3- subunit of both G- proteins, which deactivate 
Gs,;t. This is summarised in Fig. 1.4.
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Figure 1.4. The Adrenergic receptor system.
Protein Comment
Stimulatory receptor (Rc ) e.g. (3-adrenergic receptor
Inhibitory receptor (R*.) e.g. a, - adrenergic receptor
and acetyl choline muscarinic 
receptors
Stimulatory G- protein (Gs ) a- activates adenylate cyclase
(5- deactivates Gsa
Inhibitory G- protein (Gx ) a-
(3- deactivates Gsa
Adenylate cyclase (Ac) converts ATP to cAMP.
Cel I Exterior
Re
I n t e r i o r
Page 20
Further control of the |3- receptor is exerted by the 
phosphorylation of the receptor by the enzyme [3- 
adrenergic receptor kinase. This is in response to 
agonist occupancy of the receptor and leads to 
desensitisation of the receptor.
It has been shown that the interaction between 
noradrenaline and the a±- adrenergic receptor is 
enthalpy driven and that the entropy term is very small 
[30]. This suggests that any consideration of the 
noradrenaline - receptor interaction need only involve 
enthalpy parameters which are very much easier to 
evaluate that entropy terms.
Towards the end of this study, the sequence and some 
secondary structure of the adrenergic receptor was
published [31], and this is discussed in Chapter 5.
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CHAPTER 1
AN EXPLANATION OF THE EFFECT OF RING-FLUORINATION OF 
NORADRENALINE ON ADRENERGIC ACTIVITY USING MOLECULAR 
MODELLING TECHNIQUES.
1.1 INTRODUCTION
The way in which noradrenaline, Fig. I.3a, and similar 
compounds interact with the adrenergic receptor is not 
completely understood and has been the subject of much 
study in recent years. The fact that a difference
between many adrenergic agonists and antagonists is very 
often the type of functional group substituted on the 
phenyl ring [32] implies it is the. ethanolamine side- 
chain of noradrenaline-like catecholamines which is 
responsible for binding to the receptor.
This is backed up by some theoretical studies of how 
model compounds may interact with the adrenergic 
receptor [33-37]. The dissociation constant for a series 
of catecholamines binding to the (3-receptor was found to 
correlate strongly with the electrostatic potential 
around the side chain nitrogen atom. Although the
correlation can be improved if the electrostatic
potential around the catechol part of the molecule is
included as well, this indicates that the phenyl ring 
Pi ays a secondary part in binding to the receptor.
Some correlation was found between the intrinsic 
activity of a series of (3-agonists and the electrostatic
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potential around the catechol group [37], reinforcing 
the idea that the phenyl ring is responsible for 
determining the degree of activity of catecholamines and 
similar species. Simulations of the binding interaction 
at the receptor using ethanolamine as a model for the 
agonist and either phosphate, formate or formic acid to 
model the receptor suggests that the side-chain hydroxyl 
group reinforces the binding between the amine nitrogen 
and the receptor. It is thus widely assumed that 
adrenergic agents are involved in a 'three point' 
attachment to the receptor with the side-chain nitrogen 
and hydroxyl being primarily concerned with binding 
while the phenyl ring, is not only involved in binding 
to the receptor, but also in determining whether agonist 
or antagonist behaviour will be displayed by a mechanism 
as yet not understood.
The investigations of the affinity and activity of 
noradrenaline-like molecules [38-41] show that for
binding to the receptor, the requirements for the 
ethanolamine side-chain are an amine-ni trogen, |3- to
which should be a hydroxyl group in the R-configuration. 
The carbon atom bearing this hydroxyl group can be 
directly attached to the phenyl ring or have, as in the 
case of phenoxypropanolamine and propanalol (Fig 1.1), a 
-OCH2- unit inserted between the phenyl ring and the 
ethanolamine part of the molecule. Binding to the (3- 
receptor is enhanced by the presence of an alkyl group
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1.1 a) Phenoxypropanolamine 
b) Propanalol
OH
attached to the nitrogen atom, whereas for the a-site, 
the smaller the substituent on the nitrogen, the higher 
the affinity.
For agonist activity at both sites the requirements of 
the phenyl ring of catecholamine-like species are 
similar. THe hydroxyl group para- to the side chain must 
be maintained in nearly all cases, but the meta-QH group 
can be replaced by groups retaining an active hydrogen 
such as -NHSO=CHi, -CH=SO=CH3 , -NHCH3 , -NHOCH3 , 
NHOCOCH3 [39-41] and still remain active as agonists at 
the (3-receptor. Replacing the meta-GH group with - 
SO:eCH3 , -SO=NH= or CONH3 led to antagonist activity. 
Exceptions to the requirement for a para-OH group for 
activity at the (3-site are species substitutes 4-NH= , 
3,5-di Cl and 8 -hydroxy carbostyrils and similar 
compounds [42]
At the a-site, catecholamine-like species retaining a 
para-OH group which have groups such as -NHSO=CH3 or -F 
in the meta-position still show agonist activity [43]. 
It has been suggested that the phenyl ring substituents 
were involved in chelating to a metal ion [44], but the 
fact that species such as 3-NHS0=CH3 , 4-OH are active 
yet species substituted 4-NHS0=CH3 , 3-OH, which have
the same chelating potential, are inactive makes this 
seem unlikely. Other suggestions for the role of the 
phenyl ring substituents include having a water— ordering 
effect [45,46] and affecting the energy and distribution
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of molecular orbitals involved in a charge-transfer 
interaction [47].
1.2 RING FLUORINATION OF NORADRENALINE
Ring fluorination of noradrenaline can cause a degree of 
specificity for the a- and (3-adrenergic sites and a 
possible mechanism for this is given in the next
section. The results of Kirk et. al. [48] are shown in 
Table 1.1a and show that at the a-receptor the activity
of noradrenaline and the 5 and 6 -fluoro derivatives are
very similar, whereas the activity of 2-fluoro
noradrenaline is very much reduced. In contrast, at the 
(3-receptor, noradrenal ine, 5-fluoro- and 2-fluoro- show 
similar activity, whereas 6 -fluoro noradrena1ine is much 
less patent. i.e. 2-fluoro noradrenaline is exclusively 
a (3-agonist and 6-fluoro noradrenal ine is exclusively an 
a-agonist, whereas 5-fluoro noradrenaline is active at 
both sites. Displacement of a- and (3-specific radio­
ligands (Table 1.1b) show that the specificities of the 
ortho-fluorinated noradrenaline are due to a change in 
affinity for the a- and (3- receptors.
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Table 1.1 The Effect of Ring-Fluorination on a- and 
adrenergic activity.
(3-
a) Activity measured as the concentration required to 
give maximum response (EC5«:,, pm) of;
a- activity - contraction of guinea pig aorta
[3- activity - rate of contraction of guinea pig atria
a (3
Noradrenaline 2.6 0.7
2-Fluoro- '' 11.0 0.6
5-Fluoro- '' 2.4 0.1
6-Fluoro- ' 2.4 72
b) Binding measured as the concentration required to 
displace 50*/. of a specific ligand from rat cortical 
membrane;
a- ligand [3H] 2-[[[(2',6 '-dimethoxy phenoxy) ethyl]
amino] methyl] benzodioxan
(3- ligand [3H]-dihydroal prenalol
a (3
Noradrena1ine 3 0.8
2-Fluoro- "  >100 2
5-Fluoro- '' 15 4
6 -Fluoro- '' 3 >100
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Further evidence of the fact that fluoro-substitution 
can have a negative effect on the binding of 
noradrenaline to adrenergic receptors comes from the 
fluorination of the {3-specific isoproterenol [49]. At 
the {3- site isoproterenol and the 2- and 5-fluoro 
derivatives show similar activity, whereas, as in the 
case of noradrenaline, the activity of 6 -fluoro 
isoprotereno 1 is very much reduced. At the cc-receptor, 
where isoproterenol shows no activity, it was found that 
ring fluorination of isoproterenol also led to inactive 
species. This pattern of activity was, as before by 
radio-ligand binding, found to be due to the affinity of 
the species to the a- and (3- adrenergic receptor. These 
results show that ortho-fluorination of catecholamines 
may reduce their affinity for either of the adrenergic 
receptors, but will not enhance the binding.
Substitution of noradrena1ine in the 2-position reduces
the activity and affinity at the a-receptor, whereas 6 -
fluoro noradrena1ine shows reduced activity and affinity 
at the (3-receptor. The explanation offered by Kirk and 
co-workers [48] was that of a possible interaction 
between the 2 and 6 positions of the phenyl ring and the 
receptor, which could be altered by fluorine
substitution at the ortho-positions. The fact that 
dopamine, similar to noradrenaline but lacking the side- 
chain hydroxyl group,does not show any specificity when 
fluorinated in the 2- and 6 -positions, is explained by 
the fact that the lack of a side-chain hydroxyl group
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reduces the rigidity to which dopamine is held to the 
adrenergic receptor, hence it can avoid any unfavourable 
interaction between the receptor and the ortho-position 
of the phenyl ring.
It should be noted that if isoproterenol is ring 
chlorinated a similar pattern emerges for the (3- 
receptor except that the 5-chloro as well as the 6 - 
chloro derivatives are less active and the 2 -
chlorinated derivative has a slightly higher activity 
[50]. Chioroprena1ine, which has the isoprotereno1 
side-chain and a phenyl ring with chlorine in the 2 -
position and no phenolic hydroxy groups is specifically 
active at the (3-site and shows antagonist and agonist 
behaviour [51].Catecho1 amines with 2-alkyl, cycloalkyl 
and alkoxy substituents also appear to be specifically 
(3-active [40], hence it would seem that substitution 
in the 2-position of noradrenaline and similar
compounds results in reduced a-activity whilst having
little effect on (3-activity.
A theoretical investigation into the F-induced 
specificity of noradrenaline has been carried out [52] 
by investigating the effect of F-substitution on the 
conformation of the phenyl ring. The potential energy 
curves for the phenyl ring rotation for 2- and 6-fluoro 
noradrenaline are shown in Fig 1.2. Note that the side- 
chain Hydroxyl group is oriented towards the phenyl ring
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(t.3 =0 °), and the curves are essentially similar, 
suggesting that the F....H-0 interaction is not 
responsible for the a- and (3-specificity. The potential 
maps of Tx vs. t= for 2- and 6 -fluoro noradrenaline 
(with t.3=-60° ) are also very similar (Fig 1.3a & b)
hence it was not thought that any change in conformation 
is responsible for a- and (3- specificity of the ortho- 
substituted noradrenalines and the explanation given by 
Kocjan [52] is very similar to the one given by Kirk 
and co-workers [48,49].
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Figure 1.2 Potential Energy Curves for the Phenyl Ring 
Rotation of 2- and 6— Fluoro—Noradrenaline.
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TABLE 1.2 The Geometry of Noradrena1ine and similar
molecules by X-ray crystallography.
Molecule Goun ter— ion Ti(° ) Tt? ( ° ) T.-s ( ° ) Reference
Ephedrine HPCU(a) 109 177 205 [53]
Isoprena1ine SCU (a j 101 182 258 [54]
Ephedrine HC1 100 191 295 [55]
Ephedrine H^PCU 99 194 249 [56]
Noradrenaline• HC1 86 184 166 [57]
Ephedrine HPCU(b) 84 181 106 [53]
Salbutamol 74 178 - [58]
Isoprenaline SCU( b) 69 169 164 [54]
X C2 Ci C -7- Cg T2 Ci“C7 n
z1IDU1 Ci-C7-0 -H
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TABLE 1.3 The minimum energy geometries of Noradrena1ine
and similar molecules by theoretical methods.
Molecule Ti(#) T.s_(_°) T*D. Method Refere
Ephedrine 90 -60 - EHT [59]
Ph-ethy1amine 140 145 - MM [60]
Ph-ethy1 amine 90 60 - PCILQ [61,62]
- - 90 180 -
* • 90 300 -
Noradrenaline 120 180 -60*
Norad rena1ine 90 -60 -60* / '
Norephedrine 120 180 -60* ' '
Epin ine 120 180 -60* • '
Ephedrine 120 180 -60*
Ph-ethylamine 90* 180 - EHT [63]
90* 60 - CND0 ' •
90* 60 - IND0 - '
90* 60 - PCIL0 - •
90* 180 - ST0-3G
H+ 90* 180 - EHT
H+ 90* 30 - CND0
H+ 90* 30 - IND0 ' '
' ' H+ 90* 60 - PCIL0
H+ 90* 60 - ST0-3G « '
* Angles fixed at this va lue
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TABLE 1.4 Minimum energy conformations of Noradrena1ine 
and 2-fluoro noradrena1ine calculated by molecular 
mechanics.
Ti(°) T^(°) T3 (°) E (Kcal/mol)
Noradrenaline -102 -175 -58 0.00
71 -172 -57 0.03
82 -68 61 0.23
-91 -67 62 0.67
-97 65 -60 0.77
2-Fluoro- -75 -175-58 0.00
noradrenaline -80 68 57 0.78
-95 -61 -63 0.84
67 -66 22 1.11
-60 -171 49 1.12
-60 103 -58 1.37
59 47 58 2.09
143 -169 45 3.03
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1.3 THE CONFORMATION OF NORADRENALINE
Much work has been carried out to investigate the 
conformation of the ethanolamine side-chain of 
noradrenaline and similar molecules, which can be 
described by torsion angles Ti, T2 and t.3 (Fig. 1.2). X- 
ray crystallographic evidence (Table 1.2) suggests that 
an extended conformation (t=~180) predominates with the 
phenyl ring oriented such that Tx is approximate1y 90°. 
The orientation of the side-chain hydroxyl group depends 
on the position of the counter ion used to crystallise 
the salt.
Theoretical calculations (Table 1.3) show energy minima 
corresponding to not only the extended form but also a 
gauche conformation with t = ~ 60° . The phenyl ring 
orientation shows two minima with Tx at 90° and 120°. 
The hydroxyl group gives the lowest energy conformation 
with t3 at -60° [61,62]. All potential energy contour
maps of Tx vs. t= show that there are many conformations 
which are within one or two Kcal/mol of the global 
minimum.
In the present work molecular mechanics has been used to 
compare the low energy conformations of noradrenaline 
and 2-fluoro noradrena1ine. The CHEMLAB [64] routine 
ESCAN was used to search through the three torsion angle 
Tx> T= and Ts and the resulting conformations refined by
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molecular mechanics using the White geometry optimising 
program [65]. The final conformations and energies 
obtained are shown in Table 1.4. As can be seen both 
molecules show several minima within a few Kcal/mol of 
each other and no definite conclusions could be made 
about a preferred conformation for noradrenaline or the 
2-F derivative.
1.4 MODELLING THE ADRENERGIC RECEPTOR
To further investigate the conformation of noradrenaline 
it was decided to include a possible receptor unit to 
see if this would have any effect on the orientation of 
the side chain and whether or not the conformations of 
the fluoro- derivatives would show sufficient 
differences to explain their differing activities at cc- 
and (3- receptor sites.
The nature of the adrenergic receptor is as yet unsure 
although the phosphate unit from ATP has been suggested 
[44,47] as being present. At physiological pH 
noradrenaline exists predominantly in the protonated - 
NH3'*‘ form hence it was thought likely that this group 
would interact with a negatively charged group in the 
receptor. Phosphate and carboxylate were considered as 
possible receptors since both occur naturally and both 
groups carry a negative charge, but as not all of the 
methods which were likely to be used e.g. PCILO and INDO
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were parameterised for phosphorous, carboxylate was
chosen and for the initial modelling of the adrenergic 
receptor the simplest carboxy compound, formate, was 
selected.
To calculate the minimum energy location of a formate
ine, the modelling package MOL 
formate units around the X-ray 
ture of noradrena1ine [57], 
idge Crystallographic Database, 
itions superimposed in Fig 1.4a 
1 structures were minimised by 
RMS values of less than 0.2 
inimisation was found not to 
he RMS value, unless very many 
formed. The results are shown in 
Fig 1.4b and it can be seen that the formate groups 
converge to a common position. To confirm this as a
possible noradrenaline-receptor model, the lowest energy 
structure from Fig 1.4b was taken and more trial 
structures generated by 'spreading out' the formate 
groups to give the structures superimposed in Fig. 1.5a. 
These were again minimised by molecular mechanics to 
give the positions shown in Fig 1.5b, with the formate 
groups again converging towards each other. The 
noradrenaline-formate complex giving the lowest energy 
was taken as the receptor model and is shown in Fig. 
1.6 .
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group around noradrenal 
[6 6 ] was used to place 
crystallographic struc 
obtained from the Cambr 
shown in the various pos 
and each of these tria 
molecular mechanics to 
Kcal/mol/A. Further m 
improve the energy or t 
more iterations were per
oI-
o
Figure 1.4 a) Starting and b) Resulting Geometries, 
Calculated Using Molecular Mechanics, of the Interaction 
of Formate with Noradrenaline.
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Figure 1.5 a) Starting and b) Resulting Geometries, 
Calculated Using Molecular Mechanics, of the Further 
Calculation of the Interaction of Formate with
Noradrenaline.
4 0
Figure 1.A The Minimum Energy Geometry for Noradrena1ine 
and Formate, Calculated by Molecular Mechanics.
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F iqure 1.7 X-ray Crystal 1ographic Evidence for 
Proposed Receptor Model; a) Ephedrine Phosphate and 
D-(-)-Threo-l-phenyl-2-amonio-l,3-propanediol (+)- 
isopropyl-propylcyanoacetate.
the
b)
Some evidence for this sort of interaction involving 
both the amine and hydroxyl groups of noradrenaline 
comes from the X-ray crystallographic structure of 
ephedrine phosphate [53], Fig. 1.7a, where the phosphate 
oxygens can be seen to be close to both the hydroxyl and 
amino groups of ephedrine. The X-ray crysta1lographic 
structure of D-(-)-Threo-l-pheny1-2-amino-l,3-
propanediol (+)-isopropy1-propyl cyanoacetate [67], Fig. 
1.7b, also supports the proposed receptor model with the 
acetate group close to the hydroxyl and amino groups.
1.5 THE EFFECT OF THE RECEPTOR ON THE CONFORMATION THE 
AGONIST.
With the hydroxyl and amino groups strongly attracted to 
formate in this way the torsion angle t=> and t.3 are 
effectively 'locked' with Ta in the extended trans 
conformation and the OH group directed towards one of 
the formate oxygens such that T3~-140o. This orientation 
of the hydroxyl group would not have been expected 
unless a receptor unit had been considered. A major 
difference between this study and previous work on the 
conformation of noradrena1ine is the consideration of 
part of the receptor and its effect on the orientation 
of the hydroxyl group.
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The next step was to investigate the rotation of the 
phenyl ring of noradrena1ine and to see if it differed 
in any way from the (3-specific 2-fluoro noradrenal ine. 
To improve the accuracy of the rigid rotor system 
commonly used to evaluate rotational barriers, it was 
decided to 'soften' the rotation by taking structures 
which correspond to maxima and minima as the phenyl 
ring is rotated. Advantage was taken of the fact that 
molecular mechanics minimisation (strictly speaking 
optimisation) proceeds towards the nearest turning point 
on a potential surface so that maximum energy 
conformations of Ti could be maintained while the energy 
of any electrostatic or Van der Waals repulsions were 
minimised by opening out angles such as Ci-C7--Ce , thus 
four rotamers each of noradrenaline and 2 -fluoro 
noradrenaline were taken, with Ti set to 60° and 300° 
(minima), and 0 ° and 180° (maxima).
Each of these rotamers was fully minimised by molecular 
mechanics and, as expected, the value of Ti did not 
change significantly during minimisation. The rotational 
barrier of Tx for each rotamer of each comp1 ex was 
measured, again by molecular mechanics. The four plots 
of energy vs. Tx for each complex were superimposed and 
the minimum energy at each angle step was taken as a 
better approximation to the potential energy as the 
phenyl ring is rotated. The results for;’ the two 
complexes are shown in Fig. 1.8a&b. The potential energy
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of noradrenaline varies very little as Tx is rotated and 
all orientations of the phenyl ring are calculated to be 
within 1 Kcal/mol. 2-fluoro noradrenaline shows a 
maximum at Tx = 120° which corresponds to the
orientation such that the ortho- fluorine is closest to 
the side chain hydroxyl group. It was thought
probable that the fluorine - oxygen electrostatic 
repulsion is responsible for this maximum.
To verify this Tx was again measured and the F....0 non­
bonded + electrostatic energy was plotted alongside the 
total steric energy and the resultant graph of potential 
energy vs. Tx can be seen in Fig. 1.9. The two curves 
follow each other very closely implying that it is this 
interaction which is responsible for the maximum in the 
rotation of the phenyl ring of 2-fluoro noradrenaline. 
From this result it was expected that 6-fluoro 
noradrenaline would show a similar maximum which 
differed by 180° from 2-fluoro noradrenaline, i.e. at 
300°, and this difference in the preferred orientations 
of the phenyl rings may be able to explain the differing 
activity at a- and [3- receptor sites of the two ortho- 
fluorinated derivatives. Since the fluorine atom of 5- 
fluoro noradrena1ine is some distance from the hydroxyl 
oxygen at all orientations of the phenyl ring, the 
F....0 repulsion is thought to be negligible, hence no 
maximum is expected as the phenyl ring is rotated, 
which would explain why 5-fluoro noradrenaline shows
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Figure 1.8a Potential Energy, Calculated by Molecular 
Mechanics, vs. Ti Rotation for Noradrenaline. The Curves 
a, b, c & d Refer to the Structures minimised with Ti 
set to 0°, 60°, 180° & 300° respectively. The Bold Line
Represents the Minimum Energy for Each Curve.
1 2060 1 8 0 240 3 0 0 3 6 0
r ,
Figure 1.8b Potential Energy, Calculated by Molecular 
Mechanics, vs. Ti Rotation for 2-Fluoro Noradrena1ine. 
The Curves a, b, c & d Refer to the Structures minimised 
with Ti set to 0°, 60°, 180° & 300° respectively. The 
Bold Line Represents the Minimum Energy for Each Curve.
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Fioure 1.9 Potential Energy, Calculated by Molecular 
Mechanics, vs. Ti Rotation for 2-Fluoro Noradrena1ine. 
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120 100 2A0 300 360
'Vx
<t8
similar a- and (3- activity to noradrenal ine. To verify 
this, similar calculation were performed to include 5- 
and 6-fluoro noradrenaline. In addition PCILO was also 
used to measure the energy barrier to rotation of the 
phenyl ring.
In the noradrena1ine formate complex used previously, 
the formate group was replaced by acetate. This was 
necessary as the particular PCILO program used 'crashed' 
while the formate oxygen lone-pairs were being defined, 
probably due to the fact that formate does not have 
sufficient atoms to generate a torsional reference for 
the oxygen atoms . The noradrena1ine acetate complex was 
subjected to 200 cycles of minimisation so that the 
acetate unit moved to the minimum energy position shown 
in Fig 1.10. The 2-, 5- and 6- fluoro derivatives were
generated by replacing the appropriate hydrogen atoms 
with fluorine. Partial atomic charges were calculated by 
INDO and as before an initial scan of Ti for each 
derivative was made, using MOL option ALTER P.E. to find 
the maxima and minima which are shown in Table 1.5.
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Figure 1.10 Noradrena1ine + Acetate.
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Table 1.5 Initial and Resulting values of the 
Czs-Ci-C^-C© Torsion Angle (Ti) after Molecular 
Mechanics Optimisation.
Mo1ecu1e Initial t ± 
Noradrena1ine 80.0
+Acetate 160.0
-115.0 
- 20.0
60.0
150.0
105.0 
- 20.0
90.0
160.0 
110.0 
- 20.0
6-Fluoro- 100.0
Noradrenaline 170.0 
+Acetate -120.0
-35.0
5-F1uoro- 
Noradrenaline 
+Acetate
2-Fluoro- 
Noradrenaline 
+Acetate
Resultant Ti
89.1
179.1 
-104.1 
-3.5
62.0 
-176.1 
-97.0 
-1.4
91 .3 
178.9 
-103.5
0.7
104. 5 
-174.5 
-118.3
1. 1
Energy (Kcal/mol) 
-33.4 
-32.9 
-33.5 
-32.7
-24.4
-23.4
-24.4
-23.5
-26.9 
-25.6 
-26.1 
-25.3
-19.9
-19.1
-19.7
-18.5
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Each structure corresponding to the minima or maxima was 
optimised using the CHEMLAB pattern searching routine 
PATTN followed by 200 cycles of MINIM, again taking 
advantage of the fact that these methods proceed towards 
turning points on the potential surface, hence 
maintaining the maximum energy values of To. and the 
results shown in Table 1.5 show that these maximum 
energy conformations were indeed maintained throughout 
minimisation.
The rotation of the phenyl ring was measured by PCILO, 
with the energies of the two Kekule structures of the 
phenyl ring averaged as suggested by Gerhards [68]. The 
lowest energy value given by each rotamer was taken at 
each angle step. The results of this calculation on 
noradrenaline a n d ,the three fluorinated derivatives are 
shown in Fig. 1.11.
Noradrenaline and 5-fluoro noradrenaline both show two 
minimum energy conformations at ~130° and ~310° whereas 
the ortho-f1uorinated derivatives show only one minimum 
each at ~310° for 2-fluoro noradrena1ine and ~130° for 
6-f1uoro noradrenaline. Since 2-fluoro noradrenaline is 
exclusively a (3-agonist it is suggested that the 13- 
receptor requires a conformation at ~310°, shown also by 
noradrenal ine and 5-fluoro noradrenal ine but not the (3- 
inactive 6-fluoro derivative. Similarly it is suggested 
that the a-receptor requires the phenyl ring to be at
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~130° which is a minimum energy conformation for 
noradrenaline, 5-fluoro noradrena1ine and the a-specific 
6—fluoro noradrena1ine, but not for the a-inactive 2- 
fluoro noradrenaline.
Experimental evidence for different orientations of the 
phenyl ring being required at a- and (3- receptors comes 
from some less flexible agonists. The tetralin shown in 
Fig. 1.12a is specifically a (3-agonist [69] and has the 
phenyl ring constrained such that Ti is ~340<> [70].
Clonidine, Fig. 1.12b, is specifically an a-agonist and 
the phenyl ring orientation is ~90° [76]. The
conformation and activity of clonidine and similar 
compounds is discussed in Chapters 2 and 4.
Evidence for the fact that the fluorine - oxygen 
repulsion interaction is important in determining the 
specificity of the ortho-f1uorinated noradrenalines 
comes from dopamine, similar to noradrena1ine but 
lacking the side-chain hydroxyl group. Dopamine is a 
weak a- and (3-agonist, presumably because without the 
hydroxyl group it cannot bind as effectively to the 
receptor. Ring fluorination of dopamine causes no a- or 
(3- specificity [71] which is predicted as there can be 
no F....0 repulsion to effect the conformation of the 
phenyl ring.
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Figure 1.12 X-ray Crystallographic Evidence for the 
Proposed a- and 13- referred conformations.
a ) 2-Cyc1obuty1amino-5,6-dihydroxy-l,2,3,4-tetrahydro-l- 
naphthenol.
b) Clonidine.
a.)
$
Cl
5 S
1.6 CONCLUSION
The differing a- and (3- adrenergic activity of the ring 
fluorinated noradrena1ine derivatives has been 
explained. To do this it was necessary to consider the 
interaction of the noradrenaline side chain with a 
postulated receptor unit, modelled by a carboxylate 
group.
The carboxylate group is such that the noradrena1ine 
side chain hydroxyl is oriented away from the pheny1 
ring and with the molecule in this conformation, an 
orientation of the phenyl ring with an ortho- fluorine 
substituent eclipsing the hydroxyl oxygen is 
energetical 1y unfavourable because of the fluorine - 
oxygen electrostatic repulsion. Because of this, the 
preferred phenyl conformation of the ortho- fluorinated 
derivatives differs by 180°, hence, it is suggested that 
one way in which the a- and (3- adrenergic receptors 
differ is the binding site for the phenyl ring of 
noradrenal ine. The a- and (3- preferred phenyl ring 
conformation of noradrenaline is shown in Fig 1.13. The 
result of the difference between these conformations is 
a different relative position of the hydroxyl group in 
position 3. The interaction of noradrena 1 ine with the [3- 
receptor is further discussed in Chapter 5.
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Since this work was completed, the adrenergic activity 
of phenylethylamines similar to noradrena1ine, but 
lacking the phenol group in the 4- position haV£ been
reported [72]. The same pattern of ortho-f1uorine
induced selectivity for the a- and (3- sites was noted. 
The rationale for this observation was that the ortho- 
fluorine atom was involved in an electrostatic
interaction with the benzyl hydroxyl group, but no
evidence for this was given.
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Figure 1.13 Noradrenaline + Acetate.
a) The Proposed a-Receptor Conformation (T:
b) The Proposed |3-Receptor Conformation (T:
0
~ 130°) 
~ 310°)
58
CHAPTER 2
PRELIMINARY INVESTIGATIONS INTO THE ACTIVITY OF 
CLONIDINE-LIKE IMIDAZOLIDINES
2.1 INTRODUCTION
Clonidine (2-(2,6-di-chloropheny1imino)imidazoline) (Fig 
2.1) is used in clinical medicine for the treatment of 
arterial hypertension under the commercial name
Catapresan or Catapres. The mechanism of action of this 
hypotensive effect is thought to be the stimulation of 
central, presynaptic a-adrenoreceptors [73].
A thorough review of structure-activity relationships 
has been published by Timmermans, Hoefke, Stahle and van 
Zwieten [74], the important features of which will be 
discussed. The clonidine molecule can be divided into 
three fundamental structural units (Fig. 2.2), the
phenyl ring, the bridge and the imidazoline ring.
Compounds used in nearly all structure-activity studies 
have one or more of these sub-units modified in some 
way.
Increasing the number of carbon atoms in the imidazoline 
ring leads to much reduced potency, whereas compounds 
which have one of the imidazoline >NH groups replaced 
with oxygen or sulphur retain some activity. Replacing 
the bridging nitrogen with methylene or sulphur reduces 
hypotensive activity and replacement with oxygen results 
in very much reduced activity. The effect of extending 
the bridge by groups such as -CH=-N=, -NH-N=, -CH=N-N=.
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(1*1)
Clonidine
~ ?Ure 2^2. The Structural Units of the 
Molecule.
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< •
Phenyl Bridge Im idazo l ine  
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or —0—CH^—CH;s—NH—N= is to reduce activity. Replacing the 
bridging nitrogen with -0-CH(CH3 ) gives the compound
lofexidine which has similar activity to clonidine [75].
A very large number of phenyl substituted imidazolidines 
similar to clonidine have been tested for hypotensive 
activity and the results of 156 such derivatives are 
reported in [74]. The unsubstituted species and 
derivatives with more than three phenyl substituents 
show very little activity and mono-substitution only 
leads to any activity if it is in the ortho- position. 
Di-substitution can produce active compounds if it is in 
the correct position. Changing the substitution pattern 
of the chlorine atoms leads to a loss in activity,
although the 2,3-di-Cl derivative shows a relatively
high potency. For the 2-C1 and 2-Br series of di­
substituted imidazo1 idines, the order of potency for the 
3- position is Br>Cl>F>Me with the 2-Br derivatives 
being generally more potent. Clonidine-1ike
imidazo1idines which are 2,4-di-substituted have the 
order of activity Me>Br>Cl>F for the 4- position, 
whereas for the 2,5-di-substituted derivatives the order 
is reversed for the 5- position, i.e. F>Cl>Br>Me.
In general, the more active compounds are those which 
are 2-6-di-substituted and all combinations of halogen 
(except 2,6-di-F) lead to highly active compounds. 
Adding a para- substituent to a 2,6-di-substituted
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compound results in less potent compounds; adding a 6- 
substituent to a 2,4-di-substituted species increases 
its activity. It is interesting to note that the 3,4-di­
hydroxy derivative, the analogue of noradrenaline, has a 
low activity although it must be remembered here, as 
in all cases, that the differing substitution patterns 
may not only affect the binding to the receptor but also 
the overall lipophilic behaviour which determines the 
concentration at the central adreno- receptor in the 
brain.
The hypotensive effects of clonidine and 26 phenyl- 
substituted analogues, after intravenous administration 
to anaesthetised rats, is also reported in this review 
[74] and shown in Table 2.1. The value given is log 
. ED30, where ED30 is the dose required in pmol/Kg
required to produce a 307. decrease in arterial pressure. 
The results are similar to those obtained from 
anaesthetised rabbits, mentioned earlier. For the series 
of 2,6-di-substituted compounds having the chlorine atom 
in position 2, the order of activity is Br>Cl>F>Me. 
Again, any substituent in the 4- position leads to a 
decrease in activity, particularly if the 4-substituent 
is nitro- or methoxy-. Upon changing the substitution 
pattern from 2,6- to 2,4- the hypotensive activity was 
reduced, with a further loss of potency being observed 
for mono-ortho-substituted species. The unsubstituted 
analogue, as in the case for the anaesthetised rabbits,
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is almost ineffective.
Table 2.1 Hypotensive Activity of some clonidine-1ike 
imidazolidines measured as log; ED30, the concentration 
required to give a 307. decrease in the arterial pressure 
of normo-tensive rats.
R log ED30
2 6-di-Cl 0.43
2--Br,6-C1 0.46
2 6-Br 0.74
2 -C1,6-F 1.10
2 3-di-Cl 1.11
2--C1,6-Me 1.28
2 4,6-tri-Cl 1 .32
2 6-di-Cl,4-Me 1.32
2 4-d i-Ne 1. 50
2--cl,4-Me 1.72
2 6-di-Cl,4-Br 1.78
2 4-di-Cl 1.78
2 4-di-Cl,6-Me 1.90
2 4-d i-Me,6-C1 1.90
2 5-di-Cl 2.18
2--Cl 2.23
2 6-di-Me,4-C1 2.38
2--Me,4-C1 2.44
2 4,6-tri-Me 2.45
2 4,6-tri-Br 2.76
2 6-di-F 2.78
2 6-di-Me,4-Br 2.84
2 4-Me 2.91
2- Me 2.99
2 6-di-Cl,4-OMe 2.30
2 6-di-Cl,4-N0= 3.65
H 4.40
In addition to hypotensive effects, clonidine and 
related compounds show other effects, such as anti- 
hypertensive activity, Bradycardia and an initial
Page 63
hypertensive phase caused by excitation of the 
peripheral vascular a-adreno receptors. Side effects 
caused by clonidine and related analogues include 
sedation, local anaesthesia, reduction of gastric 
activity, agonist effects on the histamine H2 receptors, 
hyperg1ycaemia and acute toxicity. It is the. hypotensive 
effect at the central a-adreno-receptor that is of 
interest here, and will be discussed in this chapter.
The pKa of clonidine is 8.05 [76], which corresponds to 
about 727. of the protonated form being present in blood. 
Since both the free base and protonated forms are 
present under physiological conditions, the structure of 
both is of interest. It has been shown that clonidine 
free base in solution is in the imino-form (double bond 
between the bridge nitrogen and the imidazoline ring)
rather than amino- form (double bond internal to the
imidazoline ring) by XH and 13C NMR [77,78], IR and UV 
[79].
Protonation of clonidine occurs at the bridge nitrogen 
and the precise structure details can be obtained from 
X-ray crysta11ographic studies of clonidine
hydrochloride [80] and phosphate [81], the details of 
which are listed in Table 2.2. The dihedral angle 
between the two rings was found to be 89° for the
phosphate and 76.5° for the hydrochloride.
Evidence of this perpendicular arrangement comes from
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NMR [78] and UV photoelectron spectroscopy studies [82]. 
Theoretical investigations predict an interplanar angle 
of 40° (by CNDO/2 [83]) and 90° (by PCILO [84]). In the 
light of this evidence, it is assumed here that the 
conformation with the phenyl and imidazoline rings 
perpendicu1ar to each other, which predominated for 
clonidine is found for the other members of the series, 
although this may not be the case for some analogues 
with smaller or no substituents in the ortho- position.
2.2 STRUCTURE-ACTIVITY RELATIONSHIPS
In order to account for the action of clonidine and 
similar compounds at the central a-adreno receptor,
several factors have to be taken into account. If the
experiment is done on whole animals, then the transport
of the drug from the site of administration to the brain 
is obviously important. Once the drug has arrived at the 
site of action, the binding to the receptor has to be 
quantified, as well as how active the bound species will 
be.
Timmermans [85] has shown that the fraction of a dose of 
clonidine and similar species administered intravenously 
accumulating in the rat brain can be accounted for by a 
parabolic relationship in logP', the apparent octanol- 
water partition coefficient at 37°C, pH 7.4. Although 
lipophilic behaviour could be used to describe transport
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of the drug to the rat brain, correlation of logP' and 
logP'2 with hypotensive activity (log 1/ED30) could only 
explain 42’/. of the variance in activity. This shows that 
although 1 ipophi1icity is important, other molecular 
properties are needed to fully describe the variation in 
hypotensive activities of cIonidine-1ike imidazolidines.
By a process of stepwise inclusion/deletion of various 
molecular properties, the following equation was derived 
to explain the variation in the hypotensive potency of 
a range of 27 c 1onidine-1ike imidazolidines following 
intravenous injection to anaesthetised normotensive rats
[85].
log 1/ED30* = -0.00032 ZPar2 + 0.105 SPar - 0.695 ApKa + 
5.333 E H0M0(p) + 6.752 EE(p) + 2.494 
n = 27 r = 0.952 s = 0.341 F = 40.34
(2 .1 )
Where log 1/ED30* is the concentration required to 
reduce arterial pressure by 30*/., corrected for the 
amount of protonated species present. ApKa is the 
apparent acid dissociation constant under physiological 
conditions (blood, 37°C ) and pKa is the difference in 
this dissociation constant from the species 
unsubstituted on the phenyl ring. E HOMO(p ) is the 
energy of the highest occupied molecular orbital of the 
protonated species and E E (p ) is the difference in energy 
between the HOMO and the LUM0 (lowest unoccupied 
molecular orbital) for the protonated species, both
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values being calculated by the PPP n-electron molecular 
orbital method. EPar is the sum of the parachor values
[86] of the substituents attached to the phenyl ring. 
Parachor is defined as the product of the molar volume 
and the fourth root of surface tension [87] and is 
assumed to represent both lipophilic and steric 
properties.
When experimental data, corrected for the amount of drug 
reaching the rat brain (from the parabolic relationship 
in logP', mentioned earlier) but not corrected for
ionisation, is used the best correlation obtained is :-
Log 1/ED30(c ) = -0.439 EEs2 -1.393 EEs + 2.18 ER + 4.719
E HOMO(p) + 6.249 EE (p ) + 7.195
n = 27 r = 0.965 s = 0.262 F = 50.78
(2.2)
Where EEs is the sum of the Taft steric parameters of
the phenyl ring substituents [8] and ER is the sum of 
the Norrington resonance parameters [7] again summed 
over the phenyl ring substituents.
From these results it was deduced that the overall size 
of the drug was important as well as its 1ipophi1icity 
and that the presence of the HOMO energy may imply some 
sort of charge-transfer interaction being important. 
Further investigations showed that it was the steric 
contribution of position 2 (ortho) which was the most 
important description of the molecular volume. If the ti-
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electron density at C* of the protonated imidazolidines 
was included, then E HOMO(p) ceased to be significant, 
indicating that an electrostatic interaction with the 
receptor may be important.
Affinity for the a-adrenergic receptor has been shown to 
correlate with the sum of the ortho-steric parameters 
(Es2+6) and also the conformationa1 entropy, Sfv [88]. 
Conformational entropy is in this case a measure of the 
extent that the phenyl ring can easily rotate. In fact 
Es2+6 and Sf,_ are co-variant (r2 = 0.93) so that it is 
not clear whether it is the size of the molecule or its 
rigidity which is important in determining a-adrenergic 
ac tivi ty.
2.3 THE CONFORMATION OF CLONIDINE AND SIMILAR COMPOUNDS
The first step in investigating the activity of 
clonidine was to investigate the conformation of the 
phenyl ring. Although it is assumed that clonidine 
exists with the phenyl and imidazoline rings 
perpendicular to each other (dihedral angle C2-Ci-N7-Ci3 
(Ti) = 90°), it was thought possible that the
unsubstituted and mono ortho- species may exist in a 
different conformation. The UV photo-electron spectrum 
analysis suggests that the most likely conformation is 
90° even for the unsubstituted species [82], but a
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molecular mechanics investigation was thought to be 
usef u 1 .
Clonidine and 2 derivatives, the mono-chloro and the 
unsubstituted, are chosen for the initial
investigation. Standard force-field values [65] are 
chosen and adjusted by trial and error so that the 
minimised structure matched the geometry from X-ray 
crystallography [80,81], shown in Fig. 1.12b. It was 
found that only one type of nitrogen was required to 
give good geometry agreement with X-ray crystallographic 
studies. The force-field used is listed in Appendix 3, 
and a comparison of molecular mechanics and X-ray 
structures is shown in Table 2.2. Note that if the 
starting geometry is such that the phenyl ring dihedral 
angle was 90°, then it remained in that conformation 
throughout minimisation. If, however, the initial value 
of Ti is 30° or 60°, then the minimised geometry showed 
an angle of 71°, with the energies, by MM and INDO, 
slightly in favour of the 71° conformation rather than 
the one at 90°. The reason for the 90° conformation 
being maintained under minimisation is due to the fact 
that the 90° conformation represents local maximum. A 
full account of the molecular mechanics procedure used 
can be found in Appendix 1.
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The effect on the conformation of removing chlorine 
atoms from the phenyl ring of clonidine was investigated 
by comparing the difference in energy between the 90° 
and the minimum energy conformation of clonidine, the 
mono-chloro- and unsubstituted derivatives. The results, 
with energies calculated by MM and INDO are shown in 
Table 2.3. As can be seen, for clonidine, the difference 
in energy between the 90° and the minimum energy (71°) 
conformation is very small, whereas the results for the 
mono-chloro- and unsubstituted compounds are very 
similar, with minima at about 40° which are more stable 
by ~0.5 Kcal/mol (~2.0 Kcal/mol by INDO) than the 
conformation at 90°.
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Table 2.2 Comparison of the Structure of Clonidine by 
Molecular Mechanics and X-ray Crysta1lography [80,81].
Molecular Mechanics X-Ray Crystallography
Counter Cl PCU
-ion
Initial
Torsion t 1 60° 90°
Final
Energy 12.14 12. 16
(Kcal/mol)
Torsion t 1 71 .4° 90.4° 76. 5° 89.0
Bond (A)
Ci-N7 1 .422 1.421 1 .418 1.420
N 7 “ c X 3 1 .336 1 .335 1.328 1.337
Cl3~Ni4 1.324 1.324 1.321 1.319
Nl4_Cl Si 1 .453 1.453 1 .447 1.457
C X s“Cx <£> 1 . 533 1 .533 1 . 533 1.528
C X 3~Nx7 1 .326 1 .326 1 .322 1 .334
C X 6~Nx7 1 .452 1 .452 1.450 1.454
Ang1e (0 )
C2-Cx-N7 121 .3 120.2 121.4 121.8
C<£j-Cx -N7 119.3 120.2 121.3 121.4
Cx-N7-Ci3 123.1 122.6 123.0 120.4
N7-Cx3-Nx4 123.8 123.9 123.1 123.1
N7 C X 3 N X 7 125.6 125. 5 125.0 124.9
Cx3“Nx7-Cx6 111.9 111.8 110.5 110. 5
C x 3 Nx4 Cx S 111.9 111.9 111.5 110.6
C x 3-C x6“Nx7 102.8 102.8 103. 5 103.0
N x4_C x3_C x6 102.9 102.0 102.6 103.2
Nx4“Cx3~Nx7 110.6 110.6 111.8 111.9
The rotation of the phenyl ring was further investii
by the PCILO molecular orbital method. The geometr’
the protonated species is obtained from the X-ray 
crysta11ographic structure of clonidine, and derivatives
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created by adding the appropriate substituents using 
standard lengths and angles [89]. The geometry of the 
unsubstituted free base is optimised using the INDO 
gradient minimiser GEOMIN and as before phenyl ring 
substituents added using standard lengths and angles.
PCILO (see Appendix 2) is then used to investigate the 
rotation of the phenyl ring. The version of PCILO/2 
available was only parameterised for atoms up to 
fluorine, hence the rotation of the following species 
could be studied:-
R = 2,4,6-tri-Me, 2,4-di-Me, 2,6-di-Me, 2-Me, H, 2,6-di-F
The results are shown in Table 2.5 and Fig. 2.3. For the 
neutral species, the minimum energy is found at 90° 
in all cases except for the -2,6-di-F derivative. The 
mono-ortho- substituted protonated species show the 
minima shifted to 130°, and the derivatives with small 
ortho- substituents (H and F) show two minima either 
side of a maximum at 90°. The activity (Log 1/ED30 [85]) 
is also listed in Table 2.4. The energy difference 
between the minimum energy and the 90° conformation 
(which is assumed to be active) does not seem to vary 
with activity and these results, as well as the results 
from the MM study of R = 2,6-di-Cl, 2-C1 and H, gave the 
impression that the energy barrier between the preferred 
and 90° conformations was not important in determining 
the hypotensive potency of these compounds.
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Figure 2.3 The C2“Ci-N7-Ci3 Rotational Barrier of Some 
Protonated and Neutral Clonidine Analogues, Calculated 
by PCILO. Energy is in Kcal/Mol.
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Table 2.3 The difference in total energy (in Kcal/mol) 
between the 90° and minimum energy conformations of
clonidine and the 2-Cl and des -CL derivatives,
calculated by molecular mechanics and INDO.
R Method
Cx N-y 
Minimum
Energy 
at Cx-Ny Min.
Energy 
at Cx-N7 90° &
2,6-di-Cl M.M.
INDO
71.4 12.14 
-81434.14
12.16 
-81436.01
-0.02 
-1 .13
2-C1 M.M.
INDO
39.4 12.71
-72921.59
13.08
-72919.45
-0.38
-2.05
H M.M.
INDO
45. 5 16.83
-64404.47
17.42 
-64406.16
-0. 59 
-2.20
Table 2.4 The difference in total energy (in Kcal/mol) 
between the Ci-N7 torsion angle minimum energy and 90° 
conformations of some imidazolidines related to
clonidine, calculated by PCILO.
Base Protonated Logl/ED30
R Cx-Ny min. ?E(90°-min.) Ci-N7 min . AE(90° -min. )
2,4,6- tri Me 90° 0.00 90° 0.00 -0.07
2,4-di Me 110° 0.05 130° 1 .25 -0. 56
2,6-d i Me 90° 0.00 90° 0.00 0.85
2-Me 110° 0.05 130° 1 .20 -0.67
H 90° 0.00 130° 1 .10 -2.1
2,5-di F 130° 0.40 50° 2.70 -0.41
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2.4 ELECTROSTATIC POTENTIAL
Agonist activity of compounds similar to UK-14304 (Fig 
2.4), which is similar to clonidine but has a bromine 
atom instead of a chlorine at position 2, no substituent 
at position 6 and a pyrazine ring fused to C3 and C^, is 
thought to correlate with the proton affinity of the 
nitrogen joined to C3 [^0].
To investigate whether clonidine and related species 
would correlate similarly, it was thought that 
measurement of the e 1ectrostatic potential in this area 
might give some interesting results. To do this, the 
protonated form of clonidine was taken, as this was 
assumed to be active, and formate was positioned off HN7 
and HNi4 as shown in Fig 2.5. This was done to mimic 
parts of the a-receptor, analogous to the receptor 
modelling with noradrena1ine discussed in the previous 
chapter. It was necessary to include a counter— ion so 
that the positive charge of the clonidine imidazoline 
ring did not 'swamp' the rest of the molecule and thus 
prevent finding areas of negative electrostatic 
potential. The clonidine-formate complex was minimised 
by MM and two analogues, the 2,6-di-methyl (which shows 
agonist activity, but not as potent as clonidine), and 
the unsubstituted (inactive) derivative were created by 
replacing chlorine with the necessary atoms using 
standard bond lengths and angles [89].
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Figure 2 :4
UK-14304
Figure 2 .5
Clonidine-h Formate
The electrostatic potential of these three drug-receptor 
models was calculated, from the INDO wavefunction, in 
the area of interest and the potential maps are shown in 
Fig 2.6a. As can be seen there are no areas of negative 
potential (corresponding to proton affinity in the UK- 
14304 series) and these models show similar potential 
maps, hence the potential in this area was not thought 
to be important in determining activity, although, as 
will be discussed in Chapter 3, the electrostatic 
potential is not necessarily the best measure of proton 
affinity.
The electrostatic potential maps in this area for the 
isolated free bases are shown in Fig. 2.6b. Clonidine 
shows an area of negative potential around the chlorine 
atom, but no corresponding negative area is found for 
the di-methyl derivative. The potential maps for the 
unsubstituted and 2,6-di-methyl derivatives are very 
similar in this area.
The charge distribution, again calculated by the INDO 
method, of the protonated drugs with formate and also 
for the free bases are shown in Fig 2.7a&b. Apart from 
the negative charges on the clonidine chlorine atoms, 
the charge distributions are essentially similar.
The electrostatic potentials around the whole molecules 
were estimated by calculating the net effect of all the
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partial atomic charges (calculated by CNDO), and 
potential energy maps were investigated for the 
protonated species where binding and activity data 
[85,91], Table 2.5, was available (R = 2,6-di-Cl, 2,6- 
di-Me, 2,5-di-Cl, 2-Me, 2,6-di-F, H). This was done to
see if differing phenyl ring substituents altered the 
potential energy such as to have an effect on binding 
and/or activity.
Table 2.5 The binding of some clonidine-1ike 
imidazolidines to rat brain homogenate (Ki). Activity 
data (Logl/ED30) is also shown.
Logl/ED30 (pmol/Kg)
1.99 
0.85 
0.25 
-0.67 
-0.41 
- 2.10
The electrostatic potential map of clonidine (Fig. 2.8) 
is not very informative; the positive charge created a 
region of positive potential around the entire molecule. 
To investigate the effect of phenyl ring substitution 
upon activity and binding, the electrostatic potential 
maps of each derivative were calculated, and the maps of 
the differences in potential between a derivative and
R
2.6-di Cl
2.6-di Me
2.5-di Cl 
2-Me
2.6-di F 
H
Ki (n m ) 
2.7 
5. 6 
9.3 
11.0 
19 
126
Page 79
3.75-
3.25-
2.75-
2.25-
.75
.25
.75-
.25
.00
.75-2.25
r 1.00
-3.50 
-3.00 
L2.50 
^2.00 
11.50 
5- 1.00 
L .5 0
1.00 q
3.50-
3.00-
2.50-
2 .00- 
1 .50- 
1 .00  -
.50-
.0 0 -
.75 .50.25
.75 .50.25 2.00-.25
2.50-.75
3.00.25 1 
-1.75 3.50
Figure 2.6a i_ The Electrostatic Potential Around He* of 
the Complex of Clonidine and Formate. Energy is in A.U..
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Figure 2.6a iii The Electrostatic Potential Around Hc* 
of the Complex of the Unsubstituted Analogue of 
Clonidine and Formate.
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Figure 2.6b i_ The Electrostatic Potential Around He* of
Non-protonated Clonidine.
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clonidine is shown in Fig. 2.9. Although differences in 
potential between clonidine and the other derivatives 
are found, no particular regions of these potential maps 
vary in line with Ki or logl/ED30.
The e 1ectrostatic potential difference maps between the 
unsubstituted (inactive) and 2,6-di methyl (active) 
derivatives are shown if Fig. 2.10. The potentials of 
these two compounds are essentially similar, both in the 
plane of the phenyl ring and in the plane of the 
imidazole ring. This suggests that electrostatic 
potential differences cannot explain the differences in 
binding or activity in this series of compounds.
2.5 CONSIDERATION OF THE RECEPTOR
The superposition of the X-ray crysta1lographic 
structures of clonidine and noradrena1ine is shown in 
Fig. 2.11. The similarity of Ci-N7-Ci-:-Ni4 of clonidine 
with the noradrena1ine side-chain suggests a similar 
receptor environment is possible, such as a carboxylate 
unit in the area around where the electrostatic
potential maxima are found. To investigate the minimum 
energy position of a carboxy unit around clonidine, the 
twelve initial models of clonidine with acetate in 
different positions (Fig. 2.12a) were subjected to 500 
cycles each of minimisation with the clonidine geometry 
constrained to its X-ray crysta11ographic structure.
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Figure 2.11 The Super-Position of the X-ray 
Crystallographic Structures of Clonidine and 
Noradrenaline.
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It was hoped that the following questions would be 
answered about the preferred position of the acetate 
un it.
1) Are the acetate oxygen atoms parallel to the 
clonidine nitrogen atoms ?.
2) Is the minimum energy position with the acetate
above N7 or N14 or between them ?.
3) Is the minimum energy position with the acetate
oxygens in the plane of the imidazoline ring ?.
The minimised geometries, in ascending order of energy 
are shown in Fig. 2.12b. It can be seen that the minimum 
energy positions are those with the acetate carbon atoms 
in the plane of the imidazoline ring and between
nitrogens N^ . and Nx^. The minimum energy position of the 
acetate oxygen atoms can be seen to be in several 
positions around the protons connected to nitrogens 7 
and 14. The acetate does not interact with the phenyl 
ring in any way hence this model gives no indication of 
how differing phenyl ring substituents may affect
binding to the a-receptor.
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2.6 CONCLUSION
Using theoretical methods to calculate preferred 
conformations, charge densities and electrostatic 
potentials failed to give results which were able to 
explain why differing phenyl ring substituents affect 
the activity of clonidine like imidazo1 idines. One index 
of activity which has been mentioned, but not studied in 
depth, is the energy and distribution of molecular 
orbitals, in particular the highest occupied molecular 
orbital (HOMO) and the lowest unoccupied molecular 
orbital (LUMO). The energies of these orbitals indicate 
the ease with which a molecule is able to donate or 
receive an electron from another molecule i.e. take part 
in a charge transfer interaction. This will be discussed 
in the next chapter.
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CHAPTER 3
THE SELECTION OF A PROCEDURE WITH WHICH TO 
MOLECULAR ORBITAL ENERGIES
CALCULATE
3.1 INTRODUCTION
In the last chapter it was suggested that that the 
energies and distribution of molecular orbitals near the 
HOMO and LUMO ,might be important in determining the 
activity of c1onidine-1ike imidazolidines. This chapter 
describes the steps taken to select the M.O. procedure 
which is best suited to calculating these orbitals. This 
is done by correlating the energy of the HOMO with a 
value for which experimental data is available. The 
experimental data used in this case is the acid 
dissociation constant, pKa.
Although experimental ionization potentials are reported 
for some members of the clonidine series [82], it has 
been shown that pKa will correlate with the ionization 
potential [92]. Since the ionization potential can be 
calculated directly from the energy of the HOMO, using 
Koopmans' theorem [93], it was thought that the HOMO
energy should correlate with pKa. Other calculated 
parameters are also investigated to see if these can 
also be used to calculate pKa.
Values of pKa are available for the clonidine-1ike 
imidazolidines which are of interest [76], therefore, a 
molecular orbital method was sought which would be able
to predict the pKa of these compounds. Since
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dissociation plays an important part in partition and 
receptor binding, the ability to predict whether a 
compound existed predominant1y as the base or protonated 
be very useful.
that pKa should correlate with ionisation
and hence the energy of the highest occupied
M.O. can be also explained if the process of protonation
is thought of in terms of charge transfer. The acceptor
(the proton) is the same in each case, hence the
reaction is limited by the ease with which an electron
can be removed from the donor, to form the covalent bond
with the proton. The change in free energy (^G) of a
a<Vv’iM
process is related to thet constant (K) by;
= -RT InK (3.1)
and since pKa = -InKa (3.2)
where Ka is the acid dissociation constant, AG, is
proportional to pKa. As the entropy change of the
process should be nearly constant over a similar series 
of compounds, then the enthalpy change, AHx should be 
proportional to pKa. Even though pKa is measured in
solution and an M.O. calculation is made on an isolated 
molecule, the effect of solvent on pKa should be
approximately constant over a similar series of 
compounds, hence the energy of the HOMO could be
expected to correlate with pKa.
form would
The fact 
poten tia1
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M.O. methods have been used to calculate proton 
affinities, and the most usual method of doing this is 
to calculate the difference in total energy between the 
base and protonated species, for example this energy 
difference has been measured by using CNDO for ammonia, 
mono-, di- and tri-ethy1 amine, and the energy difference 
is found to correlate with the gas phase basicity 
[94,95]. The difference in heats of formation, 
calculated by MNDO, of a wide range of compounds has 
been shown to be comparable with the experimental proton 
affinity [96]. Nakajima and Pullman have suggested the 
following relationship [92] for a series of diazines, 
pyridines and quinolines:
pKa = B + Ep Qp (11/pp) (3.3)
Where B is a constant, Qp is the charge on atom p and 
(11/pp) is the coulomb integral between electron 1 on 
the lone pair of the atom to be protonated and the tt-  
electron of atom p, the summation being carried over all 
non-hydrogen atoms p of the molecular skeleton.
Timmermans and van Zwieten [76] have shown that the pKa 
of the clonidine series correlates very strongly with 
the c-inductive parameters of Bari in & Perrin [97], and 
that the pKa of the series of 17 di-ortho substituted 
clonidine-1ike imidazolidines correlates with the 
difference in Ti-electron energies between base and 
protonated species. A good correlation was also found
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between pKa and the Ti-electron density of the bridge 
nitrogen of the protonated forms for the same series
[98], In both cases the Pariser-Parr-Pople (PPP) M.O. 
method was used (see App. 2) and the pKa of the mono­
ortho- substituted species also correlated with the same 
calculated properties but with a different intercept and 
a slightly different slope to the di-ortho- substituted 
compounds, hence the method could not be used to 
estimate pKa for all members of the series.
3.2 THE CHOICE OF PARAMETERS USED TO CALCULATE PKA
Since none of the previously cited attempts to calculate 
proton affinity used the energy of the HOMO, various 
other molecular properties were used as well as E HOMO 
in attempts to correlate pKa with calculated indices. To 
investigate the relationships between pKa and calculated 
values, the program REGRESS (App. 5) was used. This 
program is very useful when large amounts of data are to 
be handled, in this case 38 variables on 22 molecules. 
The number of variables included in each regression 
equation (up to four) is specified as well as any points 
which are to be ignored. The program then takes all 
combinations of the number of variables specified for 
each equation and prints out the results for regressions 
which have a significance (F value) greater than 
specified by the user.
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It was thought probable that an interaction via the HOMO 
would be important in determining pKa, hence the 
properties of the atoms over which the HOMO is 
distributed were calculated. To determine over which
atoms the HOMO is distributed, The HOMO of clonidine, 
calculated by INDO and drawn by the program 'ORBIT'
[99], is shown in Fig. 3.1. As can be seen, the HOMO is
concentrated on atoms Cj., , C* , N-7 and the ortho­
substituents (Suba and Sub?). Para- substituted members
also showed HOMO density on the para- substituent 
(Subn) , hence these atoms were also taken as the ones 
which might affect pKa.
The following properties of each of these atoms were 
calculated by INDO for the 22 c 1onidine-1 ike
imidazolidines listed in Table 3.1; n-electron density, 
as Py population since the molecule was oriented with 
the phenyl ring in the X-Z plane (pop Py), frontier 
electron density (F[E]), F[E]/E HOMO, nett atomic
t
charge (Chge), atomic polarisabi1ity (a) and the
'interaction energy' between N-7 and each atom (E Atl —
At2) to simulate Pullman's idea of the interaction of 
the lone pair with the other atoms, as well as the
energy of the HOMO and the electrostatic potential
minimum around Nt-. These values are shown in App. 4.
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RBIT (OXFORD MARCH 1984) CLONZ.MOC HOMO - 37
XROT = 290.0
TROT = -10.0
ZROT = .0
0RBITAL37+- 
0RBITAL37--
E.iqure 3_^ 1_ The Highest Occupied Molecular Orbital of 
Clonidine, Calculated by INDO.
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The most significant results from the regression
analysis of these values against pKa are shown in Table 
3.2. When variables are taken singly, the Py population
and charge on N-7 appear most significant. When two
variables are taken at a time, the population of N-^  Py
and the N7-C1 interaction (E N-7-C1 ) were significant as
well as the energy of the HOMO coupled with the charges 
on C*b and N-r and also E Taking three variables at
a time shows E HOMO plus Chge N-^  with E N-7-N-7 and N-^ -
C*>, and Chge Ci as well as E HOMO/Chge C^/Chge Sub© to
be significant.
Table 3.1 The experimental pKa of 22 imidazolidines
similar to clonidine
R
pKa 
(Expt1 • )
2,4,6-tri Me 10.72
2,4-di Me 10.56
2,6-di Me 10.53
2,6 Me, 4-C1 10.25
2-Me 10.23
H 10.05
2-Me, 4—C 1 9.99
2,4-Me, 6-C1 9.59
2-C1, 4-Me 9.41
2-Me, 6-C1 9.40
2-C1 9.15
4,6-Cl, 2-Me 9.03
2,4-di Cl S. 73
2,6-Cl, 4-OMe 8 . 57
2,3-di Cl 8 . 55
2,5-di Cl 8 . 50
2,6-Cl, 4-Me 8.29
2,6-di Cl 8.05
2,4,6-tri Cl 7.75 7 .-1
2,6-Cl, 4-N03 6.86
<3*1 g
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Table 3.1 The most significant results from the
regression of various M.O. indices against the pKa of 
some clonidine—like imidazo1 idines.
Variable r s F
1 variable, F>40
pop Py N-7 0.93 0.40 126
chge N-7 0.93 0.40 126
E N7-N7 0.85 0.57 53
E HOMO 0.90 0.48 82
2 variables, F>100
pop Py n 7 pop Py Sxx 0.96 0.27 150
II F[E] N-7 0.96 0.29 123
II F[E] Sxx 0.96 0.31 113
II chge C= 0.96 0.30 120
II a N-7 0.96 0.31 109
II a S© 0.96 0.29 128
II E N7-Ci 0.97 0.27 155
II E N7-C= 0.95 0.29 128
ll E N7-C6 0.96 0.30 122
ll F[E] N7/E HOMO 0.96 0.30 121
ll F[E] Sii/E HOMO 0.96 0.31 112
E HOMO chge C& 0.97 0.26 158
11 chge N-7 0.97 0.23 170
II E N7-Ca 0.96 0.31 112
II E N^-C^ 0.96 0.32 103
ll E N^-C* 0.97 0.24 187
3 variables, F>200
E HOMO chge pop Py S© 0.99 0.18 232
II chge N-7 pop Py Cx 0.99 0.17 266
II " chge Ci 0.99 0.15 356
It chge chge S© 0.99 0.15 343
II chge N7 a N-^ 0.99 0.19 207
ll E N^-Ci pop Py N*7 0.99 0.16 287
ll " chge N-t- 0.99 0.18 229
II E N^-C= 0.99 0.17 251
It E N^-C* 0.99 0.15 334
ll " chge S© 0.99 0.19 208
ll E N-7--N-7 chge Ci 0.99 0.18 223
II " chge N-t- 0.99 0.15 344
II E N^-C* 0.99 0.18 230
E N-7-Sj.i chge 0.99 0.18 241
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If the 2,6-di-F and 2-Cl,6-F derivatives are removed 
from the regression, then the 2-variable regression of E 
HOMO and Chge Ny becomes very significant;
pKa = 13.764 + 40.768 E HOMO - 29.441 Chge N7
r = 0.993 ' s = 0.128 F = 639.5
n = 20 (3.5)
Table 3.3 shows calculated and experimental pKa derived 
from this equation.
The fact that Chge N-r- rather than electrostatic 
potential is significant in calculating pKa is 
intriguing. E HOMO and Chge are co-variant. This is 
because if a M.O. is concentrated on a particular atom, 
causing a relatively high charge density, this will give 
rise to a high lying M.O. due to the increased electron- 
electron repulsions. Thus the significance of chge N-^  
may be due to its co-variance with E HOMO.
Using the energy of the HOMO as the sole variable and 
regressing this against pKa using the MINITAB 
statistical package [100] to flag any points which have 
calculated values more than two standard deviations away 
from the experimental values, meant that the clonidine- 
like imidazolidines showed large deviations from the 
regression line could be ignored. Once the 2,3-di-Cl,
2,6-di-F, 2-C1 6-F, 2,4,6-tri-Cl and 2,6-Cl, 4-N0=
derivatives are removed, the regression of pKa vs. E 
HOMO gives:
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pKa = 21.4 + 30.8 E HOMO
R2 = 94.9’/. s = 0.201 
n = 17 (3.6)
The result of which is shown in Table 3.3. Including the 
charge on Nr as well as the E HOMO did not significantly 
improve the correlation (R2 = 96.97.). The fact that
species containing fluorine had to be removed in order 
to obtain good regression can be explained by the fact 
that the fluorine parameters for the INDO method may not 
give the best results. The reason for the 2,3-di-Cl,
2,4,6-tri-Cl and 2,6-di-Cl, 4N0= derivatives being
outliers is not clear.
Table 3.3 Experimental and calculated pKa using
equations 3.5 and 3.6.
pKa pKa pKa
R (Expt1.) (Eq. 3. 5) A (Eq. 3. 6) A
2,4,6-tri Me 10.72 10.72 0.06 10.65 0.13
2,4-di Me 10.56 10.64 -0.08 10.56 0.00
2,6-di Me 10. 53 10.38 0.15 10.38 0.15
2,6 Me, 4-C1 10.25 10.20 0.05 9.95 0.30
2-Me 10.23 10.26 -0.03 10.28 -0.05
H 10.05 10.13 -0.08 10.22 -0.17
2-Me, 4-01 9.99 10.04 -0.05 9.88 0.11
2,4-Me, 6-C1 9. 59 9.62 -0.03 9.73 -0.14
2-C1, 4-Me 9.41 9. 53 -0.12 9.67 -0.25
2-Me, 6-C1 9.40 9.36 0.04 9.48 -0.08
2-C1 9.15 9.30 -0.15 9.42 -0.27
4,6-Cl, 2-Me 9.03 8.86 0. 17 8.68 0.35
2,4-di 01 8.73 8.77 -0.04 8. 50 0.23
2,6-Cl, 4-OMe 8. 57 8.51 0.06 8.72 -0.15
2,3-di Cl 8. 55 8.39 0.16 ---- ----
2,5-di Cl 8.50 8. 54 -0.04 8.34 0.15
2,6-Cl, 4-Me 8.29 8.29 0.00 8.44 -0.15
2,6-di Cl 8.05 8.05 0.00 8.19 -0.14
2,4,6-tri Cl 7.75 7.52 0.23 ---- ----
2,6-Cl, 4-N0= 6.86 7.14 -0.28 ---- ----
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3.3 SELECTION OF A M.O. METHOD WITH CAN BE USED TO 
CALCULATE PKA
It was thought that E HOMO was the molecular property 
which was most important in determining pKa. The next 
step was to see if a more accurate method could be found 
to calculate E HOMO and hence pKa, so that the entire 
series of 22 molecules could be included and also to see 
if E HOMO correlated with pKa for any other series of 
compounds.
The energy, calculated by INDO, of the HOMO of pyridine 
and the methyl derivatives shown in Table 3.4' is found, 
by inspection of the eigenvectors, to be associated with 
the nitrogen lone pair. For this series of compounds, 
the correlation (R2 ) between pKa and the energy of the 
HOMO, calculated by INDO is found to be 1007., whereas 
the correlation between pKa and the charge on the 
nitrogen is not as good (R2 = 96.07.), again implying
that E HOMO is a better predictor of pKa than the charge 
on the atom to be protonated, although the fact that 
only four members of the series are included means that 
a definite result cannot be expected.
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Tab 1 e 3.4 pKa [101],E HOMO and Chge N for some methyl
substituted pyridine derivatives.
R pKa E HOMO (A.U.) Chge N
5.17 -0.4047 -0.2114
6.02 -0.3980 -0.2174
6.79 -0.3922 -0.2330
7.50 -0.3864 -0.2464
pKa = 56.91 + 127.8 E HOMO 
R2 = 100.07. s = 0.017 n = 4 (3.7)
pKa = -7.754 - 62.21 Chge N 
R2 = 96.0 s = 0.247 n = 4 (3.8)
The pKa of a series of aniline derivatives is shown in 
Table 3.5 with the energy of the HOMO (which is 
concentrated on the amine nitrogen).
Using the MINITAB package and ignoring molecules which 
showed large differences between calculated and 
experimental pKa, the regression of pKa vs. E HOMO
calculated by INDO progressed as follows.
pKa = 23.3 + 51.6 E HOMO R2 = 67.77. s = 0.690 n = 15
(3.9)
Omit m-Cl and p-NO^:
pKa = 23.0 + 50.7 E HOMO R2 = 75.57. s = 0.465 n = 13
(3.10)
Omit o-F, p-Cl and o-0CH3 :
pKa = 27.3 + 62.0 E HOMO R2 = 96.17. s = 0.200 n = 11
(3.11)
H
4-Me
2,4-di-Me 
2,4,6-tri-Me
Page 109
Table 3.5 pKa [101] and E HOMO (A.U.) for some Substituted
An i1ine Derivatives.
INDO ST0-3G
R pKa E HOMO (a .u .) E HOMO
p-0CH3 5.34 -0.351 -0.2123
p-CH3 5.08 -0.358 -0.2126
m-CH3 4.73 -0.368 -0.2182
p-F 4.65 -0.370 -0.2183
H 4.63 -0.369 -0.2209
0-OCH3 4. 52 -0.349 -0.2175
0 -CH3 4.44 -0.364 -0.2165
m-0CH3 4.23 -0.371 -0.2228
p-Cl 4.15 -0.384 -0.2314
m-F 3. 50 -0.384 -0.2293
m-Cl 3.46 -0.408 -0.2378
o-F 3.20 -0.374 -0.2237
o-Cl 2.65 -0.396 -0.2351
m-N0= 2.47 -0.399 -0.2485
p-N0= 1.00 -0.403 -0.2543
Thus a very significant relationship is found between 
pKa and E HOMO if the outliers are removed. E HOMO 
va1ues calculated by the ab-initio ST0-3G (see App. 2)
method were used to see if less approximate methods were 
able to give better correlation whilst including more 
members of the series. Using the same procedure for the 
INDO results the regression analysis proceeded as 
foilows.
pKa = 23.2 + 85.4 E H0M0STo-3e R2 = 8 6 . 3  s = 0.45
n = 15 (3.12)
Omit o-F and m-N0= ;
pKa = 25.0 + 93.1 E H0M0STq -3q R2 = 9 1 . 3  s = 0.36
n = 13 (3.13)
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Omit m-Cl and p-Cl
pKa = 27.0 + 1 0 3  E HOMO3TO-3Q R2 = 9 8 . 2  
n = 12
s = 0.18 
(3.14)
Hence ST0-3G molecular orbital energies are an 
improvement on INDO when used to calculate the pKa on 
this series of substituted anilines. To see if the same 
is true for the clonidine series, the energies of the 
highest occupied M.O.'s of the clonidine series were 
calculated by the ST0-3G method. An attempt to do this 
calculation on some members of the series showed that in 
most cases over ten minutes c.p.u. time on a CRAY—IS 
supercomputer time is required, hence some atoms are 
omitted in order to save computer time. Since the HOMO 
of these clonidine-1ike imidazolidines is found 
distributed around the phenyl ring, it was thought 
likely that most of the imidazole ring system could be 
removed without significantly affecting the HOMO, hence 
ST0-3G calculations were performed on the model ,
shown in Fig 3.2, and typically 200-500 CRAY-1S c.p.u. 
seconds were required for each molecule. The results are 
shown in Table 3.6 and the regression analysis proceeded 
as follows;
pKa = 26.4 + 65.4 E HOMO s t o -s q R2 = 81.4 
n = 22
s = 0.47 
(3.14)
Omit 2,6-di-F and 2-C1 6-F
pKa = 26.9 + 67.1 E HOMO:STO-33 R2 = 9 3 . 9  
n = 20
s = 0.27 
(3.15)
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Figure 3.2 The Model Structure Used in the ST0-3G 
Calculations on 22 Non-Protonated Analogues of
Clonidine.
CH.
NH
NH,
Figure 3.3 The Model Structures Used in the ST0-3G 
Calculations on 22 Protonated Analogues of Clonidine.
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With two members of the series omitted, ST0-3G gives 
similar results to INDO with five members of the series 
removed. E HOMO's calculated by MNDO [88] are shown in 
Table 3.7 for 12 clonidine-1ike imidazo1 idines. The 
regression of E HOMO vs. pKa proceeded as fallows;
pKa = 43.0 + 3.77 E H0M0MNDo R2 = 83.6 s = 0.40
n = 12 (3.16)
Omit 3,5-di-Cl;
pKa = 48.5 + 4.39 E H0M0m n d o R2 = 9 1 . 4  s = 0.30
n = 11 (3.17)
The M.O. energies of all 22 clonidine-1ike 
imidazol idines has been calculated [83] by the PPP t t -  
electron SCF method, but the energy of the HOMO does 
not correlate with pKa (R2 =53.0).
A summary of results of these attempts to correlate pKa 
with the energy of the highest occupied molecular 
orbital is given in Table 3.8. As can be seen ST0-3G 
gives the most significant results and hence was 
selected as the preferred method to calculate M.O. 
energies.
Page 113
Tab1e 3.6 Experimental pKa, E HOMO (A.U.) calculated by 
ST0-3G and pKa calculated by equation 3.15 for some 
clonidine-1ike imidazolidine model compounds.
R
pKa . 
(Exptl. ) E HOMOs t o —3 0
pKa 
(Eq. 3.15)
A
2,4,6-tri Me 10.72 -0.238 10.96 -0. 18
2,4-di Me 10.56 -0.241 10.75 -0. 19
2,6-di Me 10. 53 -0.247 10.35 0.18
2,6 Me, 4-C1 10.25 -0.254 9.88 0.37
2-Me 10.23 -0.250 10.15 0.08
H 10.05 -0.255 9.81 0.24
2-Me, 4-C1 9.79 -0.257 9.68 0.31
2,4-Me, 6-C1 9. 59 -0.254 9.88 -0.29
2—Cl, 4-Me 9.41 -0.257 9.68 -0.27
2-Me, 6-C1 9.40 -0.263 9.28 0.12
2-C1 9.15 -0.266 9.08 0.07
4,6-Cl, 2-Me 9.03 -0.269 8.87 0.16
2,4-di Cl 8.73 -0.273 8.61 0.12
2,6-Cl, 4-OMe 8. 57 -0.268 8.94 -0.37
2,3-di Cl 8.55 -0.280 8.14 0.41
2,5-di Cl 8.50 -0.277 8.34 0.16
2,6-Cl, 4-Me 8.29 -0.270 8.81 -0. 51
2,6-di Cl 8.05 -0.278 . 8.27 -0.22
2,4,6-tri Cl 7.75 -0.284 7.86 -0.12
2,6-Cl ,4 -NO-; 6.86 -0.298 .6.93 -0.07
Table 3.7 Experimental pKa, E HOMO calculated by MNDO 
and pKa calculated from equation 3.17 for some 
neutral clonidine-1ike imidazolidines.
R
pKa 
(Exptl. )
E HOMOm m d q 
(E.V.)
pKa 
(Eq.17)
A
H 10.05 -8.669 10.35 -0.30
4-C1 9.78 -8.907 9.40 0.38
3-C1 9.56 -8.973 9.11 0.45
3,5-di Cl 8.98 -9.239 ---- ----
2,6-d i F 8.18 -9.107 8.52 -0.34
2,5-di Cl 8. 50 -9.162 8.23 0.22
2-Me 10.23 -8.671 10.43 -0.20
2-C1 9.15 -8.918 9.35 -0.20
2,4-Me 10. 56 -8.655 10.46 0.10
2,6-di Cl 8.05 -9.159 8.32 -0.28
2,6-di Me 10.53 —8.686 10.50 0.03
2,5-di Et 10.61 —8.660 10.48 0.13
Page 114
Tab1e 3.8 The molecular orbital methods used to estimate 
the pKa of some clonidine-1ike imidazolidines and the 
correlation coefficients from the regression of E HOMO 
against pKa.
Method R2 ('/.) n Eq. no.
ST0-3G 93.9 20 3.15
INDO 95.0 17 3.6
MNDO 91.4 11 3.17
PPP 53.0 22 ----
To investigate whether or not the expensive ST0-3G 
calculations would have to be repeated to calculate the 
M.O. energies of the protonated c 1onidine-1ike 
imidazolidines, the HOMO energies of the neutral and 
protonated species calculated by INDO were compared. The 
protonated derivatives were created by taking the x-ray 
crystallographic structure of clonidine [81] and setting 
the dihedral angle of the phenyl ring to 90°. The two 
chlorine atoms and all hydrogens were removed and the 
phenyl ring substituents and hydrogens were 
added using standard bond lengths and angles [89].
The HOMO energies calculated by INDO are shown in Table
3.9. The correlation coefficient between the INDO 
HOMO energies of the neutral and protonated species is 
42.77.. Hence it was thought most probable that
the HOMO energies of the neutral derivatives
calculated by ST0-3G would not be co-variant
with the HOMO energies of the protonated species, hence
Page 115
ST0-3G calculations were performed on the protonated 
clonidine-1ike imidazo1 idines. Since the positive charge 
is delocalised over the bridge and imidazole nitrogen 
atoms, it was thought possible that the model used to 
calculate the neutral species with =CH= substituted for 
imidazole might be insufficient for the protonated 
derivatives.
To verify this the HOMO energies of the protonated 
species, calculated by INDO, were compared with two 
models shown in Fig. 3.3, one with =CH=; substituted for 
the imidazole ring, similar to the neutral model used 
for the ST0-3G ca1cu1ations, and the other having 
=C(NH=;)=> substituted instead of the imidazole ring. The 
HOMO energies of the two models are also shown in Table
3.10. The HOMO energy of the =C(NH= )= substituted 
species gives a correlation coefficient of 99.87. when 
regressed against the same value for the whole molecule, 
and the =CHz; substituted derivatives give an R2 value of 
90.87. which was thought to be close enough correlation 
with the HOMO of the parent molecules.
The energies of the LUMO's for the base, protonated and 
the two models, are shown in Table 3.10. As can be seen 
the LUMO energies of the neutral and protonated species 
are co-variant, and the LUMO energies of the =CH= 
substituted species correlates with that of the parent 
protonated derivatives.
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Having made the comparisons of the M.O. energies of the 
c 1on idine-1ike imidazo 1 id ines , it was decided that =CH=: 
substituted derivatives could be used to calculate the 
M.O. energies of the protonated species, thus ST0-3G 
calculations were performed on these molecules so that 
data from these calculations could be used in regression 
analysis against experimental activity. The HOMO and 
LUMO energies used are shown in Table 3.10. The LUMO's 
of the protonated species are found to be distributed 
over the nitrogen atom. Since M.O.'s distributed over 
the phenyl ring are also of interest, the next lowest 
unoccupied M.O., which is distributed over the phenyl 
ring, (E LUMOph) is also listed.
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Table 5.9 E HOMO (A.U.) calculated by INDO for some
c 1onidine—1ike imidazo1 idines and model compounds.
R
E HOMO 
Base
E HOMO E HOMO 41 
Protonated
E HOMO
2,4,6-tri Me -0.349 -0.568 -0.607 -0.572
2,4-di Me -0.352 -0.571 -0.610 -0.575
2,6-di Me -0.358 -0.580 -0.612 -0.583
2,6 Me, 4—C 1 -0.372 -0.541 -0.569 -0.545
2-Me -0.361 -0.591 -0.630 -0.597
H -0.363 -0.600 -0.660 -0.609
2-Me, 4-C1 -0.374 -0.544 -0.572 -0.548
2,4-Me, 6-C1 -0.379 -0.561 -0.594 -0.566
2-C1, 4-Me -0.381 -0.565 -0.600 -0.570
2-Me, 6-C1 -0.387 -0.566 -0.599 -0.571
2-C1 -0.389 -0.571 -0.605 -0.576
4,6-Cl, 2-Me -0.413 -0.580 -0.609 -0.585
2,4-di Cl -0.419 -0.561 -0.605 -0.566
2,6-Cl, 4-OMe -0.412 -0.601 -0.632 -0.607
2,3-di Cl -0.481 -0.627 -0.655 -0.633
2,5-di Cl -0.424 -0.572 -0.601 -0.577
2,6-Cl, 4-Me -0.421 -0.596 -0.627 -0.602
2,6-di F -0.364 -0.595 -0.631 -0.599
2,4,6-di Cl -0.429 -0.601 -0.633 -0.607
2-C1, 6—F -0.393 -0.579 -0.612 -0.583
2,4,6-Cl -0.488 -0.632 -0.662 -0.639
2,6-Cl, 4-NO- -0.447 -0.608 -0.630 -0.614
#1 —  =CH;2 substituted for imidazoline 
42 —  =C(NH2:)2 " " .
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Table 3.10 E LUMO (A.U.) calculated by INDO for some
clonidine-1ike imidazoles and model compounds.
E LUMO E LUMO E LUMO #1 E LUMO
R Base - - - Protonated - - —
2,4,6-tri Me 0.163 -0.033 -0.162 -0.035
2,4-di Me 0. 164 -0.033 -0.164 -0.036
2,6-di Me 0.164 -0.035 -0.166 -0.037
2,6 Me, 4-C1 0.061 -0.058 -0.188 -0.064
2-Me 0.165 -0.035 -0.168 -0.038
H 0. 166 -0.036 -0.170 -0.039
2-Me, 4-C1 0.062 -0.059 -0.190 -0.065
2,4-Me, 6-C1 0.076 -0.068 -0.198 -0.076
2-01, 4-Me 0.077 -0.069 -0.200 -0.077
2-Me, 6-C1 0.077 -0.071 -0.203 -0.079
2-C1 0.076 -0.073 -0.205 -0.081
4,6-Cl, 2-Me -0.184 -0.281 -0.305 -0.291
2,4-di Cl -0.186 -0.286 -0.308 -0.295
2,6-Cl, 4-OMe -0.170 -0.272 -0.308 -0.295
2,3-di Cl -0.325 -0.427 -0.450 -0.434
2,5-di Cl -0.142 -0.239 -0.262 -0.246
2,6-Cl, 4-Me -0.173 -0.276 -0.307 -0.293
2,6-di F 0.156 -0.041 -0.177 -0.044
2,6-di Cl -0.175 -0.280 -0.309 -0.295
2-C1, 6-F 0.075 -0.075 -0.208 -0.083
2,4,6-tri Cl -0.346 -0.455 -0.479 -0.463
2,6-Cl, 4-NO- -0.181 -0.286 -0.316 -0.30Q
Page 119
Table 3.11 HOMO and LUMO energies (A.U.) calculated by 
ST0-3G for some c 1onidine-1ike imidazolidine model 
compounds, with the imidazole ring substituted by =CHz:
R
2.4.6-tri Me
2.4-di Me
2.6-di Me 
2,6 Me, 4-C1 
2-Me
H
2-Me, 4—C 1
2.4-Me, 6-C1 
2-C1, 4-Me 
2-Me, 6-C1 
2-C1
4.6-Cl, 2-Me
2.4-di Cl
2.6-Cl, 4-0M( 
2,3-di Cl
2.5-di Cl
2.6-Cl, 4-Me
2.6-di F
2.6-di Cl 
2-C1, 6-F
2.4.6-tri Cl
2.6-Cl, 4-NO:
E HOMO E HOMO E LUMO E LUMO E LUMQp
Base Pro t'. Base Prot. Prot.
-0.238 -0.418 0.270 -0.058 0.096
-0.241 -0.430 0 .26e -0.059 0.092
-0.247 -0.422 0.268 -0.061 0.090
-0.254 -0.437 0.248 -0.069 0.071
-0.250 -0.434 0.266 -0.063 0.085
-0.255 -0.447 0.264 -0.064 0.080
-0.257 -0.441 0.246 -0.070 0.066
-0.254 -0.432 0.249 -0.065 0.074
-0.257 -0.442 0.247 -0.067 0.070
-0.263 -0.436 0.247 -0.069 0.066
-0.266 -0.447 0.244 -0.071 0.062
-0.269 -0.449 0.227 -0.076 0.049
-0.273 -0.456 0.224 -0.078 0.045
-0.268 -0.452 0.221 -0.076 0.047
-0.280 -0.444 0.225 -0.078 0.047
-0.277 -0.442 0.222 -0.079 0.046
-0.270 -0.446 0.227 -0.072 0.053
-0.257 -0.426 0.253 -0.070 0.070
-0.278 -0.4 50 0.224 -0.076 0.045
-0.266 -0.438 0.236 -0.073 0.056
-0.284 -0.463 0.207 -0.083 0.029
-0.298 -0.471 0.155 -0.090 -0.005
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3.4 CONCLUSION
A method of using molecular orbital methods to estimate 
pKa has been found which only requires a calculation to 
be done on the base molecule rather than, for instance, 
calculating the difference in energy between the base 
and protonated species. The energy of the HOMO 
calculated by INDO will correlate very well with pKa if 
no members of the series of molecules studied contain 
chlorine. If chlorine is present, then the ST0-3G method 
must be used. Neither if these methods can accurately 
predict the pKa of compounds containing fluorine.
Since many of the c 1onidine-1ike imidazolidines of 
interest contain chlorine, the ST0-3G method was used to 
calculate the E HOMO and E LUMO, to be used in 
regression analysis against experimental activity. To 
save computer time, the imidazoline rings of these 
compounds were substituted by =CH2 .
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CHAPTER 4
STRUCTURE - ACTIVITY RELATIONSHIPS OF
IMIDAZOLIDINES RELATED TO CLONIDINE
SOME
4.1 INTRODUCTION
The energies of the molecular orbitals calculated in the 
last chapter can now be used in regression analyses to 
predict the activity of the c1onidine-1ike
imidazolidines. As it was not expected that the M.O. 
energy would be the only value likely to effect the 
activity of these compounds, charge densities are also 
included as well as parameters to account for transport, 
ionization and molecular size.
The HOMO and LUMO of the neutral species of clonidine 
and similar compounds are found to be largely 
distributed over the phenyl ring, as is the HOMO of the 
protonated derivatives. The LUMO of the protonated 
species is found to be centred on the atom Ci3 and the 
bridge nitrogen atom, so to account for any possible 
charge transfer donation to the phenyl ring, the energy 
of the lowest unoccupied m.o. concentrated on the phenyl 
ring (E LUMOph(p)) was also noted. E 1ectrostatic 
interactions between the drugs and the receptor (which 
is presumed to be negatively charged) were taken into 
account by including the charge on Ci3. The difference 
in energy between the HOMO and LUMO was also used as 
this value was found to be significant in previous 
regression analyses [85].
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The variation in transport of drugs through membranes 
may be accounted for by using logP', the apparent 
octanol-water partition coefficient; EPar, the sum of 
the parachor contributions of the phenyl ring 
substituents [87]; E t t , the partition substituent 
parameters [9] and EEs, the sum of the Taft steric 
parameters of the phenyl ring substituents [8]. These 
values were obtained from ref. [85]. pKa was also 
included as it was assumed that only the neutral forms 
could cross lipid membranes. The squares of these values 
were also included to account for possible parabolic 
relationships of the variable and its square with 
activity. The concentration of clonidine-1ike 
imidazo1idines in rat brain has been found to be related 
to the amount administered by intravenous injection by a 
relationship involving logP' and logP'2 [85] and it has 
also been found that significant correlations with 
activity exist if variables such as EPar and EPar2 or 
EEs and EEs2 are included [85]. Other substituent 
parameters used in this initial regression ana 1ysis were 
the CTomp values of Barlin and Perrin [97], the EF 
(inductive) and ER (resonance) parameters of Norrington 
[7] and the Taft steric parameters [8] for the 2, 4 and 
6 positions (Es2, Es4, and Es6). These values are listed 
in App. 4.
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Table 4.1 Experimental activity measured as the log of 
the concentration required to give a 307. reduction in
blood pressure after i.v. injection into normo-tensive 
rats (logl/ED30), nmol/g. For an explanation of the 
suffixes (p), (b), (c), (pb), (cp), (cb), (cpb) see
tex t.
Log1/ED30 Log1/ED30 Log1/ED30 Log 1/1
R (c ) ( P) (b
2,4,6-tri lie -0.07 0.98 -0.07 2.93
2,4-di fie -0. 55 0.86 -0. 56 2.24
2,6-di Me 0.85 2. 14 0.85 3.62
2,6 Me, 4-C1 0.04 0.54 0.04 2. 54
2-Me -0.67 0.91 -0.67 1 .82
H -2.10 -0.42 -2.10 0.24
2-Me, 4—C1 -0.05 0.80 -0.05 2.22
2,4-Me, 6-C1 0. 51 0.83 0. 52 2.41
2-C1, 4-Me 0.67 1 .07 0.68 2.38
2-Me, 6-C1 1.11 1. 57 1 .12 2.82
2-C1 0.14 0.67 0.15 1. 57
4,6-Cl, 2-Me 0. 55 0.40 0. 57 1 .87
2,4-di Cl 0.64 0. 58 0.68 1 .71
2,6-Cl, 4-OMe -0.83 -0.82 -0.78 0.11
2,3-di Cl 1.31 1 .13 1.37 2.23
2,5-di Cl 0.25 0.03 0.32 1 .13
2,6-Cl, 4-Me 1.13 0.87 1 .22 1.83
2,6-di F -0.41 -0.22 -0.29 0.21
2,6-di Cl 1.99 1.78 2.14 2. 55
2-C1, 6-F 1.30 1.13 1 .47 1 .80
2,4,6-tri Cl 1.16 0.69 1 .41 1.51
2,6-Cl, 4-NO- -1 .16 -1.68 -0.34 -1 .09
Cont'd . . .
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Table 4.1 Continued.
Log 1/ED30 Log1/ED30 Logl/ED30 Logl /I
R ( pb) (cp) (cb) (c!
2,4,6-tri Me 15 . 56 0.98 3.98 3.98
2,4-di Me 11 .89 0.86 3.65 3.65
2,6-di Me 19.19 2.14 4.91 4.91
2,6 Me, 4-C1 13.50 0. 54 3.04 3.05
2-Me 9.69 0.91 3.40 3.41
H 1 .26 -0.41 1 .92 1.92
2-Me, 4-C1 11 .78 0.81 3.07 3.07
2,4-Me, 6-C1 12.80 0.84 2.73 2.73
2-C1, 4-Me 12.69 1.08 2.78 2.79
2-Me, 6-C1 15.01 1 . 59 3.28 3.29
2-C1 8.41 0.69 2.11 2.12
4,6-Cl, 2-Me 10.04 0.43 1 .73 1.75
2,4-di Cl 9.26 0.62 1 .65 1.69
2,6-Cl, 4-OMe 0.88 -0.77 0.12 0.18
2,3-di Cl 12.12 1 . 18 2.04 2.10
2,5-di Cl 6.31 0.09 0.91 0.97
2,6-Cl, 4-Me 10.21 0.97 1. 58 1.67
2,6-di F 1 .75 -0.10 0.40 0.52
2,6-di Cl 14.27 1.93 2.33 2.47
2-C1, 6-F 10.42 1 .30 1 .63 1.80
2,4,6-tri Cl 9.35 0.95 1 .05 1.30
2,6-Cl, 4-N0= -1 .44 -0.86 -1 .61 -0.79
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4.2 INITIAL REGRESSION ANALYSIS
The experimental data initially used was the log
l/ED30(p) and log l/ED30(c) data from the rat central a- 
adreno receptor given by Timmermans [85] and listed in 
Table 4.1. Log l/ED30(p) is the concentration required 
to g i ve a 30*/. reduc tion in arte rial bl ood pressure af ter 
intravenous injection, corrected for the percentage of 
protonated species present, as this was found to give a 
better correlation than the un-corrected data [85]. The 
correction for the amount of protonated species is 
calculated by multiplying the ED30 value by the fraction 
of protonated species present. The fraction of
protonated species is calculated from the pKa° value 
which is the dissociation constant under physiological 
conditions, i.e. blood at 37°C [76]. The log of the
reciprocal of the new ED30 value is calculated to give 
the logl/ED30(p) value, the (p) suffix indicating the 
correction for protonated species. Similarly the log 
1/ED30 values are corrected for the amount of un— 
protonated, or base species to give logl/ED30(b ). If it 
is assumed that it is the protonated species which is 
active and that only the non-protonated species will 
pass through lipid membranes, then multiplying the ED30 
value by both the fraction protonated and non- 
protonated, and thus calculate the logl/ED30(pb) value, 
will bias the results in favour of compounds which have 
similar amounts of protonated and non-protonated species 
present.
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Log l/ED30(c) is the concentration required to give a 
30*/. decrease in arterial pressure, corrected for the 
amount of drug reaching the brain by the relationship 
below [85]. The suffixes (cp) etc. denote that the 
experimental data has been corrected for the 
concentration reaching the rat brain as well as for the 
extent of ionisation.
Cbrain/Civ = -0.133 (1ogP')2 + 0.574 logP' - 0.094
(4.1)
The regression analysis was performed using the program 
REGRESS, described earlier. Since it was known that the 
compounds containing fluorine do not fit the regression 
line from the previous work on pKa, these compounds are 
excluded from the regression analysis. The most 
significant results when the log l/ED30(p) data is used 
are shown below.
Taking 2 variables at a time (n = 20):
log 1/ED30(p ) = 0.130 EPar - 0.0004 EPar2 - 10.01
r = 0.743 s = 0.676 F = 10.47 (4.1)
log 1/ED30(p ) = 0.773 logP'2 + 75.46 EE(b ) - 37.13
r = 0.773 s = 0.641 F = 12.63 (4.2)
Taking 3 variables at a time (n=20):
log 1/ED30(p ) = -2.120 EEs - 0.0002 EPar2 - 14.18 
Cg C13(p) ~ 25.78
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r = 0.907 s = 0.439 F = 24.69 (4.3)
Taking 4 variables at a time (n=20):
log 1/ED30(p ) = 0.140 EPar - 0.0005 EParZ - 74.57
Cg Ci3 (p) - 1.07 Es6 - 23.44
r = 0.950 s = 0.335 F = 34.70 (4.4)
log l/ED30(p) = -2.346 EEs - 0.0002 EParZ - 136.0 
Cg Cx3 (p ) + 0.651 Es4 - 24.29
r = 0.944 s = 0.353 F = 31.02 (4.5)
log 1/ED30( p ) = 0.144 EPar - 0.0005 EParZ - 0.028 pKaZ -
1.11 Es6 - 1.114
r = 0.944 s = 0.355 F = 30.60 (4.6)
Taking the log l/ED30(c) data, the following significant 
re 1ationships were found.
Taking 2 variables at a time (n = 20):
log 1/ED30(c ) = 0.113 EPar - 0.0004 EPar* - 7.145
r = 0.761 s = 0.594 F = 11.73 (4.7)
log 1/ED30(c ) = - 1.414 EEs - 0.0001 EParZ + 1.009 
r = 0.795 s = 0.556 F = 14.58 (4.8)
log 1/ED30(c ) = 6.493 EE(b ) + 0.373 logP' - 31.79
r =0.735 s = 0.621 F = 10.02 (4.9)
log 1/ED30(c ) = 59.90 EE(b ) + 0.010 EPar -31.10
r = 0.741 s = 0.615 F = 10.32 (4.10)
log 1 /ED30 (c ) = 48.73 EE (b ) + 0.642 E ti - 24.61
r = 0.758 s = 0.597 F = 11.48 (4.12)
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log 1/ED30(c ) = 52.26 EE(b) - 0.381 EEs - 26.45
r = 0.765 s = 0.599 F = 12.75 (4.13)
log 1/ED30(c ) = 79.28 EE(b ) + 0.350 logP'z - 39.18
r = 0.779 s = 0.574 F = 13.19 (4.14)
log 1/ED30(c ) = 33.46 EE(b ) - 43.68 EE(p) + 0.100
r = 0.739 s = 0.617 F = 10.23 (4.15)
log 1/ED30(c ) = 43.43 EE(b ) - 1.385 Es2 - 22.57
r = 0.810 s = 0.543 F = 15.95 (4.16)
Taking 3 variables at a time (n = 20):
log 1/ED30(c ) = 0.096 EPar - 0.0003 EParZ + 43.87 EE(b )
- 28.95
r = 0.902 s = 0.407 F = 23.36 (4.17)
log 1/ED30(c ) = 0.471 logP' + 72.57 EE (b ) - 1.565 Es2 -
37.22
r = 0.889 s = 0.433 F = 23.36 (4.18)
log 1/ED30(c ) = 0.122 EPar - 0.0005 EParZ - 1.191 Es6 -
7.276
r = 0.920 s = 0.370 F = 29.45 (4.19)
Taking 4 variables at a time (n = 20):
log 1/ED30(c ) = 0.108 EPar - 0.0004 EParZ + 28.30 EE (b )
-0.889 Es2 - 21.31 
r = 0.961 s = 0.270 F = 45.26 (4.20)
log 1/ED30(c ) = 0.120 EPar - 0.0004 EParZ - 7.32
CgHM^ - 1.293 Es2 - 9.413 
r = 0.945 s = 0.318 F = 31.54 (4.21)
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log l/ED30(c) = 0.115 EPar - 0.0004 EParZ + 9.23
E LUMO(B) - 0.987 Es2 - 9.404 
r = 0.948 s = 0.310 F = 33.29 (4.22)
log 1/ED30(c ) = 0.117 EPar - 0.0004 EParZ 8.99
E LUMOph(p) - 1.02 Es2 - 7.736 
r = 0.944 s = 0.322 F = 30.67 (4.23)
log 1/ED30(c ) = 0.119 EPar - 0.0004 EParZ + 25.1
E LUM0(p) - 1.01 Es2 - 5.556 
r = 0.944 s = 0.323 F = 30.47 (4.24)
In both cases it can be seen that the value of the 
parachor appears to be significant in determining 
central a-activity, as does the steric value of the 
ortho-substituent. For the experimental data corrected 
for concentration at the rat brain, the difference in 
energy between the HOMO and LUMO of the neutral species 
(EE(b)) is important, as are the energies of the LUMO's 
of the neutral and protonated derivatives.
Although the results are very significant, they give 
very little indication of how clonidine-1ike 
imidazolidines might interact with the central a- 
receptor. The fact that high EE(b) values favour high 
activity has been suggested by Timmermans [85] to mean 
that intra-molecular electron promotion to an exited 
state reduces activity. Activity also seems to be 
favoured by a high LUMO value implying that a charge 
transfer interaction, whereby an electron is donated to 
the drug, leads to reduced activity.
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The significance of EPar and EParZ implies an optimum 
value of the parachor and, since the surface tension 
data of the series might be expected to be similar, this 
suggests that there is an optimum size for the molecule 
which best fits to the receptor. The ortho- steric 
parameter has a negative coefficient, which implies that 
there is a size restriction around the ortho-position of 
the phenyl ring.
To try and improve the significance of the logl/ED30(p) 
data, that is the experimental activity corrected for 
the percentage of each drug which is in the protonated 
form, it was decided to calculate the un-corrected 
values from the data given by Timmermans [85], and also 
calculate the logl/ED30 values corrected for the amount 
of neutral (base) form present (1ogl/ED30(b )). These 
values are given in Table 4.1. Timmermans had found that 
the correlation is improved if the experimental data is 
corrected for the amount of protonated species present, 
implying it was the protonated species which were 
active. It is the neutral forms which are most likely to 
penetrate into the lipophilic areas of the brain, hence 
it was thought that correcting the experimental data for 
the amount of base form present might improve the 
correlation.
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The un-corrected experimental data gives no highly 
significant results when 2 or 3 variables at a time are 
taken. The most significant results for 4 variables at a 
time are (n = 2 0 ):
1og1/ED30 = 0.120 EPar - 0.0003 EParZ + 76.73 EE ( b )
0.862 pKa - 40.72 
r = 0.944 s = 0.359 F = 30.72 (4.25)
1og1/ED30 = 0.119 EPar - 0.0003 EParZ + 74.92 EE(b ) +
1.295 domp _ 48.36 
r = 0.945 s = 0.357 F = 31.15 (4.26)
When the regression was performed on the experimental 
data corrected for the amount of neutral form present, 
very many more significant correlations resulted. Taking 
3 variables at a time (n = 20):
1ogl/ED30(b) = -1.581 EEs-0.0001 EParZ+38.71 EE(b)-18.51 
r = 0.922 s = 0.456 F = 30.24 (4.27)
1og1/ED30(b ) = -2.084 EEs-0.319 EEsZ+77.14 EE(b)-39.73 
r = 0.927 s = 0.424 F = 35.27 (4.28)
1og1/ED30(b ) = -2.133 EEs-0.0002 EParZ-3.074 ER+1.792 
r = 0.935 s = 0.417 F = 37.27 (4.29)
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1og1/ED30(b ) = 0.115 EPar-0.0003 EParZ+69.57 EE(b)-42.99 
r = 0.941 s = 0.400 F = 40.99 (4.30)
And with 4 variables (n = 20):
1og1/ED30(b ) = 0.126 EPar - 0.0004 EParZ + 55.54 E E (b )
- 0.773 Es6 - 36.10 
r = 0.971 s = 0.293 F = 60.83 (4.31)
1og1/ED30(b ) = 0.137 EPar - 0.0005 EParZ
+ 21.91 E LUMO(b) - 0.913 Es6 - 13.60
r =0.970 s = 0.300 F = 58.03 (4.32)
1og1/ED30(b ) = - 2.42 EEs - 0.0003 EParZ - 3.104 ER
+ 50.29 Es4 + 1.547 
r = 0.966 s = 0.130 F = 52.91 (4.33)
1og1/ED30(b ) = 0.076 EPar - 0.0003 EParZ - 0.847 EEs
+ 50.29 EE(b ) - 30.25 
r = 0.963 s = 0.326 F = 48.61 (4.34)
1og1/ED30(b ) = 0.115 EPar - 0.0004 EParZ + 13.78 EEsZ 
+ 50.04 EE(b ) - 32.41 
r = 0.963 s = 0.328 F = 47.90 (4.35)
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1og1/ED30(b ) = 0.116 EPar - 0.0003 EParZ + 86.28 E E (b )
+ 2.476 ER - 51.91 
r = 0.963 s = 0.329 F = 47.48 (4.36)
1og1/ED30(b ) = 0.139 EPar - 0.0005 EParZ
+ 28.36 E LUMOph(b) - 1.172 Es2 - 32.41 
r = 0.963 s = 0.330 F = 47.28 (4.37)
log1/ED30(b ) = 2.440 EEs - 0.354 EEsZ + 78.44 E E (b )
• + 1.823 ER - 40.46
r = 0.957 s = 0.355 F = 40.32 (4.38)
logl/ED30(b) = -2.508 EEs - 0.266 EEsZ - 0.0001 EParz
+ 50.76 EE(b) - 25.65 
r = 0.959 s = 0.345 F = 42.87 (4.39)
1og1/ED30(b ) = -2.00 EEs - 0.0002 EParZ - 3.120 ER
+ 0.672 Es4 + 1.527 
r = 0.966 s = 0.131 F = 52.91 (4.40)
The significant factors affecting activity are again the 
parachor, the ortho- steric parameter, the energies of
the LUMO and the difference in energy between the HOMO
and LUMO of the neutral species.
The fact that correcting the experimental activities for
the amount of neutral species leads to improved
correlations may suggest that the protonated form may
not be able to penetrate into the brain. At the
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receptor, however, it may be that it is the protonated 
form which binds, hence the experimental data is 
corrected for both the percentage of base and percentage 
of protonated present (1og1/ED30(pb) and this data is 
also shown in Table 4.1.
Using this data in regression analyses, and using the 
same variables as before, does not give as good results 
as the case when the experimental data is corrected for 
the percentage of neutral species only. The most
significant results when 4 variables are taken each time 
are shown below (n = 2 0 ):
1og1/ED30(pb) = 0.725 EPar - 0.0025 EParZ + 1.835 pKa 
- 5.929 Es6 - 59.29 
r = 0.956 s = 1.699 F = 39.96 (.4.41)
1og1/ED30(pb) = 0.427 EPar - 0.0020 EParZ + 5.945 EEs
- 4.910 Es6 - 20.06
r = 0.966 s = 1.501 F = 5.27 (4.42)
1og1/ED30(pb) = 0.687 EPar - 0.0027 EParZ + 0.954 EEs
- 4.964 Es6 - 36.10
r = 0.966 s = 1.504 F = 52.03 (4.43)
1ogl/ED30(pb) = 0.698 EPar - 0.0023 EParZ
+ 84.68 E LUM0(b) - 5.319 Es6 - 61.95 
r = 0.962 s = 1.572 F = 47.28 (4.44)
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log 1/ED30(pb) = 0.730 EPar - 0.0025 EParZ
+ 242.9 E LUMO(p) - 5.430 Es6 - 28.82 
r = 0.958 s = 1.649 F =42.65 (4.45)
1og1/ED30(pb) = 0.706 EPar - 0.0024 EParZ
+ 87.92 E LUMOph(p) - 5.486 Es6 - 46.98 
r = 0.961 s = 1.607 F = 45.11 (4.46)
1og1/ED30(pb) = 0.661 EPar - 0.0021 EParZ + 203.2 EE (b )
- 4.803 Es6 - 143.22 
r = 0.957 s = 1.689 F = 40.48 (4.47)
1og1/ED30(pb) = - 14.96 EEs - 1.412 EEsZ - 0.0009 EParZ
4.692 Es6 + 6.647 
r = 0.958 s = 1.659 F =.42.05 (4.48)
As can be seen, the best results are obtained when the 
parachor and Es6 are used in conjunction with the energy 
of a LUMO or the E E (b ) value. The coefficients of the 
LUMO energies are positive, suggesting that high 
activity is reduced by the possibility of charge- 
transfer to the drug.
As the object of the exercise is to find a molecular 
orbital index which correlates with activity, regression 
analyses were performed using molecular orbital results 
calculated by some other methods as well as the ST0-3G 
procedure.
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The PPP n-electron molecular orbital results of 
Timmermans [83] were used to give values of the energy 
of the HOMO and LUMO, and the n-electron density of Ci3 
of the protonated species. As before, the HOMO and LUMO 
energies of the neutral and protonated species 
calculated by ST0-3G were included as well as the energy 
of the LUMO distributed over the phenyl ring of the 
protonated species and the charges of C X3 and HN 7 of the 
protonated derivatives. The INDO method was used to 
calculate the same indices that were caleu1ated by STO— 
3G as well as the charges on Cx3r. and Hm-t- of the neutral 
species.
Non molecular orbital indices used are EPar, EEs, pKa 
and the squares of these values, ER, Es2, Es4 and Es6 , 
and as before, the two members of the series containing 
fluorine were excluded form the regression analysis. The 
results giving F values of greater than 30 when 3 
variables were used and F values greater than 40 with 4 
variables are shown below:
Using the experimental results un-corrected for 
ionisation results in no correlations being above this 
significance level. Correcting for 7.
protonation gives the following results for 4 variables 
(n = 2 0 ).
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1og1/ED30(p) = 0.146 EPar - 0.0005 EPar2 - 109.1
PPP tiC x 3 ( p ) + 45.63 INDO CgCX3.(p) + 69.09 
r = 0.957 s = 0.313 F = 40.45 (4.49)
1og1/ED30(p ) 
r
1og1/ED30(p ) 
PPP
r
1og1/ED30(p ) 
r
logl/ED30(p ) 
r
1og1/ED30(p ) 
r
logl/ED30(p)
= 0.143 EPar - 0.0005 EPar2 - 113.5
PPPttCX3 ( p ) + 23.48 INDO CgCX3 ( b ) +86 . 27
= 0.959 s = 0.306 F = 42.63 (4.50)
= 0.146 EPar - 0.0005 EPar2 - 112.7
TrCi3(p) + 20.86 ST0-3G Cg C13(b) +
93.09
= 0.957 s = 0.312 F = 40.76 (4.51) .
= 0.135 EPar - 0.0005 EPar2 - 1.037 Es6 +
70.23 INDO Cg C 1 3 (p) ~ 45.50 
; 0.961 s = 0.298 F = 44.98 (4.52)
= 0 . 1 3 2  EPar - 0.0005 EPar2 - 1.127 Es6 +
43.03 INDO Cg HM7 (p ) - 16.44 
0.962 s = 0.293 F = 46.56 (4.53)
= 0.131 EPar - 0.0005 EPar2 - 1.194 Es6 +
36.90 INDO Cg.C1 3 (b) - 25.67 
0.965 s = 0.282 F = 50.55 (4.54)
= 0.136 EPar - 0.0005 EPar2 - 1.051 Es6 +
32.09 INDO Cg HNi^(b) - 13.68
0.957 s = 0.311 F = 41.23 (4.55)
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The experimental data corrected for the amount of
neutra1 species gave the most significant correlations, 
which are shown below:
Taking 3 variables at a time (n = 20):-
1og 1/ED30(b ) = 0.121 EPar - 0.0004 EPar2 - 68.53
PPP tiCX3 ( p ) - 76.29 
r = 0.932 s = 0.429 F = 35.01 (4.56)
log 1/ED30(b ) = - 1.656 EEs - 0.0001 EPar2 + 0.915
PPP E LUM0(b) - 0.098 
r = 0.929 s = 0.436 F = 33.71 (4.57)
log 1/ED30(b ) = - 1.738 EEs - 0.0001 EPar2 + 2.777
PPP E LUM0(p) + 13.14 
r = 0.923 s =0.454 F = 30.55 (4.58)
log 1/ED30(b ) = - 2.133 EEs - 0.0002 EPar2 - 3.074 SR +
1.792
r = 0.935 s = 0.417 F = 37.27 (4.59)
Taking 4 variables at a time (n = 20):- 
1og 1/ED30(b ) = 0.141 EPar - 0.0005 EPar2 - 69.89
PPP nCX3 (p ) + 29.67 ST0-3G E LUMO(b ) + 75.33 
r = 0.971 s = 0.289 F = 62.74 (4.60)
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log 1/ED30(b) = 0.144 EPar - 0.0005 EPar2 - 102.6
PPP nCx3 (p) + 31.09 ST0-3G E LUMOph(p) + 85.94 
r = 0.962 s = 0.325 F = 48.92 (4.61)
1og1/ED30(p ) = 0.139 EPar - 0.0005 EPar2 - 35.43
PPP E LUMO(b ) + 36.42 ST0-3G E LUMO(b) - 40.74 
r = 0.962 s = 0.331 F = 47.07 (4.62)
log 1/ED30(b ) = 0.131 EPar - 0.0005 EPar2 - 0.742 Es6 +
36.47 PPP ttCX:t. ( p ) “ 61.68 
r = 0.953 s = 0.350 F = 41.62 (4.63)
log 1/ED30(b ) = 0.137 EPar - 0.0005 EPar2 - 0.943 Es6 +
21.91 ST0-3G E LUMO(b ) - 13.60 
r = 0.969 s = 0.300 F = 58.04 (4.64)
log 1/ED30(b ) = 0.139 EPar - 0.0005 EPar2 - 0.996 Es6 +
22.22 ST0-3G E LUMOph(p) - 9.707 
r = 0.963 s = 0.330 F = 47.28 (4.65)
log 1/ED30(b ) = - 2.420 EEs - 0.0002 EPar2 + 0.672 Es4 -
3.097 ER + 1.548 
r = 0.966 s = 0.313 F = 52.91 (4.66)
When the experimental results are corrected for both the
amount of base and protonated, the following highly
significant results are obtained:
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Tak ing 4 variables at a time (n = 20) :
logl/ED30(pb) 
PPP 
r =
logl/ED30(pb) 
PPP TIC
r =
1og1/ED30(pb) 
r =
1og1/ED30(pb) 
r =
1og1/ED30(pb) = 
r =
1og1/ED30(pb)
= 0.719 SPar - 0.002 EPar2 - 532.3
nCj.3 (p ) + 128.2 ST0-3G E LUMO(b) + 426.5 
0.962 s = 1.583 F = 46.57 (4.67)
= 0.732 EPar - 0.0024 EPar2 - 595.5
x3 (p ) + 136.4 ST0-3G E LUMOph(p) + 474.4
0.960 s = 1.607 F = 45.08 (4.68)
= 0.725 EPar - 0.0025 EPar2 - 5.893 Es6 + 
1.835 pKa - 59.29 
0.956 s = 1.699 F = 39.95 (4.69)
= 0.427 EPar - 0.0020 EPar2 - 4.910 Es6 - 
5.945 EEs - 20.08 
0.966 s = 1.500 F = 52.27 (4.70)
= 0.688 EPar - 0.0027 EPar2 - 4.954 Es6 + 
0.964 pKa2 - 36.10 
0.965 s = 1.504 F = 52.03 (4.71)
=0.672 EPar - 0.0023 EPar2 - 4.489 Es6 +
211.8 PPP tiCX3 ( b ) - 251.95
0.957 s = 1.675 F = 41.17 (4.72)
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1og1/ED30(pb) =0 . 6 9 8  EPar - 0.0023 EParZ - 5.319 Es6 +
84.68 ST0-3G E LUMO(b ) - 61.95 
r = 0.963 s = 1.572 F = 47.28 (4.73)
1og1/ED30(pb) = 0.730 EPar - 0.0025 EParZ - 5.438 Es6 +
242.9 ST0-3G E LUMO(p ) - 28.82 
r = 0.959 s = 1.649 F = 42.64 (4.75)
1og1/ED30(pb) = 0.706 EPar - 0.0024 EParZ - 5.486 Es6 +
87.92 ST0-3G E LUMOph(p) - 46.98 
r = 0.961 s = 1.607 F = 45.11 (4.76)
The experimental data corrected for the concentration at
the rat brain give the following results with F>40 when
4 variables are used in each regression equation (n =
2 0 ) :
1og1/ED30(c ) = 0.120 EPar - 0.0004 EParZ - 105.3
PPP T1C13 (p ) + 17.47 ST0-3G E LUM0(b) + 87.26 
r = 0.959 s =0.278 F = 42.45 (4.77)
1og1/ED30(c ) = 0.107 EPar - 0.0004 EParZ - 0.930 Es6 +
0.629 PPP E LUM0(b) - 74.74 
r = 0.958 s = 0.279 F = 42.11 (4.78)
1ogl/ED30(c ) = 0 . 1 0 9  EPar - 0.0004 EParZ - 0.983 Es6 -
0.983 PPP E LUM0(p) + 1.837 
r = 0.957 s = 0.282 F = 41.26 (4.79)
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Nearly all the significant regression equation include 
EPar and EPar2 which suggests an optimum value of the 
parachor is very important in determining the activity 
at the a-receptor. The n-electron density calculated by 
the PPP method features in many instances, with a 
negative coefficient which suggests that the lower the
electron density, i.e. the greater the positive charge,
the higher the activity. This further supports the idea 
of an ionic interaction between the imidazole ring and a 
negatively charged region of the receptor. The C i4 and 
Nj.^ . n-electron densities calculated by the INDO method 
were subsequently introduced into the regression 
analysis, but give less significant results than those 
obtained from the PPP n-electron densities.
The fact that Es6 , the steric parameter for the
'smaller' ortho- position appears in many of the
significant regression equations, with a negative 
coefficient, again suggests that there may be a size 
restriction in the binding site of the a-receptor.
The regression analyses using the experimental data 
corrected for the amount of protonated species show that 
the charges on C1 3 , l-Vix* and HM -7 are important in 
determining activity, and the positive regression 
coefficients of these values again suggest an ionic 
interaction with the receptor. The experimental results
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corrected for the amount of un-ionised species show that 
the energy of the LUMO is important in determining 
activity. This is also shown by the results obtained by 
correcting for both the amounts of base and protonated 
species. The fact that the energy of the LUMO has a 
positive coefficient suggests that species which are 
favourable electron acceptors in a charge transfer 
interaction are less active.
4.3 FURTHER REGRESSION ANALYSES
Correcting the experimental data for the amount of 
neutral species improves the correlation of calculated 
parameters with activity, hence it was decided to
investigate whether taking the data corrected for the 
concert tra t ion at the rat-brain ( 1 ogl/ED30 (c ) ) and 
correcting this for the percentage of neutral species
would have any effect on the significance of the
correlation equations. For the sake of completeness this 
data is also corrected for the amount of protonated 
species and also for amounts of both neutral and 
protonated species. This data is shown in Table 4.1.
The regression analyses using the experimental data 
corrected for the amount of protonated species at the 
rat brain give no highly significant results. In
contrast the data corrected for the percentage of 
neutral species reaching the rat brain give some very 
significant results, which are shown below:
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Taking 3 variables at time (n = 20):
1ogl/ED30(cb)
r =
logl/ED30(cb)
r =
logl/ED30(cb)
r =
logl/ED30(cb)
r =
logl/ED30(cb)
r =
logl/ED30(cb)
= 0.079 EPar - 0.0003 EPar2 + 117.9
PPP tiC x.3 ( p ) - 121.8 
0.967 s = 0.398 F = 79.21 (4.80)
= - 0.1221 EEs - 0.0001 EPar2 + 85.53 
PPP ti C x  3  ( p ) -  83.32 
0.963 s = 0.467 F = 56.15 (4.81)
= 0.090 EPar - 0.0003 EPar2 + 47.83 
ST0-3G E LUMO(b) - 16.11 
0.956 s = 0.467 F = 56.15 (4.82)
= -1.45 EEs - 0.0001 EPar2 + 32.56 
ST0-3G E LUMO(b) - 5.54 
0.962 s = 0.434 F = 65.85 (4.83)
: 0.107 EPar - 0.0004 EPar2 + 141.0 
ST0-3G E LUMO(p) + 45.62 
0.951 s =0.490 F = 50.36 (4.84)
0.093 EPar - 0.0003 EPar2 +50.72 
ST0-3G E LUMQph(p) -7.100 
0.955 s = 0.472 F = 54.71 (4.85)
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1og1/ED30(cb) = - 1.471 EEs - 0.0001 EPar2 + 33.87
ST0-3G E LUMOph(p) + 40.28 
r = 0.957 s = 0.457 F = 58.66 (4.86)
Taking 4 variables at a time (n = 20):
log1/ED30(cb) = 0.118 EPar - 0.0004 EPar2 + 1.204 pKa -
115.4 PPP tiCx.3 ( p ) + 9 1 . 8 8  
r = 0.979 s = 0.331 F = 87.81 (4.87)
log1/ED30(cb) = 0.121 EPar - 0.0004 EPar2 + 0.066 pKa2 -
112.5 PPP TtCx3 (p ) + 94.34 
r = 0.978 s = 0.342 F = 81.82 (4.88)
logl/ED30(cb) = 0.122 EPar - 0.004 EPar2 - 116.0
PPP ttCx.3 (p ) + 80.27 ST0-3G E LUMO(b) + 124.8 
r = 0.979 s = 0.336 F = 86.30 (4.89)
1og1/ED30(cb) = 0.101 EPar - 0.0003 EPar2 - 79.51
PPP tiCx3 (p ) + 49.61 STD-3G E LUM0(p) + 57.85 
r = 0.975 s = 0.367 F = 70.74 (4.90)
1og1/ED30(cb) = 0.106 EPar - 0.0004 EPar2 - 90.62
PPP T1C13 (p ) + 53.36 ST0-3G E LUMOph(p) + 76.93 
r = 0.978 s = 0.335 F = 85.44 (4.91)
log1/ED30(cb) = 0.111 EPar - 0.0004 EPar2 + 0.982 pKa -
1.111 Es6 - 14.19 
r = 0.981 s = 0.317 F = 95.90 (4.92)
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1og1/ED30(cb) = 0.114 EPar - 0.0004 EPar2 + pKa2 - 1.097
Es6 - 9.91
r = 0.980 s = 0.326 F = 90.82 (4.93)
1og1/ED30(cb) = 0.080 EPar - 0.0003 EPar2 + 50.13
PPP tiCx3 ( p ) - 5.837 Es6 - 474.5 
r = 0.977 s = 0.352 F = 77.43 (4.94)
1og1/ED30(cb) = 0.0114 EPar - 0.0004 EPar2 + 65.45
ST0-3G E HOMO(b ) - 1.130 Es6 + 12.21 
r = 0.981 s = 0.314 F = 97.95 (4.95)
1og1/ED30(cb) = 0.099 EPar - 0.0003 EPar2 + 42.70
ST0-3G E LUM0(b) - 0.864 Es6 - 15.01 
r =0.978 s = 0.340 F = 82.85 (4.96)
logl/ED30(cb) = 0.102 EPar - 0.0004 EPar2 + 45.25
ST0-3G E LUMOph(p) - 0.930 Es6 - 7.510 
r = 0.981 s = 0.317 F = 96.24 (4.97)
1og1/ED30(cb) = 0.115 EPar - 0.0004 EPar2 + 125.6
ST0-3G E LUMO(p) - 0.902 Es6 + 3.418 
r = 0.975 s = 0.358 F = 74.37 (4.98)
As can be seen, the parachor, the LUMO energy and the 
ortho- steric parameter give extremely significant
results when the experimental data is corrected this
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way. Correcting the logl/ED30(c) values for both the 
amount of neutral and protonated species gives results 
which are not as significant as when the data is 
corrected for the amount of base only. These results are 
given below:
Taking 3 variables at a time (n = 20):
1og1/ED30(cbp) = 0.074 EPar - 0.0003 EPar2 + 106.2
PPP nCx3 (p) “ 109.6 
r = 0.953 s = 0.438 F = 52.78 (4.99)
log1/ED30(cbp) = - 1.230 EEs - 0.0001 EPar2 + 72.98
PPP TTC13 ( p ) - 70.72 
r = 0.953 s = 0.434 F = 53.85 (4.100)
Taking 4 variables at a time (n = 20):
1og1/ED30(cbp) = 0.111 EPar - 0.0004 EPar2 + 1.096 pKa -
116.6 PPP T1C13 ( p ) + 94.54 
r = 0.973 s = 0.340 F = 68.52 (4.101)
1og1/ED30(cbp) = 0.113 EPar - 0.0004 EPar2 + 0.060 pKa
114.1 PPP irCi3 ( p ) +97.22 
r = 0.977 s = 0.321 F = 76.99 (4.102)
1og1/ED30(cbp) = 0.114 EPar - 0.0004 EPar2 - 117.0
PPP tiCx3 (p ) + 72.89 ST0-3G E H0M0(b) + 124.3 
r = 0.972 s = 0.352 F = 63.59 (4.103)
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logl/ED30(cbp) = 0.103 EPar - 0.0004 EPar2 + 0.872 pKa -
1.120 Es6 - 12.62 
r =0.975 s = 0.329 F = 73.19 (4.104)
1og1/ED30(cbp) = 0.106 EPar - 0.0004 EPar2 + 0.048 pKa}
- 1.100 Es6 - 8.856 
r = 0.978 s = 0.312 F = 81.44 (4.105)
1og1/ED30(cbp) = 0.106 EPar - 0.0004 EPar2 + 57.97
ST0-3G E H0M0(b) - 1.136 Es6 + 10.78 
r= 0.975 s = 0.333 F = 71.33 (4.106)
log 1/ED30(cbp) = 0.102 EPar - 0.0004 SPar2 + 111.7
ST0-3G E LUM0(p) - 1.282 Es6 - 3.033 
r = 0.971 s = 0.357 F = 61.83 (4.107)
1og1/ED30(cbp) = 0.112 EPar - 0.0004 SPar2 + 122.1
ST0-3G Cg C13(p ) - 1.201 Es6 + 17.24 
r = 0.970 s = 0.389 F = 61.13 (4.108)
Again, the parachor and the ortho- steric parameter are 
found to be very important in determining activity. The 
fact that pKa and E HOMO(b ) are very closely related to 
each other, shown earlier in this chapter, makes it 
difficult to determine whether it is high pKa, and 
therefore a greater percentage of protonated species, or 
high E HOMO, favouring a charge transfer interaction, 
which is important. The electron density/charge on C13
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is also found to be significant, suggesting that an 
ionic interaction may be important, and therefore high 
pKa rather that high E HOMO is the significant 
parameter. The fact that the results are much more 
significant when the activity is corrected for the 
amount of un-protonated species present, may suggest 
that it is the neutral form which interacts with the 
receptor.
To determine which of these parameters might be the most 
important in determining activity, each variable was 
taken singly and correlated with the data corrected for 
the amount of neutral species reaching the rat brain. 
The most significant results are shown below (n = 20):
1og1/ED30(cb) = 1.189 pKa - 0.872
r = 0.863 s = 0.754 F = 52.58 (4.109)
1ogl/ED30(cb) = 48.13 ST0-3G E LUM0(b) - 9.195 
r = 0.898 s = 0.659 F = 74.56 (4.110)
1og1/ED30(cb) = 99.67 ST0-3G E H0M0(p) + 46.36 
r = 0.886 s =0.691 F = 66.03 (4.111)
1og1/ED30(cb) = 150.3 ST0-3G E LUM0(p) + 12.94 
r = 0.865 s = 0.749 F = 53.51 (4.112)
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logl/ED30(cb) = 53.83 ST0-3G E LUMOph(p) - 1.018 
r = 0.894 s = 0.668 F = 71.76 (4.113)
The significance of these equations is not further 
improved by correcting the experimental data for the 
percentage of protonated species as well, hence the 
energies of the LUMO(b) and LUMOph(p) were thought to be 
the most significant in determining activity. The 
MINITAB package was used to investigate whether it is 
possible to improve the correlation of activity with 
ST0-3G E LUMO(b) and ST0-3G E LUMOph(p) by omitting any 
compounds if the calculated activity differed from the 
experimental activity by two standard deviations or 
more. The regression analysis proceeded as follows:
logl/ED30(cb) vs. ST0-3G E LUMO(b)
1og1/ED30(cb) = 48.13 ST0-3G E LUMO(b)
R2 = 80.67. s = 0.659 n = 20
□mit R = H and R = 2,6-di-Cl,4-OMe 
logl/ED30(cb) = 49.84 ST0-3G E LUMO(b )
R2 = 91.47. s = 0.434 n = 18
□mit R = 2,6-di-Me
logl/ED30(cb) = 47.11 ST0-3G E LUM0(b) - 8.854 
R2 = 93.47. s = 0.355 n = 17 (4.116)
- 9.195
(4.114)
- 9.438
(4.115)
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Omit R = 2,5-di-Cl
1og1/ED30(cb) = 46.29 ST0-3G E LUMO(b) - 8.618
R 2  =  94.9'/. s = 0.313 n = 16 (4.117)
1ogl/ED30(cb) vs. ST0-3G E LUMOph(p )
logl/ED30(cb) = 53.83 ST0-3G E LUMOph(p) - 1.018
R2 = 79.9’/. s = 0.669 n = 20 (4.118)
Omit R = H and R = 2,6-di-Cl.4-OMe
logl/ED30(cb) = 54.70 ST0-3GE LUMOph(p) - 0.917
R2 = 89.27. s = 0.488 n = IB (4.119)
Hence it is found that if the concentration of 
clonidine-like imidazolidines injected intravenous1y to 
a rat was corrected for the amount of neutral species 
reaching the brain, then the activity of the compound 
could be determined by a single variable, the energy of 
the LUMO of the neutral species,thus it is possible to 
explain nearly 95 percent of the variance in calculated 
activity in this way.
The fact that the energy of the LUMO has . a positive 
regression co-efficient, i.e. the higher the LUMO the 
higher the activity, suggests that charge transfer to 
the drug results in less active compounds. This may be 
explained in two possible ways. Either the formation of 
a charge transfer complex at the a2-receptor, with the
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drug as the acceptor, blocks the a2-receptor, hence 
lessening the extent of blood pressure reduction, or 
that the al-receptor is stimulated by the formation of a 
charge transfer complex with the drug as the acceptor, 
hence increasing blood pressure. Since the experimental 
data is measured for whole animals, it is impossible 
to differentiate between these possible modes of action 
from this data.
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Table 4.2 E LUMO ( b ) sto-3 < 3 (A.U.), Log 1/ED30 ( c b )
experimental and Log1/ED30(c b ) calculated from equation
4.117.
E LUMO(b) Log1/ED30 Logl/ED30
R (ST0-3G) (cb) Expt (c b ) Ca1c
2,4,6-tri Me 0.270 3.98 3.88 0. 10
2,4-di Me 0.268 3.65 3.79 -0.14
2,6-di Me ---- ---- ----
2,6 Me, 4-C1 0.248 3.04 2.86 0. 18
2-Me 0. 266 3.40 3.69 -0.29
H ---- ---- ----
2-Me, 4-C1 0.246 3.07 2.77 0.30
2,4-Me, 6-C1 0.249 2.73 2.91 -0.18
2-C1, 4-Me 0.247 ’ 2 .78 2.82 -0.04
2-Me, 6-C1 0.247 3.28 2.82 0.36
2-C1 0.244 2.11 2.68 -0. 57
4,6-Cl, 2-Me 0.227 1.73 1.89 -0. 16
2,4-di Cl 0.224 1 .65 1 .75 -0. 10
2,6-Cl, 4-OMe ---- ---- ----
2,3-di Cl ---- ----
2,5-di Cl 0.225 2.04 1.80 0.24
2,6-Cl, 4-Me 0.227 1.58 1.89 -0.31
2,6-di F ---- ---- ----
2,6-di Cl 0.224 2.33 1 .75 0. 58
2-C1, 6-F --— ---- ----
2,4,6-tri Cl 0.207 1.05 0.96 0.09
2,6-Cl, 4-N0= 0.155 -1.61 -1.44 0.17
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4.4 CONCLUSION
The regression analyses show that there are at least 
two important factors which determine the activity of 
this series of compounds. In all cases, parameters which 
consistently give rise to significant correlations are 
the parachor and the size of the ortho- substituent. 
When the experimental data is corrected for the amount 
of protonated species, the charges on the atoms of the 
imidazolidine part of the molecule become significant, 
suggesting an ionic interaction of the positively 
charges species with the receptor. This gives some 
indication of how these compounds may bind to the 
receptor, but gives no real idea of the mechanism by 
which the receptor is activated.
The experimental data corrected for the amount of 
neutra1 spec ies g ives many more highly significant 
results, particularly if the data is also corrected for 
the concentration at the rat brain. This may imply 
either that the neutral species is more able to cross 
lipid membranes or that is the neutral species which is 
active. The important electronic parameter which 
determines activity is the energy of the LUMO, which, as 
mentioned before, has a positive regression coefficient. 
This suggests that the acceptance of charge from the 
receptor leads to a reduction in hypotensive activity,
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either by blocking the a2- receptor or stimulating the 
d r  receptor.
The fact that the correlations from the data corrected 
for protonation are not improved by correcting the 
experimental data by the relationship in logP', which 
accounts for the concentration at the rat brain, whereas 
the results from data corrected for the neutral species 
are improved by this relationship may indicate that the 
sites of action of the protonated and neutral species 
are different. The site of the proposed charge-transfer 
interaction, involving the neutral species, which 
reduces activity may be in a more hydrophobic region 
than the site of the suggested ionic interaction of the 
protonated species which leads to hypotensive activity.
When the experimental data is corrected for both the 
amount of base and protonated species, then the 
parameters which are important in determining activity 
are similar to those which are significant for the data 
corrected for the amount of base only, but the 
correlation coefficients are lower. This again may 
suggest that the base form interacts via the charge 
transfer interaction, although it would be expected that 
a positively charged species would more readily accept 
an electron.
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CHAPTER 5
MOLECULAR MODELLING OF THE (3--ADRENERGIC RECEPTOR
5.1 INTRODUCTION
Considerations of how a molecule may react with the 
adrenergic receptor [32,33,35,36,42,52,61,102,103] have 
so far been based on circumstantial evidence concerning 
the structure of the receptor. Recently, the gene and 
cDNA for the hamster lung 3=-adrenergic receptor has 
been cloned, and the amino acid sequence deduced from 
the nucleotide sequence [31]. The B^-adrenergic receptor 
is found to be very similar in sequence and
hydrophobicity profile [104,105] to rhodopsin [106,107] 
and it has been reported that the enzyme which
phosphory1 ates rhodopsin (rhodopsin kinase) is also 
capable of phosphory1 ating Ba-adrenergic receptor, and
that B=~adrenergic receptor kinase can also
phosphory1 ate rhodopsin [108]. Also the fact that both 
rhodopsin and 3^-adrenergic receptor are involved in 
signal transduction mechanisms that involve interaction 
with the guanine nucleotide regulatory proteins, 
transducin [109] and Gs [29] is strong evidence to 
suggest that rhodopsin and (32-adrenergic receptor have 
similar secondary structures.
Electron diffraction has been used to indicate that
bacterio-rhodopsin consists of seven a-helical rods 
which span the cell membrane [110-113]. The primary 
structure of ovine [114] and bovine rhodopsin [115] is 
very similar to bacterio-rhodopsin, hence it is very
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probable that rhodopsin and the P^-adrenergic receptor 
have a similar structure consisting of seven a-helices 
which traverse the cell membrane. The amino acid 
sequence of another receptor, the muscarinic acetyl 
choline receptor (mAChR) has also been recently deduced
[116,117], and is found to be homologous with the Ps- 
adrenergic receptor and rhodopsin in both sequence and 
hydrophobicity, hence it is thought that the mAChR also 
consists of seven membrane spanning a-helices. Other 
similarities between rhodopsin, B^-adrenergic receptor 
and mAChR which suggest that the three proteins evolved 
from a similar ancestor are the fact that all three
contain two possible N-g1ycosy1 ation sites near the 
amino terminal region of the molecule. These sites in 
rhodopsin are known to be glycosylated [115]. Also the 
carboxy terminal region of the three proteins contain
several serine residues which are possible sites for
phosphory1ation [108]. Phosphorylation has been shown to 
play an important role in the regulation of rhodopsin 
[115] and {3-= adrenergic receptor [118]. The postulated 
structures of rhodopsin, I3-= adrenergic receptor and 
mAChR are shown in Fig 5.1.
It has been proposed that adrenergic agents interact
with the adrenergic receptor in a similar manner to
the binding of retinal to opsin [119] in that they 
intercalate among the hydrophobic transmembrane helices 
and hence determine whether the receptor is in its 
active or inactive conformation.
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The single-letter 
amino-acid code
G Glycine 
A Alanine 
L Leucine 
P Proline 
V Valine 
I Iso-Leucine 
S Serine 
T Threonine 
D Aspartate 
N Aspartamide 
G Glutamate 
Q Glutamide 
R Arginine 
K Lysine
F Phenyl Alanine 
W Tryptophan 
H Histidine 
C Cysteine 
M Methionine
Muscarinic acetyl choline receptor
@2 ~ Ad re n e r g i c  receptor
Figure 5.1 Secondary Structure 
Representations of Rhodopsin, |3-= 
Adrenergic Receptor and Muscarinic 
Acetyl Choline Receptor. 1 5 9
Retinal is known to form a Schiff base with a lysine
-residue in helix VII of opsin [119]. There is no
analogous lysine in the same helix of the |3=-adrenergic 
receptor, but it is interesting to note that the (Bs;- 
adrenergic receptor and mAChR both have two buried 
aspartate residues, one in helix II and the other in
helix III, which have been suggested as possible
agonist binding sites [117]. It has been found that 
labelling the binding site of purified rat brain 
muscarinic receptor, with the irreversible antagonist 
propylbenzsilylcholine mustard, followed by digestion 
yields two peptides whose properties suggest that they 
are labelled on acidic residues in hydrophobic regions 
[120,121]. One of these peptides is glycosylated thus it 
is likely that it comes from the amino terminal half of 
the receptor.
The fact that a nitrogen atom which is protonated at 
physiological pH is a feature of all adrenergic agents 
implies that the mode of binding of these molecules is 
to a negatively charged region of the receptor. The
aim of the work described in this chapter is to 
investigate how molecular modelling techniques can be 
used to gain some more information about the binding of 
noradrena 1 ine to the (3=-adrenergic receptor.
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5.2 THE RECEPTOR MODEL
The COSMIC molecular modelling program [122] was used to 
investigate the interaction between noradrenaline and 
the (32-adrenergic receptor. COSMIC can be used to 
construct amino acid sequences simply by entering the
three letter code of the required residue, and the chain 
will automatically be built from a data base of amino 
acid residues. This data base contains the coordinates 
of the amino acids with the 0 and <P torsion angles both 
in the trans- configurations, hence the first step was 
to set up a new data base of the required residues in a 
'a-helix' configuration. The values of 0 and 4* used were 
-59° and -44° respectively, suggested by Blundell et. 
al. [123] for a a-helix in a hydrophobic environment.
Helices II and III were built in this way and the
regions around the aspartate residues examined for any
group which might interact with the phenyl ring of
noradrenaline. As can be seen from the structure in Fig.
5.1, the residues around the aspartate in helix II are
largely alkyl, hence unlikely to strongly interact with 
noradrena1ine. The surroundings of the aspartate in 
helix III appeared much more interesting, especially the 
tryptophan unit which is 4 residues (~1 turn) away from 
the aspartate. It is thought possible that noradrena1ine 
could bind to this region of the receptor with the
ammonium head of the molecule involved in an
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electrostatic interaction with the aspartate while the 
phe nyl ring of noradrenaline overlaps the tryptophan 
indole ring.
To model this region of the receptor, the sequence CH3- 
Trp-Thr— Ser— 11e-Asp-CONH3 was built as before, with the 
0, ¥ and w torsion angles set to -59°, -44° and 180°
respectively. The aspartate carboxyl proton was removed 
as it was assumed that noradrena1ine would interact in 
its protonated form with a negatively charged receptor. 
Partial atomic charges were calculated by Abraham's 
method [124-126], with the calculated charges on the 
aspartate carboxyl oxygen atoms being replaced by the 
average of these charges.
The orientation of the side-chains of the peptide model 
was optimised by a sequential bond search at 30° 
torsion angle increments. This process involves 
randomising the various torsion angles, then rotating 
each in turn to its minimum (molecular mechanics) energy 
position. Five cycles of this randomisation were 
performed, and inspection showed that the found minima 
were in very similar conformations, the major difference 
being in the orientation of the iso-leucine and serine 
side chains. All the minima found show the aspartate and 
tryptophan side chains to be in identical orientations.
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The minimum energy conformation from this torsion angle 
minimisation was then subjected to 100 cycles of 
molecular mechanics minimisation to give the structure 
shown in Fig. 5.2. It can be seen that the tryptophan 
indole ring and the aspartate carboxyl group are in 
suitable positions to interact with both the amino and 
phenyl groups of noradrena1ine.
5.3 A MODEL FOR THE NORADRENALINE PHENYL RING
INTERACTION
The interaction of noradrena1ine with a carboxyl unit is 
discussed in Chapter 1. The next step is to investigate 
the interaction of the phenyl ring of noradrena1ine with 
the indole ring of the tryptophan residue. Indole is a 
well known charge transfer donor [127], hence it is 
possi ble that a charge transfer interaction, with
tryptophan as the donor and noradrena1ine as the 
acceptor, is the mechanism by which noradrena1ine 
interacts with the |3E-adrenergic receptor. It was 
suggested in the previous chapter that this sort of 
interaction may be important in the interaction of 
clonidine with the cradrenergic receptor.
The X-ray crysta11ographic structure of the charge 
transfer complex between skatole (3-methyl indole) and
tri-nitro benzene has been reported [128] and is shown 
in Fig. 5.3. As can be seen the two ring systems over—  
lap, and the interplanar distance is found to be 3.3 A.
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^  * *
Figure 5.2 The Proposed f3-= Receptor Model. The Asp-Ile- 
Ser-Thr-Trp Penta-Peptide a-Helix Minimised by Molecular 
Mec hanics.
1 6  $
Figure 5.3 The X-ray Crysta11ographic Structure of the 
Skatole - 1,3, 5-Trini trobe.nzene Charge Transfer Complex.
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The HOMO of skatole, calculated by ST0-3G, is a ti- 
orbital distributed over atoms 1 to 7. The LUMO of tri- 
nitro benzene, again calculated by ST0-3G, is also a ti- 
orbital distributed over atoms 1,2,4 and 5. Similar M.O. 
distributions are found if CNDO is used to calculate the 
orbitals, which are shown for the skatole-tri-nitro 
benzene complex in Fig. 5.4. This figure shows the 
overlap between the skatole HOMO on Nx , C.t. , Cq. and Cy 
and the tri-nitro benzene LUMO.
The HOMO of tryptophan, calculated by ST0-3G, is 
distributed over the indole ring and is very similar in 
energy and distribution to the HOMO of skatole. 
Interestingly, the LUMO of protonated noradrena1ine is 
similar to tri-nitro benzene in distribution and also 
the energies of the LUMOs of these two species are 
similar (0.1475 and 0.1229 A.U. respective1y ), hence it 
is possible that tryptophan and protonated noradrena1ine 
interact in a similar way to the skatole - tri-nitro 
benzene complex. The structure of this proposed charge 
transfer complex, with the HOMO and LUMO calculated by 
CNDO, is shown in Fig. 5.5.
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Figure 5.4 The HOMO of Skatole and the LUMO of 
Trinitrobenzene, Calculated by CNDO.
Figure 5.5 The HOMO of Tryptophan and the LUMO of 
Noradrenaline, Calculated by CNDO.
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5.4 THE NORADRENALINE - RECEPTOR MODEL
Having found a possible means of interaction for the 
amino and phenyl groups of noradrena1ine, the next step 
is to see if noradrena1ine could be docked into the 
receptor model with the protonated amine head and side 
chain hydroxyl directed towards the aspartate carboxyl, 
and the phenyl ring overlapping the tryptophan indole
ring in a similar manner to the structure in Fig. 5.5.
The interplanar distance between the noradrena1ine and
indole rings was initially set at 2.14 A, which is 
closer than the distance of 3.3 A found in many charge 
transfer complexes. It was hoped that molecular 
mechanics minimisation would result in an interplanar 
distance nearer this figure. If the interplanar distance 
was initially set to 3.3 A, then it was found that the 
noradrenaline side chain was within V.D.W contact with 
the aspartate carboxyl group.
The noradrena1ine receptor model was subjected to 100
cycles of molecular mechanics minimisation. The 
resulting structure shows that the amino head and side 
chain hydroxyl of noradrena1ine were still directed at 
the aspartate group and that the indole ring of the
receptor has moved away from the noradrena1ine phenyl 
ring, so that the two rings still overlap but the 
interplanar distance between the two rings is 3.2 A 
which is very close to the 3.3 A distance found in the
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skatole - tri-nitro benzene complex. It can also be seen 
that the threonine hydroxyl group, although directed 
away from the noradrenaline unit, could come into 
hydrogen bonding distance with the noradrena1ine side 
chain hydroxyl if the threonine Ca-CB and C(3-0 bonds are 
rotated. These bonds were thus rotated so that the 
threonine hydroxy 1 hydrogen was as close as possib1e to 
the oxygen of the noradrena1ine side chain hydroxyl. The 
distance of closest approach is 2.74 A.
This structure was again minimised by 100 cycles of 
molecular mechanics minimisation to ensure that the 
threonine hydroxyl could maintain the hydrogen bond with 
noradrena1ine. This was in fact the case, the resulting 
threonine 0-H to noradrena1ine 0-H distance being 2.84 
A. This final noradrena1ine B=-adrenergic receptor model 
is shown in Fig. 5.6.
The interaction between the noradrenaline amino and side 
chain hydroxyl and the receptor carboxyl is very similar 
to the model proposed in Chapter 1 and reinforces the 
idea about the interaction of the ring-f1uorinated 
noradrena1ines discussed in that chapter. The fact that 
the threonine residue may also be involved in the 
binding of noradrenaline to the p2-adrenergic receptor 
can be used to explain why the S-form of noradrena1ine, 
with the chirality around C-? inverted, is much less 
active than R-noradrenaline. With the side chain
Page 169
g-iqur; 5^- Noradrenaline Docked into The Proposed 3 
Receptor Model
1 7 0
hydroxyl in the S-configuration it is still able to 
interact with the aspartate carboxyl group, but is too 
distant from the threonine residue to form the 
additional hydrogen bond.
A CNDO calculation was performed on the noradrena1ine-
f3s-ad renerg ic receptor model to confirm that the
molecular orbital close in energy to the HOMO and LUMO
are similar to those of the isolated noradrenaline-
tryptophan complex. The two highest lying occupied
(NHOMO and HOMO) and lowest lying unoccupied (LUMO and
NLUMO) are shown in Fig. 5.7. The HOMO of the complex is
oriented around the aspartate carboxyl group. This is
not surprising as this carboxyl group carries an overall
unit negative charge. The NHOMO and LUMO are found to be
distributed- over the noradrena1ine and tryptophan
aromatic rings and the NLUMO is found to be
predominant1y over the noradrena1ine phenyl ring. The
fact that the high lying occupied and low lying
unoccupied orbitals are found to be distributed around
the noradrenaline phenyl and tryptophan indole rings 
/
means that, from this calculation, there is very strong 
evidence for the suggested charge transfer interaction.
The molecular orbitals of interest, the NHOMO and LUMO, 
of the agonist receptor model differ from those 
calculated for the isolated noradrenaline : tryptophan
complex, where the HOMO is found on the tryptophan ring
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Fiqure 5.7a The Highest Occupied Molecular Orbitals of 
the Noradrena 1 ine - |3=-Receptor Model. The HOMO is 
coloured green/cyan and the NHOMO is coloured red/blue.
Figure 5.7b The Lowest Unoccupied Molecular Orbitals of 
the Noradrenaline - fl2-Receptor Model. The LUMO is 
coloured green/cyan and the NLUMO is coloured red/blue.
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only and the LUMO found only on the noradrena1ine phenyl 
ring. It is un-clear whether the finding that the NHOMO 
and LUMO of the naradrenalineiB^-adrenergic receptor 
model are both found on both rings means that charge 
transfer between the two rings is calculated as having 
taken place. Further investigation into why the receptor 
model seems to cause these orbitals to be distributed 
over both rings would be very interesting.
5.5 CONCLUSION
The results from Chapter 1 provide an insight into how 
the ammonium head of noradrena1ine may interact with the 
adrenergic receptor; the results from Chapter 4 show how 
the phenyl ring of adrenergic agonists may interact.
This information, combined with the amino- acid sequence 
of the p2_receptor and the similarity of the (3=-receptor 
to other receptors, enabled a detailed study of the 
interaction of noradrenaline with the fl^-adrenergic 
receptor to be carried out. A possible binding site 
identified using this information, and molecular 
modelling techniques were successfully used to show that 
noradrenaline would fit this site. The results of CNDO 
calculations on the noradrenaline-receptor model complex 
indicate that an interaction involving high lying
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occupied and low lying unoccupied orbitals may indeed be 
the mechanism by which the phenyl ring of noradrena1ine 
interacts.
The 'extra' hydrogen bond between the receptor model 
threonine residue and the noradrena1ine side-chain 
hydroxyl was not expected from initial investigations of 
the model, but proved to be a useful explanation of why 
chirality is very important amongst adrenergic agents.
Since this work was completed, the sequences of several 
other adrenergic and muscarinic receptors have been 
reported. These include the human platelet ct2-adrenergic 
[129], the human (3*- [130] and (3=- [131-133] and the 
turkey erythrocyte (3- adrenergic [134], the pig brain 
mx~ [135] and pig heart m=- muscarinic [136] and the 
rat mi-, n)3- and rru- muscarinic receptors [137]. All 
these receptors are similar to the (3=- adrenergic 
receptor in sequence and hydrophobicity profile and it 
is suggested that they all possess a similar structure 
to rhodopsin and the (3=- adrenergic receptor. If the 
sequences of these proteins are aligned to give the best 
residue match, then all show an aspartate residue on the 
"outside" end of helix 3, i.e. the proposed binding site 
of the (3:2- adrenergic receptor. The muscarinic and (3- 
adrenergic receptors also conserve the tryptophan 
residue 4 units from this aspartate group, whereas in 
the adrenergic receptor there is a tyrosine residue
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in this position. Thus an important difference between 
a^- and (3- adrenergic agents may be the difference in 
their interaction with tyrosine and tryptophan.
Further evidence of the importance of the aspartate
residue proposed as part of the binding site in this
study comes from oligonucleotide-directed mutagenesis of 
the (3= adrenergic receptor [138]. If this aspartate is 
replaced by asparigine, the receptor is processed 
normally, but shows no affinity towards the antagonist 
iodocyanopindo1o 1. The lack of a suitable radio-1abe1ed 
agonist prevented the agonist binding properties of this 
mutant to be studied. If the aspartate residue in helix 
2 or the asparigine residue in helix 7 is replaced by 
alanine and lysine respectively, then the binding of 
iodocyanopindolol is similar to the native f3=- 
adrenergic receptor, as is the displacement of this
antagonist by the the antagonists propanalol and
alprenalol. The displacement of iodocyanopindolol by the 
agonists isoproterenol and adrenaline is reduced by a 
factor of ten with these two mutant receptors, 
suggesting that agon ists may also bind to other reg ions 
of the receptor.
The sequence of‘a further type of receptor, the bovine 
substance K receptor, has also been recently reported 
[139], and it is suggested that this receptor may also 
be similar in structure to the rhodopsin, adrenergic and
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muscarinic receptors. A human gene sequence has been 
found which is predicted to express itself as a similar 
structure [140] to the rhodopsin types, but the 
associated protein has not been identified. This leads 
to the conclusion that the adrenergic receptors may be 
part of a much larger family of similar receptor 
proteins [141].
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APPENDIX 1
MOLECULAR MECHANICS
Al.l MOLECULAR MECHANICS
Molecular mechanics is a method of calculating molecular 
structures and energies, based on empirically derived 
equations. The method assumes that bonds have "natural" 
lengths and angles to which a molecule will adjust its 
geometry, and any deviations from these 'strain free' 
values can be accounted for in terms of energy. The 
equations used to describe the molecule's potential 
energy surface are derived from classical mechanics and 
require a set of parameters, often known as a "force- 
field", which are adjusted to obtain the best fit of 
calculated and experimental observations such as 
geometries, conformational energies, heats of formation 
etc. [142]. Molecular mechanics can, for example, be 
used to investigate the rotation around a • bond by 
calculating the molecule's energy over a series of 
torsion angle steps, and subsequently to calculate the 
preferred conformation of a molecule by using a geometry 
optimising procedure. Although the method is limited to 
giving only structures and energies, it has the 
advantage over S.C.F. molecular orbital methods by 
being very much faster.
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The steric energy is calculated as the following sum of 
terms:
Vs = Z Vb + S .+ Z W,* + Z V* +•Z VQ Al.l
Where Vto is the potential energy due to a bond 
stretching from its equilibrium value. , Vnb> Vt anc*
Vq are the potential energies for angle bending, non­
bonded interactions, bond torsion and electrostatic 
interactions respectively. The potential energy
functions used to account for these interactions 
employed by the program used in this study [65] are 
described below:
A1.2 BOND STRETCHING AND ANGLE BENDING
Bond stretching is accounted for by a Hooke's law 
harmonic potential which is written as:
Vto = 'k k. ( 1 - 10 )2 A1 .2
Where k» is the bond stretching force constant and 10 is 
the equilibrium bond length, both values being obtained 
as force field parameters for a particular bond. This 
expression is sufficient for small deviations from the 
equilibrium value, which is the case for the systems 
used in this study. Each bond is treated as being 
independent from the others and the sum of these 
stretching potentials is taken as the potential energy 
of the molecule due to bond stretching.
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Angle bending is expressed by the same type of function 
as bond stretching i.e.:
= V* k« ( 6 - eo )2 A1.3
Where is the angle bending force constant and 0O is
the equilibrium bond angle, and as before both values 
are force-field parameters. In general, bond angles are 
found to deviate from the mean position far more than 
bond lengths and this type of function is thought to be 
adequate for deviations up to about 5°. If a system is
expected to show deviations greater than this, then an
anharmonicity correction should be included.
A1.3 NON-BONDED INTERACTIONS
A non-bonded potential function must be able to account 
for a wide range of non bonded distances, from the close 
separation hyd rogen bond to distances ac ross
the whole system, and a simple harmonic function is 
inadequate. This problem is overcome by using a function 
which contains a repulsive part at short distances and 
an a ttrac tive part which approaches zero at very 1arge 
distances. Two types of function are common in molecular 
mechanics [142], the Lennard-Jones potential;
Page 179
Vr,b = e [ (r0/r)1= - 2(r0/r)^ ] A1.4
and the Buckingham potential, used in this study:
Vnb = e [ -2/a*> + EXP(12(l-a)) ] A1.5
a = r/r0
Where e is the depth of the potential well and r0 is the
separation at the potential minimum, related to Van der
Waals radii of the atoms involved. Both <= and r^ are 
force-field parameters.
A1.4 BOND TORSION
Bond torsion is defined by the standard IUPAC convention 
where the torsion angle A-B-C-D is the clockwise 
rotation around the bond B-C required so that bonds B-A 
and C-D are eclipsed. Although is is possible in theory 
to account for the rotation around a single bond by 
employing non-bonded functions alone, this method will 
obviously be inaccurate for a molecule such as ethene 
which prefers a planar conformation. The torsion 
function used in this study is expressed as:
= ’£ h ( 1 + s COS( j w) ) A1.6
Where w is the torsion angle, j the number of minima 
found in a 360° rotation, s is ± 1 depending on whether 
the 0° conformation refers to an energy minimum or 
maximum and h is related to the rotational barrier
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height for a particular set of four atoms. The potential 
energy of a particular torsion angle is expressed as a 
sum of the individual torsions across the central bond ( 
9 for two tetrahedral atoms, 4 for two trigonal atoms 
etc. ) and hence the value of h which appears in the 
force field comes from the experimentally measured 
rotational barrier divided by the number of "routes" 
across the central bond.
A1.5 ELECTROSTATIC INTERACTIONS
A coulombic potential is used to calculate the potential 
energy between two charged species and is expressed as:
Vq = qx q-,/ D r A1.7
Where qx-and q^ are the partial atomic charges and D the 
dielectric constant. The molecular mechanics program 
used here treats charges in a very simplified manner; 
charged atoms are collected into groups by the user and 
only electrostatic interactions between atoms in 
different groups are calculated, assuming they are not 
bonded together. Electrostatic interaction between atoms 
in the same group are ignored. The dielectric constant 
in this work has been treated in two ways. One method is 
to use the value of 4 which is thought to represent the 
dielectric of a hydrophobic pocket of an enzyme 
[143,144], and the other is to set the dielectric equal 
to the distance between the two atoms under
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consideration. This is done to take account of the fact 
the further two atoms are apart, the more solvent there 
is likely to be between them, hence the dielectric will 
be higher [145]. For systems studied in this work such 
as the interaction between noradrena1ine and acetate the 
choice of dielectric made little difference to the 
position of the acetate unit as in both cases it was 
very close to the side-chain hydroxyl and amine 
hydrogens and the repulsive part of the non-bonded
interaction these hydrogens and the acetate oxygens was 
the overriding factor in this system.
The partial atomic charges were calculated by either a 
CNDO or INDO semi-empirica1 molecular orbital method. 
Charges calculated by this method are perfectly adequate 
for molecular mechanics, bearing in mind the other
approximations of the method, and have been found to be 
in good agreement with more rigorous ab-initio
calculations and with experimental dipole moments.
A1.6 PARAMETERISATI ON
The ability of molecular mechanics to predict
experimental structures and energies depends not only on 
the potential functions used, but is also critically
dependent on the parameters incorporated into these
functions. These parameters are known as the "force 
field" and not only include the various force constants
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but also the reference values such as equilibrium bond 
length. The parameters can be determined by a least
squares fit to structural and thermodynamic data, or by
trial and error. Usually data on well characterised 
simple molecules is used and it is assumed that similar 
atoms in larger systems behave in much the same way.
Force field optimisation is a continuous process and if 
a system is found which cannot be accounted for by the 
present parameters, then they will have to be altered to 
fit and/or new atom types defined until the required 
results are obtained. This is a complicated process as 
the parameters are often interdependent and changing one 
may necessitate the revision of the rest of the force
field. Optimisation of the parameters is almost always 
necessary if a system which the force field has not been 
designed for is to be investigated. The force field 
parameters used in this study are listed in Ref. [146]
as well as a list of the atom types involved.
A1.7 ROTATIONAL BARRIERS
In the simplest case, the calculation of potential 
energy as a torsion angle is rotated involves summing 
the non-bonded, torsional and electrostatic interactions 
over a series of angle steps and plotting a graph of 
potential energy vs. torsion angle. This can be extended
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to two rotatable bonds to give a "surface" with the 
peaks corresponding to potential maxima and the valleys 
to minima.
To investigate the rotation about three or more bonds a 
searching routine was used. The bonds are systematica 11y 
rotated and conformations whose energies lie within a 
certain range ( typically 5 k.cal.mol-1 ) of the lowest 
minima are saved and the subjected to further smaller
rotational increments. These conformations are then
ordered in terms of energy and then saved so that 
geometry optimisation procedures can be used to find the 
global minimum.
With all these methods the rigid rotor approximation is 
made and thus the height of the barrier is almost a 1 ways 
calculated as too large, although the torsion angle
corresponding to potential minima is usually in good 
agreement with experimental data.
A1.8 GEOMETRY OPTIMISATION
To calculate a minimum energy conformation of a molecule 
a geometry optimisation procedure is used. The first 
step is to calculate the steric energy of the system 
using the potential functions and parameters already
described. The improved geometry is then calculated by
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the Newton-Raphson technique whereby the cartesian 
coordinates of the molecule are in turn incremen ted by a 
small amount ( typically 0.0001 A ) and the first and 
second derivatives with respect to energy calculated. 
The improved geometry is given by:
Xx = x.;> - F-i TV(x) A1.8
Where F is the matrix of second derivatives and TV (x )
is the vector whose elements are the first derivatives 
of the steric energy V with respect to the cartesian
coordinates. Inversion of the F matrix requires a 
considerable amount of computer time which can be 
simplified by reducing the F matrix to a block diagonal 
form. This only requires a matrix containing the 3x3 
blocks along the leading diagonal of the F matrix which 
correspond to the x, y and z coordinates of a particular 
atom and a set of 3x3 blocks off the diagonal which 
correspond to cross terms between different atoms.
The block-diagonal method requires much less computer 
time and is , much more tolerant of poor starting 
geometries than the full matrix approach although the 
b1ock-diagona1 method may converge rather slowly near 
the minimum. The program used in this study has the 
capability of using both methods but the block diagonal 
method was used used exclusively as the limiting factor 
to the accuracy of the method was thought to be the
force-field parameterisation hence it was not thought
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worthwhile involving a large amount of computer time 
calculating extremely precise minima based on these 
parameters.
Geometry optimisation is an iterative procedure and once 
the improved geometry is calculated the method repeats 
itself until the R.M.S. of the first derivatives of 
energy with respect to the coordinates is less than a 
set value ( typically 0.05 k'.cal. mol.-1 A-1 ). It
should be noted that the method proceeds towards the 
nearest turning point on the molecules potential surface 
and care must be taken so that local minima are not
taken as the global minima. In the extreme cases a
potential maximum can be reached. This can be overcome 
by using several starting geometries and using the one 
giving the lowest energy as the best approximation to 
the global minimum or by searching through some of the 
molecule's rotatable bonds as described in the previous
section. The fact that a potential maximum can be
reached can be useful in calculating transition states 
and also is useful when optimising the structure on the 
maximum of a rotational barrier as has been done in this 
study.
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APPENDIX 2
MOLECULAR ORBITAL METHODS
A2.1 MOLECULAR ORBITAL THEORY
Molecular Orbital theory can be used to calculate the 
electronic structure of a molecule or system. The 
methods used to do this are based on the Schrodinger 
equation which in its simplest form states:
H5» = ET A2.1
Where H is an operator, known as the Hamiltonian 
operator, which operates on a mathematical function, 
known as the wave function and E is the energy of the 
system.
The Schrodinger equation can be solved exactly for a 
system which contains just one nucleus and one electron 
e.g. the hydrogen atom, He'*’ etc., providing the wave 
function is physically reasonable i.e. it is continuous, 
single valued and tends to zero as the distance from the 
nucleus approaches infinity. The fact that the wave 
function is constrained in this way leads to a set of 
discreet energies and their corresponding wave 
functions, often known as orbitals.
For a system containing more than one electron the 
orbital approximation is made, where each electron is 
treated separately as a hydrogen-like orbital, and the 
wave function for the system is written as a product of 
these orbitals:
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¥ = XA X2  X3  ........  Xx A2.2
The electronic structure of, for example, helium is 
written as ls= . This is shorthand for:
He: Is- Is* A2.3
Where a and [3 refer to electrons of opposite spin. This
can also be written as:
He: Is Is A2.4
Where Is refers to a hydrogen-like Is orbital of a spin 
and Is refers to a Is orbital of (3 spin. These are known 
as spin orbitals. The Pauli principal states that the 
wave function for a system must change sign if any pair 
of electrons are interchanged. If the electrons in 
helium are labelled (1) and (2) and are interchanged:
? He = ls(l) 15(2) A2.5
9'He = 1s (2) 15(1) A2.6
We see that the wave function does not change sign. This 
is overcome by expressing the wave function as a linear 
combination of spin orbitals:
9H„ = 1/T2 [ ls(l)ls(2) - Is(2)15(1) ] A2.7
Where the value of 1/T2 is included to retain the 
normalising condition, i.e. the probability of finding
an electron somewhere in space ( the integral 
is 1.
9*9 dT )
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Equation A2.7 is the expansion of the determinant:
j ls(1) Is(2) 
I 15(1) 15(2) A2.8
The diagonal of A2.8 is sufficient to define it and the 
normalisation factor is obvious (l/Tni, where n is the 
number of electrons), hence the expanded spin orbital 
wave functions are usually written as simple products, 
so for helium;
I'm- = Is 15 A2.9
or even 9M- = ls= A2.10
and generally 9 = Xx X= X3 ... Xn A2.il
remembering that this is a shorthand notation for a 
determinantal function.
A2.2 MOLECULAR ORBITALS
A molecular orbital is thought of as an orbital which 
extends over the entire molecule and is thus subject to 
the potentials of all the nucleii and the charge 
distributions of all the other electrons in the system. 
A molecular orbital is treated in much the same way as 
an atomic orbital and the orbital approximation is made:
'i' = 0i 03 03 ... 0n A2.12
Where 'P is the wave function for the entire molecule and
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0i represents the wave function for a molecular orbital 
and is a three dimensional function which describes the 
properties of a particular electron (i.e. a one-electron 
molecular orbital) in the molecule. It of course must be 
remembered that equation A2.12, as in the atomic orbital 
case, represents the diagonal of a determinant.
To calculate the constituent molecular orbitals, the 
linear combination of atomic orbitals ( LCAO ) 
approximation is made whereby each molecular orbital is 
expanded as a sum of known atomic orbital functions 
i.e.:
0i = Cih Xj,: A2.13
Where k is the number of atomic orbitals in the system 
and clk is a coefficient which is used to determine the
probability an electron in the atomic orbital k of the
molecular orbital i.
For each molecular orbital we can express the 
Schrodinger equation as:
H 0i = 0i A2.14
Where H is the one-electron Hamiltonian operator and 
is the energy of molecular orbital i. If the LCAO 
approximation is made to A2.14 then we get:
H Sk Cik Xk — €± S C i k X A 2  . 15
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Since the X^: are known hydrogen-like atomic orbitals we 
can solve this equation by finding the coefficients cik 
and this is done by the solution , of the secular 
equations.
A2.3 SECULAR EQUATIONS
Since it is only the square of the wave function which 
has any real meaning, i.e. the probability of finding an 
electron in some region of space and since over all 
space this probability is 1, the next step in solving 
equation A2.15 is to multiply through by Xi ( which is 
any member of a normalised set of hydrogen-1ike atomic 
orbitals which includes XK ) and integrate over all 
space to give:
2  V*: C i h  ( Xa H Xk dv ) = e4 ( Xa Xk dv ) A2.16
By using conventional notation;
And
H i =
Sih =
Xi H X*
Xx X*
A2.17
A2.18
where is the one-electron hamiltonian and Sin is the
overlap integral between Xi and XVi;, we are left with the 
secular equation;
21< C  i ( Hi k Sik ) — 0 A2. 19
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solutions of which will only be non trivial if the 
determinant of the coefficients is zero, and this is the 
basis of all molecular orbital methods.
All the matrix elements Hi* and are then computed
and the determinants multiplied out to give a polynomial 
in E, which is solved to give the allowed molecular 
orbital energies. Each e* is then put into the secular 
equations so that the coefficients, cik., can be 
computed.
Most of the various molecular orbital methods available 
differ in the way H m ,  the one electron Hamiltonian is 
treated. In ab-initio methods, H is precisely defined 
whereas, in the simplest Huckel treatment, H is never 
defined and all elements are replaced by parameters. The 
neglect of differential overlap ( NDO ) methods, 
described later, depend on parameters derived from 
experimental data to calculate some elements of the 
Hamiltonian, whilst others are considered small enough 
to be neglected.
A2.4 SELF-CONSISTENT MOLECULAR ORBITALS
The elements of a one-electron Hamiltonian contain the 
terms to describe the energy of that particular 
electron, i.e. kinetic and potential terms.
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If we select our units so that the electronic charge and 
mass are both 1 and the unit of length is the Bohr 
radius for hydrogen then the kinetic energy can be 
represented as:
y2 A2.20
Where V, the Laplacian operator is:
d/dx + d/dy + d/dz A2.21
The potential energy of an electron includes two terms, 
the attraction of the electron to the nucleii and the 
repulsion of that electron from the other electrons.
The electron-nuclear attractions are given by:
/ riv
Where Zv is the charge of nucleus v and riv is the 
distance of nucleus v from electron i.
To calculate the repulsion between two electrons, we 
note that;
05. (1) dvi A2.22
is the charge distribution for electron (1) and 
similarly;
05 (2) dv= A2.23
is the charge distribution for electron (2), hence the
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repulsion between electrons (1) and (2) is given by;
05.(1) l/r1= 05(2) dvx dv2 A2.24
where ri= is the distance between them.
This might suggest that the expanded form of the one- 
electron Schrodinger equation ( eqn. A2.14 ) can be
written as the Hartree equation:
{-^v2-2 v, 2^/r lv + 2 ?.a. 05 (2 ) l/ri=2dv= > 05(1) = eJL0 ± (l)
A2.25
However it must be remembered that the wave function is 
a determinant and not a simple product. To account for 
this we must include an 'exchange integral' Kj to give 
the full self consistent field, or Hartree-Fock, 
equations.
From equation A2.14 we get;
A2.26
and we denote the kinetic energy and electron-nuclear 
attraction terms by HM i .e .;
HM = -£ v2 -Sv. Zr-/r± A2.27
and use the shorthand notation for the Coulombic 
repulsions;
J A 0 i. ( 1 ) = ( 05(2) l/ri= dv2 ) 0i(1) A2.28
then we have:
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HSCFr = { HM + 2j Jj — Zj Kj ) A2.29
Where the exchange integral, Kj, is defined as;
K ^ i v d )  = ( 0j (2) 0i (2 ) l/ri=2 dv= ) 0j (1) A2.30
the prime indicating summing only over pairs of 
electrons of the same spin.
This means that the Hamiltonian contains the various 0* 
which we are trying to determine, therefore we need to 
know the values of ciM for the other electrons before we 
can determine 0± . To do this the coefficients are first 
calculated from simple ( often Huckel-type ) equations. 
The integrals required for HVcl and S^i are then 
calculated so that the secular equations can be solved 
to give 0± which are then substituted back to give new 
values for c*.*. These are then used to re-calculate the 
full Hamiltonian ( known as the Fock matrix ) and the 
process repeated until the coefficients from one cycle 
are similar to within prescribed limits to those from 
the previous cycle. This is known as the variational 
method, based on the variational theorem which states 
that the best wavefunction is the one that gives the 
lowest energy; as the method proceeds the energy of the 
system should progressively lower until the desired 
wavefunction is reached. The results are then said to 
be self-consistent, hence the term self-consistent 
field used to describe this type of calculation.
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A2.5 NEGLECT OF DIFFERENTIAL OVERLAP
Differential overlap refers to the overlap region
between two different atomic orbitals. The neglect of
differential overlap ( NDO ) methods neglect, to a
greater or lesser extent, electron repulsion in this
region. Also, nearly all of these methods apply to
valence electrons only, the inner electrons being 
treated as part of a non-ionisable core. Both these 
approximations considerably reduce the computer time 
required for a calculation, enabling quite large systems 
such as drug molecules to be considered.
Neglect of differential overlap is achieved by
considering matrix elements FL.: i of the type;
Xm (1) X„(l) 1 / r xz X i (2) X»(2) dTi dT=: A2.31
written in the Dirac bracket notation as:
< mn | Is > A2.32
These integrals are particularly time consuming to 
evaluate, especially when three or four centres are
being considered. With the NDO approximation:
< mn j Is > = < mm | 11 > Smrt Slm A2.33
Where 6mn and Slm are Kronecker deltas which have values 
of 1 if the subscripts are equal and zero otherwise.
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Thus all three and four centre integrals are neglected 
as are one and two centre integrals where different 
atomic orbitals are involved for either of the two 
electrons.
In addition, the off diagonal one-electron integrals are 
similarly neglected i.e. the overlap integral;
Sit,: = Xi(1) X*(l) dTi = 8lk A2.34
and the nuclear— electron attraction integral;
X*(l) Xi(l)
dTx = 0 unless k = 1 A2.35
Where Zp, is the effective charge of the nucleus A.
The consequence of the NDO approximation of the Fock 
matrix elements are thus:
For one-electron terms H ik includes the electron-nuclear 
attraction terms and the kinetic energy terms i.e.:
Hxk = -S.' Z,
r x . d j X i d )
rfti
h2
dTi -
8n2 m t
X d D ^ X d l )  dT 
A2.36
When k=l, none of the terms are cancelled by the NDO 
approximation. The terms which represent the attraction 
in orbital k to its own core, A, are grouped together 
and given the symbol , and the terms representing the
attraction of the electron to the core of the other 
atoms, B, are given the symbol . H** thus becomes:
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Hkk = Llf?* - Eb #a A2.37
When k ^ 1 all the core-electron terms are neglected by 
the NDO approximation. The off-diagonal terms are 
usually treated as an empirical parameter set 
proportional to the overlap integral i.e.;
Hki = Ski Pki A2.38
which are known as the resonance integrals and the 3 
parameter represents the bonding between two types of 
orbital.
The two-electron terms involve integrals of the type;
T = < kl | mn > - < kn | lm > A2.39
( the coulomb and exchange integrals ). Applying neglect 
of differential overlap we get:
For l=k and m=n:
■ T = < U  | mm > - £ (0) = Tlm A2.40
For k=n and 1=m:
T = (0) - £ < kk | 11 > = I'm A2.41
For k=n=1=m:
T = < kk | kk > - 'k < kk | kk > = %
A2.42
Thus the Fock matrix elements can be written as:
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Diagonal terms:
F** = U6* - Vf?h + sm PmJkm ~ P**r** A2.43
□ff-diagonal terms:
F*x = H*i - £ PkiTki A2.44
Where Pki is the density matrix given as;
P k i  = 2?= = clk C n  A2.45
occ being the number of occupied orbitals.
The secular determinant is thus;
| Fk i - E Sm | = 0  A2.46
the molecular orbital energies are expressed as;
= Zi Cik c* i F k 1 A2.47
and the total energy of the system can be written as:
Zp» ZB Hki + Fki
E = 2 2 ------ + 2* 2 a P ki ----------
rAB 2 A2.48
The remainder of this appendix will now concentrate on 
the molecular orbital methods used in this study.
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A2.6 AB-INITIO METHODS
The term ab-initio is used to describe molecular orbital 
calculations where the full Hartree-Fock SCF field 
operator is used in the equation:
det | HkX - Ski j = 0  A2.49
H = [ HM + 2j Jj - Ej Kj ] A2.50
and all the integrals in Hkl and Ski are evaluated, and 
each molecular orbital is represented as:
0 jl — 2 k c i_ k X k A 2 . 5 0
The number of two-electron integrals increases as n4 , n 
being the number of atomic orbitals included in the 
expansion, hence increasing the number of . atomic 
orbitals, or basis set, under consideration requires 
very much larger amounts of computer time.
For this reason, if calculations are to be done on large
molecules, then short expansions of atomic orbitals are
used, hence the wave function is approximate. This may
lead to a total energy being calculated which is far 
from the best possible result, despite the fact that it 
is of ab-initio origin.
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One set of atomic orbitals which are often used are the 
Slater type, which take the form:
Xk = N e-=r- Yu m A2.51
Where N is the normalising constant, Y,_M is the angular 
part of the function and z is the orbital exponent, 
zeta. If one of these functions is used to describe each 
filled atomic orbital, then the set of atomic orbitals 
i^ known as a minimal basis set.
Functions of the type e“ir~ are difficult to evaluate by 
computer, and this is often overcome by using a gaussian 
function which has the form e*'"2 . This function is less 
appropriate, particularly at distances close to the 
atomic centre, hence several gaussian functions are 
fitted to a Slater type function. The ab-initio method 
used in this study is the ST0-3G method, which indicates 
that a minimal basis set of Slater exponents has been 
used, and each exponential function has been fitted 
using three gaussian functions. The program used to 
perform these calculations was the GAUSSIAN 82 program 
running on a Cray IS supercomputer at the University of 
London Computer Centre.
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A2.7 THE CNDO METHOD
The simplest of the SCF NDO methods is the complete 
neglect of differential overlap, or CNDO, and most 
commonly used is the CNDO/2 parameterisation of Pople 
and Segal [147]. In these methods the two centre 
repulsion terms are dependent on the nature of the atom 
associated with a particular orbital rather than the 
nature of the orbital itself thus:
T K 1 ^ 5ASA j 5b 5b /* = r
Where and sB are the Slater hydrogen-like s
To ensure that the results of any calculation do not
depend on the relative orientation of the molecule ( the 
invariant space requirement ), all two-centre repulsions 
are treated as if the orbitals are spherically 
symmetrical.
The terms are given by:
U£* = - '£ ( IPk + EAk ) - ( Z. - % ) Faa A2.53
Where the ( IPK + EA^ ) term is the mean of the
ionisation potential and the electron affinity, the
values of which are given as parameters.
The Vg term is expressed as;
Vg = ZB Ta e A2.54
A2. 52 
orbi ta1s .
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i.e. Vg depends on the nature of atom A and not the 
orbi ta1.
The off-diagonal terms, H^i, are given by:
Hkl = Ski ( |3£ + |3£ ) / 2 A2.55
Where (3,2, is the bonding parameter for atom A.
The total electron density of atom A is expressed as;
P a a = 2 ^ P I* >■: A 2 • 5 6
and the Fock matrix elements can now be written as:
FtaM Uf)ta + ( p ,0,,^ '/£P ta ta ) T + Zb^iO, ( PBdT AA Vg )
A2. 57
F I-*: 1 = H ta 1 — '■£ P ta X r ^ B
A2.58
This method gives satisfactory agreement with experiment 
for a wide range of properties including geometries and 
dipole moments, hence its use in calculating net atomic 
charges. Results for heats of formation are rather poor 
and the method does not take into account interactions 
between electrons of parallel and anti-parallei spin 
hence can only be used to calculate closed-shell
systems.
A method similar to CNDO referred to in the study is 
Parisier— Parr-Pople (PPP) [148] method, which uses
similar approx imations, but only Ti-electrons are
included in the calculation. u-electrons are assumed to 
be part of the non-ionisable atomic core.
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A2.8 THE INDO METHOD
The INDO ( intermediate neglect of differential overlap 
) method was introduced by Pople, Beveridge and Dobosh 
[149] in order to overcome some of the 
over— simplifications of CNDO, particularly the neglect 
of one-centre exchange integrals. In the INDO method 
these integrals are evaluated by using Slater— Condon 
parameters and are given the values below:
< ss [ ss > = < ss j p»p«
0Li.IIA —  F  p p
< Pk P,< ] p „p «  > = F° + ( 4/25 ) F2
< p«p« j P v P v  > = F° - ( 2/25 ) F2
< s p „  | sp,t > = 1/3 G1
< P « P v  | p „ p v > = ( 3/25 ) F2 A2. 59
The F° term is calculated as F^ p, as in CNDO/2 and the G*
and F2 parameters are determined f rom the UV spectra of
the corresponding atoms.
The terms are calculated, as in CNDO/2, by using the
average of the ionisation potential and electron 
affinity, modified to include the SIater-Condon 
parameters. All other terms are evaluated using the 
expressions for CNDO/2.
INDO can be used to deal with open-shell systems as a- 
and [3-spinned electrons are treated separately, but no 
used of this was made in this study as only closed-shel1
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systems were encountered.
INDO is a considerable improvement on CNDO/2 and
requires a negligible amount of extra computer time, 
hence was used whenever possible. Most versions of INDO 
are only parameterised up to fluorine as the Slater—  
Condon parameters are not available for heavier atoms. 
As CNDO/2 and INDO are so similar ( INDO reduces to 
CNDO/2 if the one centre exchange integrals G* and F2 
are omitted ) that it is possible to perform an INDO
calculation on a system containing atoms heavier than
fluorine, using CNDO/2 parameters for the heavy atoms.
The MNDO (Modified Neglect of Differential Overlap) 
method [150] is also referred to in this study. This
method is similar to INDO, but parameterised to 
reproduce experimental results rather than ab-initio 
results, which is the case with CND0/IND0.
A2.9 THE PCILO METHOD
The perturbation configuration interaction using 
localised orbitals method ( PCILO ) [151] method differs
in many ways from the standard molecular orbital 
methods, such as CNDO and INDO. Most methods use a 
variational procedure where an initial guess is made at 
the density matrix, which is used to construct the Fock
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matrix and an often lengthy series of cycles is then 
necessary in order to minimise the energy with respect 
to the orbital coefficients.
The PCILO method differs by expanding the molecular
orbitals in terms of localised bond orbitals rather than 
a linear combination of atomic orbitals, and uses
perturbation theory to construct the energy and the wave 
functions, known as the zero'th order wave function.
This avoids the need for the time consuming variation
procedure. A set of localised anti-bonding orbitals are 
used so that mono- and di- exited stated can be included 
and a limited amount of configurational interaction is 
performed to give the second-order energy correction.
Third order terms are also included to account for all 
the possible interactions between the orbitals arising 
from the second-order expressions.
The energy contribution uses much the same approximation 
as CNDO, and PCILO has the advantage of requiring very 
much less computer time than variational methods. It is 
widely used, and has been in this study, to investigate 
the effects of rotating around single bonds.
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APPENDIX 3
MOLECULAR MECHANICS FORCE FIELD PARAMETERS FOR CLQNIDINE 
AND SIMILAR MOLECULES
tou types used in tn is  fo r c e - f ie ld :
1 C sp3
2 C sp2
3 C aromatic
9 N sp2
11 O-carboxylate
15 H
17 Cl
1b h H-bondin^
IMP ST KETCH IMG PARAMETERS 
ATOM TYPE
a b Ks Lo
1 1 316.8000 0.0000 1.5200
2 319.5000 0.0000 1.5010
1 3 320.0000 0.0000 1.5250
1 9 379.0000 0.0000 1.4500
1 15 331.2000 0.0000 1.1000
2 2 070.0000 0.0000 1.3350
2 3 500.0000 0.0000 1.4700
2 9 441.0000 0.0000 1.3300
2 11 632.0000 0.0000 1.2600
2 15 340.0000 0.0000 1.0890
3 3 547.2000 0.0000 10930
3 9 440.0000 0.0000 1.4150
3 15 346.0000 0.0000 1.0840
3 17 250.0000 0.0000 1.7200
9 19 300.0000 0.0000 1.0000
LE BEaOH.U PARAMETERS
ATuh TYPE
a b c Ka Ka* 6o4 •6o3 Bo2 00 1
1 1 1 0.0120 0.0096 110.70 110.40 110.10 105.50
1 1 2 0.0090 0.0096 0.00 110.40 110.10 109.50
1 1 3 0.0090 0.0096 0.00 109.50 109.50 109.50
1 1 9 0.0120 0.0096 0.00 110.70 109.50 109.50
1 15 0.0088 0.0096 110.50 109.50 109.20 109.20
1 2 1 0.0233 0.0096 0.00 0.00 116.40 116.40
1 2 2 0.0120 0.0096 0.00 122.30 121.00 121.00
1 2 9 0.0100 0.0096 0.00 0.00 117.00 117.00
1 2 15 0.0060 0.0000 0.00 117.50 117.50 117.50
1 3 3 0.0120 0.0096 120.00 120.00 120.00 120.00
1 3 9 0.0120 0.0096 0.00 . 120.00 120.00 120.00
1 9 1 0.0120 0.0096 0.00 117.00 117.00 117.00
1 9 2 0.0170 0.0096 0.00 120.00 120.00 120.00
1 9 3 0.0170 0.0096 0.00 120.00 120.00 120.00
1 9 19 0.0080 0.0096 0.00 117.00 117.00 117.00
2 1 2 0.0090 0.0096 0.00 111.00 110.10 109.50
2 1 3 0.0090 0.0096 0.00 110.00 110.00 110.00
2 1 9 0.0090 0.0096 0.00 109.50 109.50 109.50
2 1 15 0.0088 0.0096 110.50 110.20 110.20 110.20
2 2 2 0.0120 0.0096 0.00 122.30 121.00 121.00
2 2 9 0.0100 0.0096 0.00 0.00 117.00 117.00
2 2 15 0.0060 0.0096 120.00 120.00 120.00 120.00
2 3 3 0.0120 0.0096 0.00 120.00 120.00 120.00
2 9 2 0.0170 0.0096 0.00 124.00 124.00 122.00
2 9 3 0.0170 0.0096 0.00 120.00 120.00 120.00
2 9 19 0.0080 0.0096 119.00 119.00 119.00 119.00
3 1 9 0.0090 0.0096 0.00 109.50 109.50 109.50
3 1 15 0.0080 0.0096 109.50 109.50 109.50 109.50
3 2 9 0.0120 0.0096 0.00 120.00 120.00 120.00
3 2 15 0.0060 0.0000 120.00 120.00 120.00 120.00
3 3 3 0.0120 0.0096 0.00 120.00 120.00 120.00
3 3 9 0.0120 0.0096 0.00 120.00 120.00 120.00
3 3 17 0.0120 0.0096 0.00 120.00 120.00 120.00
3 3 15 0.0060 0.0000 0.00 120.00 120.00 120.00
3 9 3 0.0120 0.0096 0.00 120.00 120.00 120.00
3 9 19 0.0080 0.0096 119.00 119.00 119.00 119.00
9 1 15 0.0080 0.0096 109.50 108.55 108.55 108.55
9 2 9 0.0180 0.0096 0.00 120.00 120.00 120.00
11 2 11 0.0150 0.0096 0.00 123.00 123.00 123.00
11 2 15 0.0060 0.0000 120.00 120.00 120.00 120.00
15 1 15 0.0072 0.0096 108.20 109.10 109.50 109.50
15 2 15 0.0055 0.0096 118.60 118.60 118.00 118.60
19 9 19 0.0080 0.0096 120.00 120.00 120.00 120.00
2 08
Gi»— XjOhGLu f5/lHrtl'it.i tUo
i Cs i i
Cl
T ^ L
o Ku e
1 1 j .o60u 0.OOGG G • 1200
1 2 j.OGOG 0.GGOG O.GGGO
1 3 j.ooCG G.GGGG G.GGGG
1 y J.OoUG G.OGOo 0.12GG
1 16 j o OOO O.GGGO 0.G2yy
1 17 3.7b00 O.UGOO 0.0160
1 iy Z.30OO 0.G00G o,ozoo
z z 4.00G0 O.OOoG G.07 GO
z 3 4.0000 0.0000 0.G7GG
z j 3.7000 0.GGOG G • 1200
d 3 «6 jGG G.GGGG O . O g g G
z 17 j.SOGG G.GGGG 0.1400
z iy 2.46GG G.GGOG 0.0200
3 3. 70u0 G.GGGG o.oy64
3 y 3.7000 O.GGGO 0.1200
3 iy 3.330U G.GGGG O.OJ3O
3 17 3.VJ00 O.GGGO 0.140G
3 iy 2.3000 O.GGGO 0.0200
y y 3. :j000 0.0000 0.1200
y 1j 3.ZH00 G.GGGG 0.0400
y 17 j .u600 O.GuOG G.15GG
y iy 2.2000 G . G G G G G.2000
Iy 16 3.1000 0.0000 0.0160
16 17 3.2600 0.GCOG G.02GG
It) iy cr .OOUO G . G G G G o.ooyo
17 17 3.^000 G . G G G G 0.2600
17 iy 2.4000 0 .OGuO 0.0200
1y iy o.youo 0.0000 G.GjOG
1 11 j . 6 g g o G . G G G G 0.1200
2 n j.L> oGG G . G G G G G. 1^ :00
3 11 j . 6 g o g O . G u G O 0.1200
3 11 j•joGO O . O O o O G • 12GU
1 y n j .12o0 G . G G G g G.0400
17 11 3.0000 G . G G G G 0.1600
1* 11 2  . G u O O G . G G G G 0.2600
ru
ro
iu
rv
jiv
jiv
jr
cf
vj
fu
rv
jfv
jfo
ro
OND TQKSIUN PAKjUilTLKS
AT Oh TYPE 
b c d ii s / j
1 1 0.0629 3.0000
1 2 0.0629 3.0000
1 3 0.0629 3.0000
1 9 0.0629 3.0000
1 15 0.1100 3.0000
2 1 0.0629 3.0000
2 2 0.0629 -3 .0000
2 9 0.0629 -6 .0000
2 15 0.1367 3.0000
3 3 0.0629 -3 .0000
3 9 0.0629 -3 .0000
9 1 0.0629 3.0000
9 2 0.0629 -3 .0000
9 19 0.0629 3.0000
1 2 0.0629 3.0000
1 15 0.1100 3.0000
2 1 6.2500 -2 .0000
2 2 6.2500 -2 .0000
2 9 6.2500 -2 .0000
2 15 6.2500 -2 .0000
9 1 3.0000 -2 .0000
9 2 3.0000 -2 .0000
9 3 3.0000 -2 .0000
9 19 3.0000 -2 .0000
3 1 3.0000 -2 .0000
3 3 3.0000 -2 .0000
3 9 3.0000 -2 .0000
3 15 3.0000 -2 .0000
1 2 0.0629 3.0000
1 15 0.0629 3.0000
2 2 3.0000 -2 .0000
2 3 3.0000 -2 .0000
2 9 0.6000 -2 .0 000
1 2 0.0200 3.0000
1 3 0.0200 3.0000
1 9 0.0629 3.0000
1 15 0.1100 3.0000
2 2 0.0629 -3 .0000
2 15 0.1367 3.0000
3 3 0.0629 -3 .0 000
9 2 0.0629 3.0000
9 19 0.0629 3.0000
1 15 0.0629 -3 .0 000
2 15 6.2500 -2 .0000
9 2 3.0000 -2 .0000
3 3 3.0000 -2 .0000
3 15 3.0000 -2 .0000
1 3 0.0629 3.0000
1 15 0.0629 -3 .0000
2 9 3
3 1 1
3 1 1
3 1 1
3 1 2
3 1 3
3 1 9
3 2 1
3 2 9
3 2 9
3 3 1
3 1
3 3 2
3 2
j 3
3 3
3 3 3
3 3 3
9 2
3 3 9
3 9 1
9 1 1
9 1 1
9 1 2
9 2 1
9 2 2
9 2 9
9 3 1
9 3 3
9 3 3
15 1 1
15 1 2
15 1 3
15 1 9
15 3 3
15 2 2
15 3 3
1.6000 -2 .0000
0.0200 3.0000
0.0200 3.0000
0.1100 3.0000
0.0629 -3 .0 0 0 0
0.0629 -3 .0 0 0 0
0.0629 3.0000
0.0629 -3 .0 0 0 0
3.0000 -2 .0 000
3.0000 -2 .0 000
0.0629 -3 .0 0 0 0
0.0020 -6 .0 000
0.2500 -2 .0 000
0.8000 -2 .0000
3.0000 -2 .0000
3.0000 -2 .0000
3.0000 -2 .0000
3.0000 -2 .0000
3.0000 -2 .0 000
0.0020 -2 .0000
0.0629 -3 .0 000
0.0629 3.0000
0.1100 3.0000
0.0629 -3 .0 0 0 0
0.0629 -3 .0 000
6.2500 -2 .0000
3.0000 -2 .0 000
0.0629 -3 .0 0 0 0
3.0000 -2 .0000
3.0000 -2 .0 000
0.1100 3.0000
0.1367 3.0000
0.1100 -3 .0 000
0.0629 3.0000
3.0000 -2 .0 000
6.2500 -2 .0 000
3.0000 -2 .0 000
3
j
9
15
9
o
19
15
3
19
9
15
9
15
3
9
15
17
9
19
15
9
15
9
15
15
19
15
15
17
15
15
15
19
17
15
15
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APPENDIX 4
THE REGRESSION ANALYSIS DATA USED IN CHAPTERS 3 AND 4
The numbering scheme for the 
imidazolidines under consideration.
clonidine-like
N o . Pheny1
1 2,4,6-
2 2,4-di
3 2,6-di
4 2,6 Me
5 2-Me
6 H
7 2-Me,
8 2,4-Me
9 2-C1 ,
10 2-Me, .
11 2-C1
12 4,6-Cl
13 2,4-di
14 2,6-Cl
15 2,3-di
16 2,5-d i
17 2,6-Cl
18 2,6-F
19 2,6-di
20 2-C1, «
21 2,4,6-
22 2,6-Cl
Population Nt- Py
Cx C=
1 0.9327 1.0285
2 0.9251 1.0321
3 0.9292 1.0320
4 0.9031 1.0307
5 0.9214 1.035B
6 0.9142 1.0429
7 0.8934 1.0342
8 0.8968 1.0346
9 0.8878 1.0186
10 0.8919 1.0384
11 0.8832 1 .0219
12 0.8692 1.0367
13 0.8598 1.0220
14 0.8797 1.0118
15 0.8849 0.9938
16 0.8831 1.0042
17 0.8616 1.0223
18 0.9848 0.9927
19 0.8563 1.0260
20 0.9177 1.0125
21 0.8369 1.0255
22 0.8372 1.0249
Ring Substituent.
hri Me 
Me 
Me 
, 4-C1
-Cl
, 6-C1 
-Me 
>-Cl
2-Me
Cl
4-OMe
Cl
Cl
4-Me
Cl
-F
ri Cl 
4-N0a
(INDO)
c* c* Nt-
1.0057 1.0281 1.4468
1.0108 1.0348 1.4471
1.0033 1.0316 1.4467
0.9877 1.0303 1.4364
1.0081 1.0389 1.4469
1.0127 1.0428 1.4358
0.9926 1.0400 1.4358
1.0140 1.0155 1.4330
1.0192 1.0432 1.4324
1.0140 1.0188 1.4325
1.0192 1.0478 1.4322
0.9975 1.0190 1.4217
1.0022 1.0484 1.4212
0.9557 1.0122 1.4207
0.9974 1.0251 1.4234
0.9974 1.0170 1.4233
1.0226 1.0223 1.4185
0.9853 0.9932 1.4302
1.0248 1.0261 1.4181
1.0058 1.0080 1.4236
1.0072 1.0256 1.4069
1.0559 1.0248 1.4074
Sube Sub«? S u b n
0.9281 0.9285 0.9470
0.9282 0.0000 0.9458
0.9280 0.9285 0.0000
0.9326 0.9329 1.7464
0.9281 0.0000 0.0000
0.9328 0.0000 1.7460
0.9328 0.0000 1.7460
0.9325 1.9218 0.9472
1.9249 0.0000 0.9470
0.9325 1.9219 0.0000
1.9250 0.0000 0.0000
0.9366 1.9186 1.7392
1.9218 0.0000 1.7388
1.9213 1.9183 1.7341
1.9012 0.0000 0.0000
1.9194 0.0000 0.0000
1.9320 1.9202 0.9482
1.9317 1.9301 0.0000
1.9231 1.9202 0.0000
1.9237 1.9302 0.0000
1.9200 1.9171 1.7325
1.9207 1.9178 1.0116
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Frontier Electron Den
Ci c=
1 0.2620 0.1828
2 0.2467 0.2177
3 0.2441 0.1944
4 0.1699 0.1123
5 0.2188 0.2348
6 0.0722 0.0912
7 0.1554 0.1261
8 0.1879 0.0868
9 0.1675 0.1556
10 0.1610 0.0701
11 0.1422 0.1571
12 0.1483 0.0830
13 0.1340 0.1155
14 0.1994 0.1122
15 0.1273 0.1680
16 0.1011 0.1594
17 0.1716 0.1039
18 0.2534 0.1715
19 0.1549 0.1013
20 0.1785 0.1369
21 0.1357 0.0867
22 0.1332 0.0978
Frontier Electron Den
Cx c =
1 -0.7495 -0.5230
2 -0.6994 -0.6169
3 -0.6815 -0.5427
4 -0.4662 -0.3081
5 -0.6062 -0.6505
6 -0.1975 -0.2497
7 -0.4238 -0.3440
8 -0.5147 -0.2379
9 -0.4578 -0.4252
10 -0.4347 -0.1892
11 -0.3831 -0.4230
12 -0.3883 -0.2173
13 -0.3487 -0.3007
14 -0.5294 -0.2980
15 -0.3232 -0.4267
16 -0.2598 -0.4095
17 -0.4477 -0.2712
18 -0.6891 -0.4665
19 -0.3977 -0.2601
20 -0.4731 -0.3629
21 -0.3393 -0.2168
22 -0.3251 -0.2386
ity, F[E] (INDO)
CU N7
0.3025 0.1792 0.6734
0.3153 0.1475 0.6861
0.2874 0.1904 0.7622
0.1687 0.1107 0.3835
0.2801 0.1420 0.7869
0.0103 0.0909 0.8366
0.1708 0.0942 0.3865
0.1951 0.1445 0.4601
0.1872 0.0658 0.4345
0.1624 0.1425 0.4430
0.1528 0.0505 0.4078
0.1424 0.1065 0.3674
0.1401 0.0668 0.3525
0.1780 0.0962 0.4654
0.1242 0.0373 0.4248
0.1441 0.0146 0.2946
0.1780 0.1006 0.4540
0.2450 0.1682 0.8255
0.1552 0.0973 0.4504
0.1711 0.0951 0.5375
0.1315 0.0851 0.3685
0.1482 0.0948 0.4410
ity / Energy of HOMO (a
c* C* N-7
-0.8654 -0.5127 -1.9262
-0.8988 -0.4180 -1.9446
-0.8025 -0.5316 -2.1279
-0.4628 -0.3037 -1.0521
-0.7760 -0.3935 -2.1803
-0.0282 -0.2489 -2.2903
-0.4659 -0.2569 -1.0544
-0.5345 -0.3958 -1.2606
-0.5117 -0.1797 -1.1874
-0.4385 -0.4011 -1.1964
-0.4116 -0.1359 -1.0984
-0.3727 -0.2788 -0.9617
-0.3646 -0.1789 -0.9175
-0.4726 -0.2554 -1.2358
-0.3153 -0.0948 -1.0787
-0.3700 -0.0376 -0.7568
-0.4643 -0.2625 -1.1846
-0.6664 -0.4573 -2.2450
-0.3986 -0.2499 -1.1566
-0.4535 -0.2520 -1.4247
-0.3289 -0.2127 -0.9216
-0.3618 -0.2315 -1.0766
SubQ Sub.? S u b n
0.0057 0.0055 0.0128
0.0069 0.0010 0.0128
0.0067 0.0067 0.0018
0.0031 0.0031 0.8415
0.0072 0.0039 0.0013
0.0158 0.0163 0.0000
0.0037 0.0004 0.8684
0.0025 0.6894 0.0075
0.7648 0.0004 0.0071
0.0022 0.8444 0.0007
0.9237 0.0004 0.0006
0.0023 0.3959 0.5973
0.4486 0.0004 0.5945
0.3262 0.2736 0.1409
0.9201 0.0015 0.0009
0.8153 0.0001 0.0005
0.4132 0.3923 0.0069
0.0520 0.0510 0.0008
0.4735 0.4425 0.0007
0.6932 0.0271 0.0007
0.2876 0.2780 0.5008
0.4944 0.4619 0.0010
u.), F[E]/E H (INDO)
Sube Sub9 Subxi.
-0.0162 -0.0159 -0.0367
-0.0195 -0.0029 -0.0362
-0.0188 -0.0187 -0.0050
-0.0086 -0.0085 -2.3087
-0.0198 -0.0108 -0.0035
-0.0434 -0.0447 0.0000
-0.0100 -0.0012 -2.3689
-0.0068 -1.8888 -0.0204
-2.0901 -0.0012 -0.0193
-0.0060 -2.2803 -0.0020
-2.4877 -0.0011 -0.0015
-0.9617 -0.0061 -1.0363
-1.1675 -0.0009 -1.5636
-0.8663 -0.7264 -0.3741
-2.3365 -0.0037 -0.0022
-2.0940 -0.0003 -0.0012
-1.0780 -1.0234 -0.0181
-0.1414 -0.1386 -0.0020
-1.2160 -1.1365 -0.0018
-1.8374 -0.0718 -0.0020
-0.7191 -0.6953 -1.2524
-1.1827 -1.1277 -0.0024
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Nett Atomic Charge (Chge) (INDO)
Cx Czz
1 0.1795 -0.0420 -0.0044 -0.
2 0.1857 -0.0435 -0.0047 -0.
3 0.1825 -0.0433 -0.0015 -0.
4 0.2063 -0.0497 0.1027 -0.
5 0.1901 -0.0446 -0.0030 -0.
6 0.1963 -0.0437 -0.0039 -0.
7 0.2175 -0.0509 0.0995 -0.
8 0.2432 -0.0521 -0.0111 0.
9 0.2525 0.0666 -0.0135 -0.
10 0.2489 -0.0535 -0.0145 0.
11 0.2577 0.0653 -0.0168 -0.
12 0.2703 -0.0589 0.0846 0.
13 0.2803 0.0504 0.0820 -0.
14 0.2856 0.0721 0.1958 0.
15 0.2477 0.1150 0.0362 -0.
16 0.2530 0.0766 0.0391 -0.
17 0.3055 0.0506 -0.0200 0.
18 0.0624 0.2571 0.0524 0.
19 0.3107 0.0479 -0.0274 0.
20 0.1904 0.0828 0.0114 0.
21 0.3301 0.0355 0.0673 0.
22 0.3277 0.0426 -0.0602 0.
Atomic Polarisabi1ity (a) (INDO) 
C X Ca C^q.
1 -0.1245 -0.1270 -0.1253 -0.
2 -0.1232 -0.1269 -0.1253 -0.
3 -0.1241 -0.1269 -0.1292 -0.
4 -0.1240 -0.1271 -0.1259 -0.
5 -0.1228 -0.1269 -0.1292 -0.
6 -0.1215 -0.1309 -0.1292 -0.
7 -0.1226 -0.1271 -0.1259 -0.
8 -0.1236 -0.1272 -0.1254 -0.
9 -0.1221 -0.1275 -0.1254 -0.
0 -0.1231 -0.1272 -0.1294 -0.
1 -0.1216 -0.1274 -0.1293 -0.
2 -0.1228 -0.1274 -0.1261 -0.
3 -0.1212 -0.1277 -0.1260 -0.
4 -0.1229 -0.1279 -0.1214 -0.
5 -0.1219 -0.1292 -0.1305 -0.
6 -0.1219 -0.1282 -0.1304 -0.
7 -0.1221 -0.1278 -0.1256 -0.
8 -0.1246 -0.1201 -0.1588 -0.
9 -0.1215 -0.1277 -0.1295 -0.
0 -0.1237 -0.1274 -0.1292 -0.
1 -0.1211 -0.1280 -0.1262 -0.
2 -0.1210 -0.1277 -0.1273 -0.
N^ Subs Sub«? Subxi
-0.3807 0.0912 0.0914 0.0852
-0.3824 0.0918 -0.0350 0.0858
-0.3810 0.0917 0.0918 -0.0389
-0.3836 0.0915 0.0917 -0.0380
-0.3809 0.0923 -0.0341 -0.0380
-0.3823 -0.0348 -0.0330 -0.0370
-0.3813 0.0921 -0.0183 -0.3946
-0.3648 0.0924 -0.4176 0.0859
-0.3649 -0.4194 -0.0188 0.0865
-0.3632 0.0929 -0.4161 -0.0221
-0.3625 -0.4180 -0.0175 -0.0206
-0.3624 0.0927 -0.3840 -0.3627
-0.3624 -0.3850 -0.0035 -0.3599
-0.3429 -0.3840 -0.3782 -0.2624
-0.3628 -0.3649 -0.0085 0.0078
-0.3615 -0.3856 0.0120 0.0091
-0.3450 -0.3897 -0.3859 0.0868
-0.3534 -0.2566 -0.2552 -0.0281
-0.3453 -0.3872 -0.3832 -0.0061
-0.3476 -0.4108 -0.2493 -0.0168
-0.3417 -0.3588 -0.3550 -0.3311
-0.3422 -0.3623 -0.3586 0.6448
N-r Subs Sub? Subx j.
-0.1079 -0.1256 -0.1255 -0.1255
-0.1077 -0.1255 -0.0355 -0.1255
-0.1078 -0.1256 -0.1255 -0.0354
-0.1080 -0.1256 -0.1256 -0.0721
-0.1077 -0.1255 -0.0354 -0.0354
-0.1075 -0.0355 -0.0354 -0.0354
-0.1079 -0.1256 -0.0355 -0.0719
-0.1080 -0.1256 -0.0740 -0.1255
-0.1079 -0.0740 -0.0355 -0.1255
-0.1080 -0.1256 -0.0739 -0.0354
-0.1079 -0.0739 -0.0355 -0.0354
-0.1083 -0.1257 -0.0738 -0.0718
-0.1082 -0.0738 -0.0355 -0.0716
-0.1080 -0.0741 -0.0739 -0.0645
-0.1078 -0.0861 -0.0354 -0.0354
-0.1077 -0.0742 -0.0355 -0.0354
-0.1083 -0.0740 -0.0739 -0.1256
-0.1068 -0.0302 -0.0302 -0.0353
-0.1082 -0.0739 -0.0737 -0.0354
-0.1076 -0.0737 -0.0304 -0.0354
-0.1088 -0.0738 -0.0737 -0.0714
-0.1089 -0.0735 -0.0734 -0.1117
C*
0418
0412
0430
0495
0425
0443
0537
0675
0555
0661
0578
0514
0679
0704
0367
0037
0496
2572
0470
2240
0345
0419
C*
1270
1310
1269
1271
1310
1309
1311
1276
1313
1275
1312
1277
1314
127*7
1322
1329
1278
1201
1277
1208
1279
1277
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teraction Energy of N-7 - Atom n (E N-^-Nn) (INDO , a.u.)
Ci c= c* c* N-7 Sube Sub<? S u b n
1 -30.8719 0.5234 -0.0159 0.5234 -262.9388 -0.0549 -0.0567 -0.0917
2 -30.8412 0.5103 -0.0167 0.5043 -26239573 -0.0551 0.1445 -0.0826
3 -30.8905 0.5251 -0.0207 0.5247 -262.9380 -0.0564 -0.0583 0.0393
4 -31.2702 0.5439 -0.1565 0.5439 -26238967 -0.0596 -0.0614 0.3632
5 -30.8654 0.5107 -0.0194 0.5053 -262.9477 -0.0559 0.1420 0.0384
6 -30.8341 0.4893 -0.0190 0.4921 -262.9632 0.1475 0.1411 0.0376
7 -31.2736 0. 5286 -0.1523 0.5343 -262.8958 -0.0582 0.1075 0.3589
8 -31.0156 0.5108 -0.0115 0.8594 -262.7535 -0.0466 -0.6909 -0.0789
9 -30.9925 0.3487 -0.0095 0.4981 -262.7524 -0.7188 0.1111 -0.0791
0 -31.0544 0.5123 -0.0085 0.3616 -262.7405 -0.0473 -0.6997 0.0209
1 -31.0297 0.3456 -0.0064 0.5021 -262.7446 -0.7239 0.1081 0.0195
2 -31.4061 0.5274 -0.1300 0.3948 -262.6913 -0.0488 -0.7667 0.3124
3 -31.3980 0.3797 -0.1276 0.5282 -262.6960 -0.7919 0.0788 0.3099
4 -30.9173 0.3264 -0.2575 0.3311 -262.5597 -0.8295 -0.8188 0.2301
5 -31.1225 0.2402 -0.0734 0.4654 -262.7427 -0.8213 0.0891 -0.0083
6 -31.1438 0.3257 -0.0781 0.3813 -262.7374 -0.7938 0.0520 -0.0096
7 -31.1040 0.3717 -0.0057 0.3745 -262.5443 -0.8077 -0.7930 -0.0754
8 -30.1895 -0.2578 -0.0904 -0.2536 -262.8898 0.4932 0.4889 0.0265
9 -31.1540 0.3767 0.0018 0.3794 -262.5370 -0.8125 -0.7983 0.0050
0 -30.6780 0.2761 -0.0426 -0.1502 -262.7057 -0.7955 0.4707 0.0153
1 -31.4766 0.4048 -0.1072 0.4075 -262.4784 -0.8751 -0.8398 0.2676
2 -31.4569 0.3906 0.0375 0.3927 -262.4774 -0.8676 -0.8522 0.5590
lectrostatic Potential Minimum, Energy of the Highest Occupied M.O.
(Epot Min, E HOMO
1 -5. 12 -0.3496
2 -5.17 -0.3528
3 -5.11 -0.3582
4 -4.80 -0.3645
5 -5.15 -0.3609
6 -5.20 -0.3653
7 -4.83 -0.3666
8 -4.98 -0.3650
9 -4.99 -0.3659
10 -4.96 -0.3703
11 -4.99 -0.3713
12 -4.64 -0.3820
13 -4.65 -0.3942
14 -4.83 -0.3766
15 -4.74 -0.3938
16 -4.70 -0.3893
17 -4.82 -0.3833
18 -4.99 -0.3677
19 -4.78 -0.3894
20 -4.86 -0.3773
21 -4.48 -0.3999
22 -4 .25 -0.4096
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fi LOG P» £  PAK
2 , 4 , 0 - t r i - h e -1.26 197.50
2 ,4 -d i-M e - 1.06 157.30
2 ,0 -d i-M e -1.54 157.50
2 ,0 -d i-M e ,4 -C l -0.62 197.50
2 - Me -1.82 117.50
H -1 .92 77.50
2 -h e ,4 -C l -1 .06 157.20
2 ,4 -M e ,0 -C l -0 .36 197.20
2-C l,4 -M e -0 .48 157.20
2 -h e ,6 -C l -0.57 157.20
2 - Cl -0.67 117.20
4 ,6 -a i -C l ,2 -M e -1.04 196.90
2 ,4 - d i - C i 0.29 156.90
2 ,o -d i-C l,4 -0m e 0.15 216,70
2 ,3 - d i - C l 0.57 156.90
2 ,5 - d i - C l 0.65 156.90
2 ,0 -d i-C l,4 -fo e 0 . 7 j 196.90
2 ,6 -d i -E -0 .16 98.70
2 ,0 -< i i-C l 0.62 156.90
2 -C it 6-F 0.52 127.80
2 , 4 , 0 - t r i - C l 1.47 196.60
2 ,0 -d i-C l ,4 -N 0 2 ! 1.52 217.10
Z
LOG P* '^PAK2*
1.64 39006.20
2.76 24806.20
2.37 24806.20
0.38 39006.20
3.31 13806.20
3.69 6006.20
1.12 24711.80
0.13 38887.80
0.23 24711.80
0.32 24711.80
0.45 13735.80
1.08 38769.59
0.08 24617.60
0.02 46958.90
0.32 24617.00
0.42 24617.60
0 .5 j 38709.59
0.03 9741.70
0.38 24617.60
0.27 16332.80
2.16 38651.4*
3.69 47132.40
£  pi PKA £  Es
1.06 10.7o -3 .7 2
1.20 10.30 -2 .4o
1.30 10.3 j -2 .4 6
2 .06 10.25 -3 .43
0.68 10.23 -1 .2 4
0.00 10.05 0.00
1.36 9.99 -2 .21
1.79 9.59 -3 .4 5
1.11 9.41 -2 .21
1.27 9.40 -2.21
0.59 y .15 -0 .97
1.97 9.03 — 3*18
1.25 6.73 -1 .9 4
1.14 8.57 -2 .45
1.35 8.55 -1 .94
1.35 8.50 -1 .54
1.70 8.29 -3«1o
0.02 6.18 -0 .5 2
1.16 6.05 -1 .94
0.60 8.01 -1 .4 3
O.06 7.75 - 2 .y i
1.42 0.66 - 2.90
Z p i * “
z
PnA
3.53 116.21 13.64
1.44 111.51 6.15
1.85 110.88 6.15
4.24 105.06 11.90
0.46 104.05 1.54
0.00 101.00 0.00
1.90 99.oO 4.68
3.20 51.97 11.90
1.23 88.55 ■ 4.66
1.61 66.36 4.68
0.35 63.72 0.94
3.88 61.54 10.11
1.66 76.21 3.70
1.30 73.44 6.20
1 .62 73.10 3.76
1.o2 72.25 3.70
2.89 68.72 10.11
0.00 66.91 0.65
1.39 64.60 3.7o
0.30 04.16 2.04
0.77 60.00 8.47
2.02 47.00 8.41
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orap Z  F Z  K Es2 Es4 Es6
-0 .4 3 -0 .19 -O.jO -1 .2 4 -1 .2 4 -1 .2 4
-0 .J 0 -0 .1 2 -0 .2 6 -1 .2 4 -1 .24 0.00
-0 .2 0 -0 .1 4 -0 .2 4 -1 .2 4 0.00 -1 .2 4
-0 .0 3 0.55 -0 .4 0 -1 .2 4 -0 .9 7 -1 .2 4
-0 .1 3 -0 .0 7 -0 .1 2 -1 .2 4 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00
0.10 0.62 -0 .2 8 -1 .2 4 -0 .9 7 0.00
0.30 0.74 -0 .4 0 -1 .2 4 -1 .2 4 -0 .9 7
0.31 0.81 -0 .2 8 -0 .9 7 -1 .2 4 0.00
0.53 0.79 -0 .2 6 -1 .2 4 0.00 -0 .9 7
0.60 0.86 -0 .1 4 -0 .9 7 0.00 0.00
0.78 1.48 -0 .4 2 -1 .2 4 -0 .9 7 -0 .9 7
0.91 1.55 - 0.30 -0 .9 7 -0 .9 7 0.00
1.03 1.86 -0 .7 8 -0 .9 7 -0 .5 4 -0 .3 7
1.05 1.54 -0 .2 0 -0 .9 7 0.00 0.00
1.03 1.54 -0 .2 0 -0 .9 7 0.00 0.00
1.19 1.67 -0 .4 2 -0 .9 7 -1 .2 4 -0 .9 7
1.08 1.76 -0 .5 8 -0 .4 6 0.00 -0 .4 6
1.36 1.72 -0 .2 6 -0 .9 7 0.00 -0 .9 7
1.22 1.74 -0 .4 3 -0 .9 7 0.00 -0 .4 6
1.59 2.41 -0 .4 4 -0 .9 7 -0 .9 7 -0 .9 7
2.14 2.83 -0 .1 2 -0 .9 7 -0 .9 6 -0 .9 7
E HOMO(b) E HUNU(p) E LUMO(b) E LUMO(p) Ch$e Ch6e
( e . v . ) ( e . v . ) ( e . v . ) ( e . v . ) C U (b ) C13(p)
-6 .391 -11 .568 2.323 -5 « 9 j 6 1.058 0.935
-6 .190 -11.342 1.363 - j .974 1.027 0.946
-6 .5 60 -11.707 2.117 -4 .0 03 1.033 0.934
-6 .511 -11.711 2.003 -4 .0 0 4 1.031 0.934
-6 .3 4 2 -11 .632 1.811 -4 .0 5 6 1.020 0.944
-6 .4 7 0 -11.845 1.744 -4 .1 1 2 1.015 0.942
-0 .3 6 5 -11 .498 1.721 -4 .0 6 5 1.017 0.944
- 6 .5 j2 -11.657 2.053 -5*941 1.025 0.955
- 6 .3 j 1 -11 .430 1.675 -4 .051 1.016 0.944
-6 .4 1 0 -11.520 1.320 -4.001 1.020 0.934
-6 .4 90 -11.786 1.717 -4 .1 2 5 1.009 0.942
-6 .539 -11.791 2.053 -4 .0 1 3 1.025 0.9^4
-0 .518 -11.607 1.636 -4 .1 34 1.006 0.34V
-6 .4 1 0 -11.661 2.035 -3 .329 1.017 0.934
-6 .467 -11.726 1.735 -4 .1 1 0 1.011 0.942
-6 .4 7 0 -11.702 1.664 -4 .1 1 3 1.011 0.342
-6 .3 95 -10.429 1.958 -3 .9 8 3 1.017 0.933
-6 .613 -11.595 1.769 -4 .1 1 0 1.006 0.9 j 6
-6 .525 -11.616 1.917 -4 .0 54 1.012 0.932
-6 .569 -11.887 1.766 -4 .1 00 1.006 0.937
-6 .656 -12.001 1.824 -4 .0 5 6 1.010 0.932
—6 .ouO -11.785 0.196 -4 .507 0.599 0.950
217
E tiOMQ(b) E HOi-iU(p) E LUMO(b) E LUMuCp) E LUMOpii (p )
( a . u . ) ( a . u . ) (a . u . ) ( a . u . ) ( a . u . )
-0 0 4 9 -0 .568 0.103 -0 .0 3 3 0.005
-0.352 -0 .571 0.164 - o .0 3 j 0.006
-0.356 -0 .5 60 0.164 -0 .0 3 5 0.005
-0.372 -0 .541 0.061 -0 .0 5 6 - 0 .0 2 j
-0.301 -0 .591 0.165 -0 .035 0.006
-0.363 -0 .6 0 0 0.166 -0 .0 36 0.006
-0.374 -0 .544 0.062 -0 .0 5 9 -0.031
-0 .379 -0.561 0.076 -0 .0 6 6 -0 .033
-0 .381 -0 .5 6 5 0.077 -0 .0 69 -0 .036
-0 .387 -0 .5 66 0.077 -0 .071 -0 .032
-0 .389 -0 .571 0.076 -0 .071 -0 .037
-0 .413 -0 .580 -0.184 -0 .0 7 3 -0 .062
-0.419 -0 .565 -0 .186 -0 .281 -0 .0 65
-0.430 -0.601 -0 .1 7 0 -0 .2 72 -0 .0 32
-0.461 -0 .6 27 -0 .3 25 -0 .427 -0 .107
-0.424 -0 .5 7 2 -0 .1 4 2 -0 .235 -0 .068
-0.421 -0 .5 9 6 -0 .173 -0 .2 7 6 -0.064
-0 .364 -0 .555 0.156 -0.041 -0 .010
-0.429 -0.601 -0 .1 7 5 -0 .260 -0 .069
-0 .393 -0 .579 0.075 0.075 -0 .043
-0 .488 -0 .6 3 2 -0 .3 4 6 -0 .4 55 -0.112
-0 .447 -0 .608 -0 .181 -0 .2 8 6 -0 .125
IWOO ChbeC1 3(b) ChgeHN7(b) Ch*eC13(p) Ch*ehN7(p)
0.435 0.119 0.504 0.155
0.4^6 0.118 0.505 0.156
0.436 0.116 0.505 0.156
0.442 0.123 0.506 0.161
0.435 0.118 0.505 0.157
0.436 0.118 0.506 0.158
0.443 0.124 0.506 0.162
0.451 0.134 0.514 0.168
0.450 0.134 0.515 0.170
0.450 0,135 0.514 0.170
0.452 0.134 0.515 0.170
0.458 0.143 0.516 0.176
0.460 0.144 0.515 0.177
0.466 0.157 0.523 0.164
0.476 0.157 0.523 0.192
0.465 0.146 0.520 0.133
0.470 0.157 0.525 0.165
0.436 0.120 0.504 0.157
0.469 0.152 0.525 0.167
0.452 0.135 0.514 0.170
0.450 0.185 0.527 0.157
0.475 0.160 0.52b u.190
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STO-^G
STU-3G
E HOMD(b) E HOHO(p) E LUMG(o) E LUIkJ(p) E LUhOph(fcj)
( a . u . ) ( a .u . ) ( a . u . ) ( a . u . ) ( a . U . )
-0.23o -0.416 0.270 -0 .0 56 0.096
-0.241 -0.429 0 .2o6 -0 .0 5 9 0.092
-0 .247 -0.421 0.265 -0 .061 0.090
-0.254 -0.437 0.246 -0 .0 65 0.071
-0 .2 50 -0 .433 0.266 -0 .063 0.065
-0 .255 -0.447 0.264 -0 .0 6 4 0.080
-0 .257 -0.441 0.246 -0 .0 7 0 0.066
-0 .254 -0 .432 0.249 -0 .0 6 5 0.074
-0 .257 -0 .442 0.247 -0 .067 0.070
-0.263 -0 .4^6 0.247 -0 .0 6 9 0.066
-0 .206 -0.447 0.244 -0 .071 0.062
-0 .209 -0.449 0.227 -0 .0 7 6 0.049
-0 .273 -0 .456 0.224 -0 .0 7 8 0.045
-0 .260 -0 .452 0.221 -0 .0 7 6 0.047
-0.2o0 -0 .443 0.225 -0 .078 0.047
-0 .277 -0 .442 0.222 -0 .0 7 9 0.046
-0 .270 -0.446 0.227 -0 .0 7 2 0.053
-0 .257 -0 .426 0.253 -0 .0 7 0 0.070
-0.276 -0 .450 0.224 -0 .0 7 6 0.045
-0 .206 -0.436 0.236 -0 .073 0.056
-0.204 -0.463 0.207 -0 .0 6 3 0.029
-0 .290 -0.471 0.155 -0 .0 90 -0 .005
EE(b) EE(^) Chfc,eC13(p) CbfceHN7(p)
( a . u . ) ( a . u . )
0.500 0.360 0.174 0.312
0.509 0.370 0.175 0 o 17
0.515 0.360 0.175 0.314
0.502 0.366 0.176 0.315
0.516 0.370 0.176 0.315
0o19 0.363 0.177 0.317
0.503 0.371 0.179 0.317
0.503 0.367 0.164 0.318
0.504 0 o 75 0.185 0.320
0.510 0.367 0.165 0.230
0.510 0.376 0.166 0.321
0.496 0.373 0.187 0.321
0.457 0.376 0.168 0.323
0.409 0.376 0.193 0.325
0.505 0.365 0.189 0.324
0.499 0.363 0.159 0.324
0.497 0.374 0.193 0.324
0.510 0.356 0.185 0.319
0.502 0.374 0.194 0.325
0.502 0.365 0.190 0.322
0.491 C.360 0.196 0.327
0.453 0.361 0.19 o 0 .2 j 9
APPENDIX 5
OTHER PROGRAMS USED IN THIS STUDY
A5.1 REGRESS
This program is used for regression analysis when 1arge 
amounts of data are to be considered. The present
program is capable of handling up to 80 data points with 
up to 100 variables for each. Up to four of the
variables may be taken at a time for the regression 
analysis, and the results with a significance (F-value) 
higher than the requested significance are printed out. 
The actual regression analysis is carried out by NAG
routine G02CGF [152]. This program was originally 
written by Dr. Martin Saunders, and has been modified by 
myse1f .
It should be noted that this type of regression 
analysis, which automatical 1y processes large amounts of 
data and can take many variables at a time for each 
regression, can give misleading results as data which is 
not significant may appear in some significant
regression equations. Is it, however, useful for 
spotting trends and variables which appear in a large 
no. of significant regression equations are likely to be 
significant. These variables can be further investigated 
using other regression analyses packages.
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♦ NGUT(35),NV(15).SSR(15,15),COR(15,15),NHOLS,KVARS,NPNTS,NDROPT 
CO^;Oii/HTS/RES(13),COEFF(1Mf 3 ) ,C O iN (3 ) ,A (m ,l4 ) fBClMt 1M)#C(1^,1M)
CHARACTER* 32 NAME 
CHARACTERS LINE 
C READ IN NAME OF DATA AND OUTPUT FILES 
PRINT*,1 1
WRITE( * , ' (A25,$ ) * ) *  ENTER DATA FILENAME — > ’
READ (1,120) I.AME 
120 FQRMATCA32)
OP lit ( UNITsti,FILEs NAME ,STATUS= * GLD1)
PRINT*,* *
URITE(*, 1(A27 »$)*)*  ENTER OUTPUT FILENAME — > *
READ(1,120)NAME
CPENCUNIT=5fFILE=NAME,STATUS=* UNKNOWN*)
C READ IN NO OF POINTS TO BE DROPPED 
PRINT*,* *
wftITE(*, * (A 42 ,$ )* )*  ENTER THE NO. OF POINTS TO BE IGNORED — > * 
READ*,NDRGPT 
PRINT*,* *
DO Bo 1=1,NDROPT
WRITE(*, * (A9,13»A5»$)* )*  POINT N O .* , I , *  — > *
READ*,NGUT(I)
Lb CONTINUE 
PRINT*,* »
NRITE(*, * ( A53 * ^ ) * ) *  ENTER THE No. OF INDECIES BE TAKEN AT A TIME 
+ — > *
HE AD*,NIND 
PRINT*,* *
V<R IT E (* ,* (A 4 0 ,h,)*)*ENTER THE MINIMUM F-VALUE REQUIRED — > *
READ*,FMIN 
PRINT*,* *
PRINT*,*READING IN DATA...*
PRINT*,* »
C READ IN DATA
READC6 , * ) NH0L5,NVARS,NC0L3 
JJ=C
DO 1 J = 1, N VARS, NCOLS 
JJsJJ+1
READ(G,101)LINE
ViRITE(5» 101 )LINE '
DO 2 1=1,NMOLS 
JL= NCOLS*( J J -1)+1 
JU=MIN(JL+NC0LS,NVARS+1) -1  
KEAD(8,*)(DAT(I,K),K=JL,JU)
2 CONTINUE 
1 CONTINUE 
CLOSE(UNIT=o)
PRINT*,*HERE GOES...*
PRINT*,* »
C HOW MANY VARIABLES 
IJKS=2 
IJ LS= 1 
IJ MS = 1 
IJKF=NVAKS-1 
IJLF=NVARS-1 
IJ MF=NVARS-1 
IJNF=NVARS-1 
IF ( NIND. LE. j ) THEN 
IJKF=IJKS 
IJLS=2 
END IF
IF(NIND.LE.2)11IEN 
IJ LF= IJ LS
6S) DC 5004 IJK=IJKS,IJKF
70) IF ( NIHD.GE. 4 ) IJLF=IJ K -1
71) IX) 5003 IJL=IJL5,IJLF
72) I F ( ElMD• GE. 3 ) IJ HF = IJ L - 1
75) DO 5002 IJK=IJMS,IJIiF
7*1) IF ( HIHD. GE.2) IJ NF= IJ M-1
75) DO 5001 IJN=1,IJHF
7c) C IF(IJK.EQ.19)TCEN
77) C I  F( IJ M.EQ. 15 .AND. IJ  li.EQ .12) GOTO 5001
73) c IF(IJL.EQ.13.AND.IJM.EQ.12)GCTO 5001
79) c END IF
30) c IF(IJL.EQ.19)THEN
81) c IFCIJH.EQ. 13.AND.IJN.EQ.12)GOTu 5001
32) c END IF
85) c IF(IJK.EQ.20)THEH
34) c I  F( IJ M. EQ • 15 .AND. IJ  N.EQ•14) GOTO 5001
c5) c IF (IJL .Ew . 15.AND.IJN.EQ. 14)GOTO 5001
£6) c END IF
r r >  \
Of J 0 IF(IJL.Ew.20)THEN
83) c IFUJK.EQ. 15.AND.IJN.EQ. 14)GOTO 5001
oi») c END IF
50) NV (1) = IJII
51) NV(2)=IJM
52) NV(3)=IJL
55) KV(4)=IJK
5*0 I«V C NI ND+1)=NV ARS
55) C SET UP ARRAYS X,Y,XS,YS
56) CALL SETUP
97) IF(KE8(4).LT.FMIN)G0T0 5001
56) NRITE(5t 115)
59) DO 302 1=1,HIND
1CC) WRITE(5» 116) NV( I )  ,CGEFF(1 ,1 )  ,COEFF(1 ,2 )
101) ^C2 CONTINUE
1C2) WRITE(5t 117)C0N( 1) ,CCN(2) ,RES( 11) ,HES( 10) ,RES(4)
105) V.RITE(5i 106)
1C4) 5001 CONTINUE
10-3) 5002 CONTINUE
106) 5005 CONTINUE
10 V) 5004 CONTINUE
106) C
10*) 101 FORHATCA60)
110) 108 FORMAT(//)
111) 115 FORMAT(//* VARIABLE COEFF* ,6X, * + / - » ,  10X,* h ' , 11X, * S
112) 116 F0RMAT(/15»2E14.6)
11j) 117 FuRMATC1 CONST 1 ,E12.6 ,2X ,E12.0 ,3F12.6)
m ) STUP
115) END
116) C
117) SUBROUTINE SETUP
113) IMPLICIT REAL*8 (A -H ,0-Z )
115) COi-jMGN/ DATA/DAT(80,100) ,SS( 15) ,SD( 15) ,RD( 15) ,AMEAN( 1
120) + NGUT(55),NV(15),SSR(15,15),COR(15,15),NMOLS,NVARS
121) COMilON/RTS/RE5(13),COEFF( 14 ,3 ) ,CON( 5) ,A( 14,14) ,B( 14 ,
122) C SlT UP ARKnYS OF CROSS PRODUCTS ETC FOR 002CGF
1*0) li P NT 5= KMCLS- I*D ROP T
124 ) DO 1 1= 1 ,IiIND+1
125) 6B(I)=G.G
126) AMEAN(I)=C.O
127) DO 2 J=1,NMOLS
123) IF(HDROPT.EQ.O)GOTO 31
12*) DC 3 K= 1 ,N'DROPT
13C) 3 IF(NOUT(K).EQ.J)GOTO 2
151) 31 CONTINUE
152) NVI=I»V(I) 222
133) 2 CONTINUE
136) AMEAN ( I  )= AMEAN ( I ) /  RE AL ( NP NTS )
137) SS(I)=SS(I)-REAL(NPNTS)*AHEAN(I)**2
Ijw ) 1 CONTINUE
133) DO 6 I=1,NIND
140) NVI=NV(I)
141) SD(I)=CPD(I,NIND+1,NVI,NVARS)
142) 6 hD(I)=SD(I)/SQhT(SS(I)«SS(NIND+-1))
143) call filcor
144) RETURN
145) END
146) C
147) C
146) 0
149) FUNCTION CPD(K,L,M1,M2)
150) c K,L ARE POSITION6 IN AWEAN AND SS
151) c i-i 1,M2 ARE POSITIONS IN DAT
152) IMPLICIT REAL*6 U -H ,0 -Z )
15j>) COfraiON/ DATA/DAT(80,100) ,3S( 15),SD( 15) ,RD( 15) ,AMEAN(15) ,NIND,
154) + NGUT(35),NV( 15 ) ,SSR( 15 * 15 )*COR(15»15),NMuLS,NVAhS,NPNTS,NDROPT
155) COMiiON/RTS/RES(13),COEFF(14,3),CON(3),A(14,14),B(14,14),C(14,14)
156) CPD= -REAL( NPNTS) * AMEAN( K)*AMEAN( L)
157) DO 1 1=1, NMOLS
16o) li- ( NDROPT.EQ. 0 ) GOTO 21
153) DO 2 J=1,NDH0PT
160) 2 IF(NOUTCJ).EQ#I)G0T0 1
161) 21 CONTINUE
1o2) CPD = CPD+DAT( I ,M 1)*  DAT( I,M 2)
160 ) 1 CONTINUE
164) RETURN
165) END
166) 0
167) c V
16o) c
103) SUBROUTINE FILCOR
170) IMPLICIT REAL*6 (A -L .u -Z)
171) CO MiiuN/ BATA/DAT(6 0 ,1 0 0 ) ,SS( 15) , ld ( 15),RD(15),AMEAN( 1 5 ) ,NIND,
172) «■ nCUT(35) ,NV.( 1u) ,SSR( 15 ,15 ) ,COR( 1 5 ,1 5 ) ,NMOLS,NVAiiS,NPNTS,NDROPT
176 ) CumON/RTS/iiES(13),COEFF(14,3),CON(3),rt(l4,14),L(14,14),C(14,14)
174) M=NIND+1
175) DO 3 I=1,NIND
176) 11=NV( 1)
177) S S R (I, I )= S B (I)
176) I F ( I . l O.NIND)GOTO 2
175) IP=1+1
160) DO 1 J=1P,NIND
16 1) JJ = i.V( J)
162) S S R (I,J )= C P D (1 ,J , I I ,JJ )
163) 1 C0R(I,J)=SSR(I,J )/SQRT(S3(I)*SS(J))
164) 2 SSH(I,M)=SD(I)
1o3) COR(I,M)=RD(I)
1o6) DO 3 U=1,M
167) SSn(J ,I)=SSR(I,J )
10u) COR(J,I)=COR(I,J)
1o5) 3 COR( J , J ) = 1 .0
150) S3R(K,M)=SS(h)
151) CALL 002CGF(NPNTS,h.WlND,AMEAN,SSK,15,COR,1 5 ,RES,CuEFF,14 ,
132) + CON,A,14, b, 14 ,0 ,14 ,0 )
15 j ) RETURN
1^4) END
2 2 *.
A5.2 DRAW
This program enables the user to display and manipulate 
a molecular structure as a 'stick' diagram on a Tetronix 
T4014 graphics terminal. It was written by myself 
primarily to check that molecular structured are correct 
before performing molecular mechanics or molecular 
orbital calculations. It can also be used to orient a 
series of similar molecules on the same X-Y plane.
A menu is displayed on the right-hand side of the screen 
and the various options are selected by typing a number 
corresponding to the option. Prompts for further data, 
if necessary are given at the top of the screen. The 
options are:-
1) GETFILE: To read in as structure file of internal or
cartesian coordinates.
2) PUTFILE: To write a structure file of cartesian 
coordinates corresponding to the present orientation.
3) QUIT:
4) LABELS: Toggles labels on and off.
5) CUE: Toggles a simple form of depth cueing. If the Z- 
coordinate of two atoms is negative, they are joined by 
a dotted rather than a solid line.
6) CALCOMP: Plots the structure on a CALCOMP pen 
plotter.
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7) ROTATE: Rotates the structure around the screen X, Y 
or Z-axis.
8) ORIENT: Orients the structure on the X,Y plane.
9) SHIFT: Translates the structure along the X, Y or Z- 
axis.
10) ZOOM: Alters the size of the displayed structure.
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t i m*s graphics program
•
COMPILE, LOAD AND RUN WITH:-
* FTN77 DRAW -NOCHECK -SILENT -LGO TEKTRC LIQ>VGIN0
•
•««»*» TEKTRC.3IN CONTAINS THE CODE TO LET A TEKTR0NIC3
* T4014 TERMINAL ERASE LINES. IT CAN ALSO BE FOUND
* IN DIRECTORY CMP005>PL0TTING
*
DIMENSION C(3,100),IBOND(100,100)
DIMENSION NAME(2,100),XO(100),YO(100),ZO(100)
DIMENSION X(100),Y(100),Z(100),TITLE(20)
CHARACTERS NAME,TITLE
LOGICAL FIRST
COMMON/INFO/ X,Y,Z,NATOMS
COMMON/SZ/DX,DY,FAC
LOGICAL LABS
MODE=0
LAB3=.FALSE.
SCA= 1 
IT=2
i
«**«t»5ET UP SCREEN*****
CALL GINO 
CALL T4014 
CALL PICCLE
CALL SHIFT2(125.,125.)
CALL SETUP
t
******GET INPUT COORDS ETC.******
CALL GETZM(C,I30ND,NAME,TITLE)
t
CALL PRINT(126.,TITLE,2,20)
*
»
***«**CENTRE AND SCALE COORDS TO FIT SCREEN******
«
FIRST*.TRUE.
CALL SIZE(FIRST)
FIRST*.FALSE.
§
*****»DRAW MOLECULE*****
#
CALL DRAW(IBOND,MODE,2,X,Y,Z,NATOMS)
#
******select OPTION*********
1 CALL SEL0PTC2)
READ-*,IOPT 
******CALL ROUTINE FOR OPTION*******
IFdOPT.EQ. 1 )THEN 
CALL DRAW(IBOND,MODE,1,X,Y,Z,NATOMS)
IF(LA3S)CALL LABELS(1,NAME)
CALL PRINTC126.,TITLE,1,20)
CALL SCRUB 
CALL SELOPT(I)
CALL GETZM(C,IBOND,NAME,TITLE)
FIRST*.TRUE.
CALL PRINT(126.,TITLE,2,20)
CALL SIZE(FIRST)
FIRST*.FALSE. 22 7
CALL SELOPTd)
CALL SCRUB
CALL PUTZM(3CA,NAME,TITLE)
ELSE IF(I0PT.EQ.j)THEM 
CALL PICCLE 
CALL DEVEND
PRINT*, *' /* RETURN TERMINAL TO BASIC MODE
STOP
ELSE IF(IOPT.EQ.il)THEN 
CALL SELOPTd)
CALL SCRUB
CALL LABELS(IT.NAME)
LABS=.NOT.LABS 
IF(IT.EQ.1)THEN 
IT=2 
ELSE 
IT= 1 
END IF 
ELSE IF(IOPT.EQ.5)THEN 
CALL SELOPTd)
CALL DRAW(IBOND,MODE,1,X,Y,Z,NATOMS)
IF(MODE.EQ.0)THEN
MODE=1
ELSE
M0DE=0
END IF
CALL SCRUB
CALL DRAW(IBOND,MODE,2,X,Y,Z,NATOMS)
ELSE IF(IOPT.EQ.6)THEN 
CALL CALCOM(TITLE,LABS,IBOND,NAME)
CALL PENSEL(0,0.,2)
CALL SETUP
CALL DRAW(IBOND,MODE,2,X,Y,Z,NATOMS)
ELSE IF(IOPT.EQ.7)THEN 
CALL SELOPTO)
CALL SAVE(XO,YO,ZO)
CALL SCRUB
CALL ROTATE(LA3S,NAME)
CALL SIZE(FIRST)
CALL DRAW(IBOND,MODE,1,XO,YO,ZO,NATOMS)
CALL DRAW(IBOND,MODE,2,X,Y,Z,NATOMS)
IF(LABS)CALL LABELS(2,NAME)
EL.SEIF (IOPT. EQ. 8 )THEN 
CALL SELOPTd)
CALL SAVE(XO,YO,ZO)
CALL SCRUB
CALL ORIENT(LABS,NAME)
CALL SIZE(FIRST)
CALL DRAW(IBOND,MODE,1,X0,Y0,Z0,NATOMS)
CALL DRAW(IBOND,MODE,2,X,Y,Z,NATOMS)
IF(LABS)CALL LABELS(2,NAME)
ELSE IF(IOPT.EQ.9)THEN 
CALL SELOPTd)
CALL SAVE(XO,YO,ZO)
CALL SCRUB.
CALL MOVE(LA3S,NAME)
CALL DRAW(IBOND,MODE,1,XO,YO,ZO,NATOMS)
CALL DRAW(IBOND,MODE,2,X,Y,Z,NATOMS)
IF(LABS)CALL LABELS(2,NAME)
ELSE IF(IOPT.EQ.!0)THEN 
CALL SELOPTd)
CALL SAVE(XO,YO,ZO)
CALL SCRUB
1 j5) IF (LAJo)CAL.L. L.A62L.5 (2 , NA.1E)
1 j 7) EL.52 IF (IJPT. ciy . 1 1) THEN
1 ) 5AL.L. JEL.JPT(I)
i_,9) ■-.nlili ouEvJO
Nu; 5AL.L. D2L.2T2 (150.«'J , NA.iE, L.A55)
’-*1) iF (L.Ad5)CAL.L. L.A3EL.5 (2 , Na.iE )
132)
1^3) END IF
:^) *
:-5) 50TJ 1
136) END
1*7) *
1*3) 4 4 4 4 4 x 4 * 4 * * 4 * 4 * 4 * 4 4 * 4 4
1*9) *
150) 3U3R0UTINE PRINT(Y,CHARS,IT,IDI.V
151 ) *
1 52) 4 * 4 4 4 4 4 4 4 4 4 4 4 * 4 4 * 4 4
155) 4
’54) CHARACTERS CHARo(IDIiJ)
155) *
156) DATA X/-120./
’57) CALL. PSN5EL. LO,0 • , IT j
153) CALL M0VT02(X,Y)
i30) *
’.60) CALL CHAARR(CHARo, IDIM,2)
lol) CALL M0VT02(-120.,1j9.)
1o2 J CALL CRAMOD
’6 j) 4
164) RETURN
155) 250
166) *
16 7) 4 4 4 4 4 4 4 X 4 4 * 4 4 4 4 4 4 4 4 4 *
163) 4
169) SUBROUTINE SSLOPT(IT)
170) 4
171) 4 4 4 4 4 4 4 4 4 4 * 4 4 4 4 4 4 4 * * 4 4
172) 4
175) CHARACTERS NOTE(7)
174) DATA (NOTE(I) ,1=1, 7)/ * ' ,  ’LE1, '
175) 4 •
176) CALL PRINT( 147.,NOTE,IT,7)
177) RETURN'
175) END
179) *
130) 4 4 4 4  4 4 * 4 * 4 4 4 4 4 4 4 4 4 4 4 4 4 4
131 ) *
152) SUBROUTINE SCRUB
13. ) 4
134) 4 4 4 4 4 4 4 4 4 4 X 4 4 4 * * 4 * * 4 4 4 4
155) 4
155) DO 10 Y=1j9.,14o.
137) CALL PEN3EL.(0,0.0,1)
156) CAL.L :i'JVT02(-124.,Y)
139) CALL L.iNi3Y2(2**. ,0.)
190) 10 CONTINUE
191 ) CAL.L P^ i)ou>L*^ oyij«}2)
132) RETURN
19j) END
194) 4 4 4 4 4 4 4 * 4 4 * 4 4  4 4 4 4 4 4 4  4 * 4  4 4 4 4 4
195) 4
196) SUBROUTINE DRAH(X30ND,CODE,L.INE,]
137) 4
193) 4 4 * 4  4 4 4  4  4 4 4 * 4  4 4 4 4 4 * 4  4 4 4  4 4 4 4  4
.
J’ ,’PT* '10 , 'N '/
229
202 •
203 CALL WIND02( 0 . , 2 5 0 . , 0 . ,2 5 0 . )
20* *
205 CALL PENSEL( 0 ,0 .0 , LINE)
206 DO 30 1=1,NATOMS
207 CALL iM0VT02(X(I) , Y ( I )  )
203 DO *0 J= I+1, NATOMS
209 IF(IBOMD(I, J),NE.0)THEN
210 IF(Z(I).LT.O.AND.Z(J).LT.O)CALL DASHED(MODE,5 . ,2 .5 , 2 . 5 )
211 C CALL CHAMOD
212 C PRINT*, MODE
213 CALL L.INT02(X(J),Y(J))
21* CALL M 0 V T 0 2 (X (I ) ,Y ( I ) )
215 CALL DASHED( 0 , 0 . , 0 . , 0 . )
216 END IF
217 *0 CONTINUE
218 30 CONTINUE
219 *
220 CALL WINDOW(0)
221 RETURN
222 END
223
^  I t22*
225 •
225 SUBROUTINE SIZE(FIRST)
227 «
228
229 *
230 ****CENTRE5 MOLECULE ON ORIGIN AND SCALES IT * * *« » *
231 *
232 REAL MAXX, MAXY, MINX, MINY
233 DIMENSION X(10Q),Y(100),Z(100)
23* LOGICAL FIRST
235 COMMON/INFO/ X,Y,Z,NATOMS
236 COMMON/SZ/DIX, DIY, FAC
237 •
238 IF  (.NOT.FIRST)THEN
239 DO 5 1=1,NATOMS
2*0 X(I)=X (I) /FA C
2*1 Y(I)=Y (I) /FA C
2*2 Z (I)= Z (I) /F A C
2*3 5 ■ CONTINUE
2 * * END IF
2*5 MAXX=X(1)
2*6 MINX=X(1)
2*7 MAXY=Y(1)
2*8 MINY=Y(1)
2*9 •
250 DO 10 1=2,NATOMS
251 IF(X(I).GT.MAXX)MAXX=X(I)
252 IF(X(I).LT.M INX)MINX=X(I)
253 IF(Y(I).GT.MAXY)MAXY=Y(I)
25* IF(Y(I).L.T.MINY)MINY=Y(I)
255 10 CONTINUE
256 *
257 •
253 ""CENTRE MOLECULE*****
259 •
260 DIFX=MAXX-MINX
261 DIFY=MAXY-MINY
262 DIX=MINX+DIFX/2
263 DIY=MINY+DIFY/2
26* DO 20 1=1.NATOMS
2 30.
270) **###*SCALE MOLECULE
271) 1
272) IF(DIFX.GE.DIFY)THEN
273) FAC=DIFX
274) ELSE
275) FAC=DIFY
276) END IF
277) FAC=250/FAC*.85
278) CALL CHAMOD
279) DO 30 1=1,NATOMS
280) X(I)=X(I)*FAC
281) Y(I)=Y(I)#FAC
282) Z(I)=Z(I)*FAC
283) 30 CONTINUE
284) *
285) RETURN
286) END
287) *
288)
289) *
290) SUBROUTINE ROTATE(LABS,NAME)
291) •
292)
293) *
294) DIMENSION X(100),Y(100),Z(100),N0TE(13)
295) CHARACTER*2 NOTE,NAME(2,100)
296) LOGICAL LABS
297) COMMON/INFO/ X,Y,Z,NATOMS
298) DATA PI/3.1415926/
299) DATA (NOTE (I), 1 = 1,13)/*EN*, 'TE' , 'R V X , 1,' Y\' A ’.'ND',* Z»,
300) + * R',1OT','AT’,'10',*NS'/
301) »
302) CALL PRINT(147.,NOTE,2,13)
303) READ*, XROT,YROT,ZROT
304) IF(LABS)CALL LABELS(1,NAME)
305) *
306) ****** R=DISTANCE OF ATOM FROM AXIS
307) ****** phi = ANGLE ATOM-ORIGIN-AXIS
303) ****** TriETA = ANGLE ROTATED ATOM-ORIGIN-AXIS-
309) *
310) IF(A3S(XR0T-0).GT.1E-2)THEN
311) XR0T=XR0T«PI/180.
312) DO 10 1=1,NATOMS
313) *
314) IF(Z(I).NE.O.OR.Y(I).NE.O)THEN
315) R=SQRT(Y(I)*Y(I)+Z(I)*Z(I))
316) PHI=ATAN2(Y(I),Z(I))
317) THETA=PI/2-(XR0T+PHI)
318) Y(I)=R*COS(THETA)
319) Z(I)=R*SIN(THETA)
320) END IF
321) *
322) 10 CONTINUE
323) END IF
324) *
325) IF(ABS(YROT-O).GT.1E-2)THEN
326) YR0T=YR0T*PI/180.
327) DO 20 1=1,NATOMS
328) *
329) IF (X(I).NE.O.OR.Z(I).NE.O)THEN
330) R=3QRT(X(I)*X(I)+Z(I)*Z(I))
33*0 Z(I)=R«SIN(THETA)
335) END IF
335) »
337) 20 CONTINUE
338) END IF
339) *
390) IF(A8S(ZROT-0).GT.1E-2)THEN
391) ZSOT=ZROT*PI/180.
392) DO 30 Isi,NATOMS
393) •
399) IF (X(I).NE.O.OR.Y(I).NE.O)THEN
395) RsSQRT(X (I) *X (I )+X (I) *Y (I) )
396) PHI=ATAN2(X(I),X(I))
397) THETA=PI/2-(ZROT+PHI)
398) X(I)=R*COS(THETA)
399) X(I)=R*3IN CTHETA)
350) END IF
351) *
352) 30 CONTINUE
353) END IF
359) CALL PRINTC197.,NOTE,1,13)
355) CALL SCRUB
356) »
357) RETURN
353) END
359) *
360) •«
361) »
362) SUBROUTINE GETZMCC,IBOND,NAME,TITLE)
363) *
369) *«
365)
366) DIMENSION C(3,100) , ICON(100,4) ,ITYPE(;100) ,IB0ND(100,100)
367) DIMENSION X(100),Y(100), Z(100),TITLE(20)
368) DIMENSION IREF(3,100),BOND(100),ANG(100),TOR(100)
369) DIMENSION NOTE(12),IATN(100),NAME(2,100)
370) CHARACTER#2 NOTE,TITLE,NOTE 1(16)
371) CHARACTERS INFIL
372) CHARACTER#2 NAME -
373) CHARACTERS IATN
379) DIMENSION NI(100),IN(100),V(3)»EX(3)iEY(3),EZ(3)
375) COMMON/INFO/ X,Y,Z,NATOMS
376) COMMON/ZM/ICON,ITYPE
377) COMMON/NI/NI
378) DATA (NOTE(I),1=1,12)/*EN','TE1,'R •,»Z.','MA•,'TR•,
379) + ' I X ' F ’,*IL1,'EN1,'AM’,'E '/
380) *
381) 500 CALL PRINT(147.,NOTE,2,12)
382) READ(1,'(A)1)INFIL
383) OPEN (5, FILE=INFIL., STATUS = ' OLD', ERR=501)
389) DO 50 I=2,32,2
385) J=I/2
386) 50 N0TE1(J)=INFIL(I-1:I)
337) *
388) READ(5,120,ERR=502 ) (TITLE(I),1=1,20)
389) READ(5,*,ERR=502 ) IOPT,NATOMS
390) 120 FORMAT(20A2)
391) IX=1+I0PT
392) DO 2 I=1,NAT0M3
393) 2 READ(5» *,ERR=502 )NI(I)
399) REWIND(5)
395) READ(5,120,ERR=502 )(TITLE(I),1=1,20)
396) READ(5,•,ERR=502)IOPT,NATOMS
2 32
400 ♦ ,ITYPE(M)
401 1 IN(N)=NO
402 do 15 m=ix,natoms
403 NO=NI(M)
404 READ(5,*,ERR=502 ) N,IATN(NO),K1,K2,K3,3D,BA,DA, 
+ (ICON(NO,K),K=1,4),ITYPE(NO)405
406 IREF(1,M)=K1
407 IREF(2,M)=K2
408 IREF(3,M)=K3
409 BOND(M)=BD
410 ANG(M)=BA
411 TOR(M)=DA
412 IN(N)=NO
413 THT=(180.O-BA)*0.0174 5329252
414 PHIa DA *0.01745329252
415 IFCiM.LT. 3) THEN
416 DO 4 1=1,3
417 4 C(I,N0)a0.0
418 IFCM.E0.2) C(1,N0)=BD
419 ELSE IF (M.EQ.3) THEN
420 C(1,N0)=C(1,2)+BD*C0S(THT)
421 C(2,N0)=BD*SIN(THT)
422 C(3,N0)=0.0
423 ELSE
424 i(1 =IN (K1)
425 K2aIN(K2)
426 DO 7 1=1,3
427 7 EZ(I)=C(I,K1)-C(I,K2)
428 R=SQRT(EZ(1)**2+EZ(2)**2+EZ(3)**2)
429 DO 8 1=1,3
430 8 EZ(I)=EZ(I)/R
431 IF(ABS(BA-180.0) .LT. 0.001) THEN
432 DO 9 1=1,3
433 9 C(I,N0)=C(I,K1)+BD*EZ(I)
434 ELSE
435 K3=IN(K3)
436 DO 11 1=1,3
437 1 1 « V(I)=C(I,K2)-C(I,K3)
438 EY(1)=V(2)*EZ(3)-V(3)*EZ(2)
439 EY(2)=V(3)*EZ(1 )-V(1)*EZ(3)
440 EY(3)=V(1)*EZ(2)-V(2)*EZ(1)
441 R=SQRT(EY(1)**2+EY(2)**2+EY(3)**2)
442 DO 12 1=1,3
443 12 EY(I)=£Y(I)/R
444 EX C1)=EY(2)*EZ(3)-EY(3)*EZ(2)
445 EX(2)=EY(3)*EZ(1)-EY(1)*EZ(3)
446 EX(3)=EY C1)*EZ(2)-EY(2)*EZ(1)
447 DO 13 1=1,3
448 V(I)= 3D*(SIN(THT)*C0S(PHI)*EX(I) +
449 * SIN(THT)*SIN(PHI)*EY(I)+
450 * COS(THT)*EZ(I))
451 13 C(I,N0)=C(I,K1)+V(I)
452 END IF
453 END IF
454 15 CONTINUE
455
456
C
in it n  t n n n  ^  n  a  a i i t  n  a n  m  ■ a m m•SET UP IBOND FROM ICON*****
457 ******IB0ND(I,J)=1 IF x and j BONDED**” *
458 #
459 c DO 22 1=1,NATOMS
460 c PRINT*,(IC0N(I,J),J=1,4)
461 c 22 CONTINUE
462 DO 5 1=1,NATOMS
D uunJLxnuc>
466) DO 10 1=1,NATOMS
467) DO 20 J = 1,4
468) IF(IC0N(I,J).NE.0)THEN
469) IBOND(I,ICON(I,J))=1
470) END IF
471) 20 CONTINUE
472) 10 CONTINUE
473) C DO 99 1=1,NATOMS
474) C 99 WRITE(*,98)(IBOND(I,J),J = 1,14)
475) c 98 FORMAT(1413)
476) *
477) CLOSE(5)
478) •
479) •SET UP NAME ( CHAR»2 ) FROM IATN ( CHAR*4 )**
480) DO 40 1=1,NATOMS
481) NAMEO ,I)=IATN(I) (1:2)
482) NAME(2,I)=IATN(I)(3:4)
483) 40 CONTINUE
484) DO 30 1=1,NATOMS
485) X(I)=C(1,I)
486) Y(I)=C(2,I)
487) Z(I)=C(3,I)
438) 30 CONTINUE
489) CALL PRINT047.,NOTE, 1,12)
490) CALL PRINT(139.,N0TE1,1,16)
491) *
492) RETURN
493) •
494) 501 CALL PRINT(147.,NOTE,1,12)
495) CALL PRINT(147.,'ERROR IN OPENING FILE*,2,11)
496) CALL SCRUB
497) CLOSE (5)
498) CALL PRINT(147.,'ERROR IN OPENING FILE*,1,11)
499) GOTO 500
500) 502 CALL PRINT(147.,NOTE,1,12)
501) CALL PRINT(147.,’FORMAT ERROR IN FIL.E’,2,10)
502) CALL SCRUB
503) CLOSE(5)
504) CALL PRINT(147.,*FORMAT ERROR IN FILE’,1,10)
505) GOTO 500
506) END
507)
508) t
509) SUBROUTINE LABELS(IT,NAME)
510) *
511)
512) *
513) DIMENSION X(100),Y(100),Z (100)
514) DIMENSION NAME(2,100)
515) CHARACTER*2 NAME
516) COMMON/INFO/ X,Y,Z,NATOMS
517) *
518) CALL WIND02(0.,250.,0.,250.)
519) CALL PEN3EL(0,0.0,IT)
520) *
521) DO 10 1=1,NATOMS
522) CALL M0VT02(X(I),Y(I))
523) CALL CHAARR(NAME(1,I),2 ,2)
524) 10 CONTINUE
525) CALL WINDOW(O)
526) RETURN
527) END
528) *
P  J  J y J U O n v U A A  i l t t  V A U V  V t  l  V A A  ^ M U  I  w n  WM y ^  v  I  u n i  iw  /
532) •
533) •••••••••*••••••••••*•*••••
534) •
535) CHARACTERS PLOTFI
536) CHARACTERS NAME(2,100)
537) INTEGER INF0(29),BUFFER(400),C0DE
538) DIMENSION X(100) ,Y(100),Z(100),TITLE(20)
539) DIMENSION IB0ND(100,100)
540) EXTERNAL SPOOLS
541) SAVE N
542) DIMENSION N0TE1(10),N0TE2(10)
543) CHARACTERS NOTE 1 ,N0TE2,TITLE
544) LOGICAL LABS
545) C0MM0N/INF0/ X,Y,Z,NATOMS
546) •
547) DATA (N0TE1(I),1=1,10)/’PL',’OT',' S','EN’, ' T ','TO*,
548) + 1 C' 'AL' *C0* 'MP'/
549) DATA (N0TE2CI) ,1 = 1,10)/'ER', 'R0', 'R *, *PL', '0T', ' N ’,'0T',
550) + • S ',* EN',' T '/
551) DATA PLOTFI/'PLOTFI’/
552) »
553) N=1
554) 0PEN(UNIT=9, FILE=PL0TFI)
555) CALL CC906N
556) CALL SHIFT2C125.,125.)
557) CALL SCALE(210./250•)
558) CALL DRAW(IB0ND,MODE,2,X,Y,Z,NATOMS)
559) IF(LABS)CALL LABELS(2,NAME)
560) CALL M0VT02(-120.,126.)
561) CALL CHAARR(TITLE,20,2)
562) CALL SCALE(250./210.)
563) CALL DEVEND
564) CALL T4014
565) CALL PICCLE
566) CALL SHIFT2(125.,125.)
567) *
568) INF0(1)=0
569) INF0(2)=0
570) INF0(3)=:1100
571) INF0(4)= *PE'
572) INF0(5)='N '
573) INF0(6)=' ’
574) INF0(7)=0
575) INF0(13)='NC»
576) INF0(14)=’AL'
577) INF0(15)=*C0’
578) INF0(16) = *MP'
579) INF0(17)=* '
530) INF0(18)=’ '
531) INF0(19)=' '
532) INF0(20)=' »
583) CALL SP00L$(1,PLOTFI,6,INFO,BUFFER,400,CODE)
584) CALL WINDOW(O)
535) IF(C0DE.N£.0)THEN
586) CALL PRINT(147.,N0TE2,2,10)
587) DO 10 1=1,2000
588) 10 CONTINUE
589) CALL PRINT(147.,N0TE2,1,10)
590) ELSE
591) CALL PRINT(147.,N0TE1,2,10)
592) DO 20 1=1,2000
593) 20 CONTINUE
594) CALL PRINT(147. .NOTE1,1 *_10) j -
598) N=N+1
599) •
600) RETURN
601) END
602) *
603)
604) »
605) SUBROUTINE MOVE(LABS,NAME)
606) «
607) • H H H I H f l . H H H . H . H I .
608) *
609) DIMENSION X(100),Y(100),Z(100),N0TE(17)
610) CHARACTERS NOTE,NAME(2,100)
611) LOGICAL LABS
612) COMMON/INFO/ X,Y,Z,NATOMS
613) DATA (NOTE(I),1=1,17)/*EN*,'TE*,'R ','X •,' ,Y',’AN•,'D ',*Z »
614) + ,' CR',' EM','EN','TS *,’ (’,' M ’,'M »,') '/
615) *
616) CALL PRINT(147.,NOTE,2,17)
617.) READ*,XS,YS,ZS
618) IF(LABS)CALL LABELS(1,NAME)
619) *
620) DO 10 1=1,NATOMS
621) X(I)=X(I)+XS
622) Y(I)=Y(I)+YS
623) Z(I)=Z(I)+ZS
624) 10 CONTINUE
625) CALL PRINT(147.jNOTE,1,17)
626) CALL SCRUB
627) RETURN
628) END
629) *
630) #*#«»•##«#*#*##***#***#.#
631) #
632) SUBROUTINE EXPAND(SCA,LABS,NAME)
633) *
634) DIMENSION N0TE(9),X(100),Y(100),Z(100)
655) CHARACTERS NOTE,NAME(2,100)
636) LOGICAL LABS .
637) COMMON/INFO/ X,Y,Z,NATOMS
638) DATA (NOTE(I),1 = 1,9)/'EN’,'TE*,»R ',»SC*,»AL',’E ','FA', 'CT',
639) + 'OR'/
640) *
641) CALL PRINT(147.,N0TE,2,9)
642) READ*,SCA
643) IF(LA3S)CALL LABELSO ,NAME)
644) * .
645) DO 10 1=1,NATOMS
646) X(I)=X(I)»SCA
647) Y(I)=Y(I)»SCA
648) Z(I)=Z(I)»SCA
649) 10 CONTINUE
650) CALL PaiNT(!47.,NOTE,1,9)
651) CALL SCRUB
652) •
653) RETURN
654) END
655) *
656) «»i»*m »«h «..«*«#.i h #h «i h h «««#
657) •
658) SUBROUTINE SAVE(XO,YO,ZO)
659) *
660) *«»#«««*t»»i»««»»H«i«»*««#»«»i#»*- - , - . . ■
, ' I N ’
6&3J COMMON/INt o/ A , I , L , NATUMS
664) *
665) DO 10 1=1,NATOMS
666) X0(I)=X(I)
667) Y0(I)=Y(I)
668) Z0(I)=Z(I)
669) 10 CONTINUE
670) *
671) RETURN
672) END
673) *
674) • • • H . H l H . H t . H . M I . H . I . H .
675) *
676) SUBROUTINE SETUP
677) •
678) *****.**<*«<»#**.**»*»***«*****
679) *
680) CHARACTERS MENU(4S)
681) DATA (MENU(I),1 = 1,48)/' G','ET1,'FI','LE',» P1, 'UT','FI',
682) + 'LE*,» 0','UI','T ',* ',' L','AB','EL*,'S ',' C','UE',
683) + ’ ' , '  ' , '  C' , ' AL' , ' CO' , » MP' , '  R ' , 'OT*, 'A T ' , 'E ' , '  O ',
684) + »RI','EN','T ',» S','HI','FT',' ',' Z',’00','M ','
685) + 'DE','LE','TE',' ','AD','D ',' »,' '/
636) *
687) *
688) *##t#*«#sET UP SCREEN********
689) *
690) CALL M0VT02(-125.,-125.)
691) CALL LINT02(-125.,154.)
692) CALL LINT02(236.,154.)
693) CALL LINT02(236.,-125.)
694) CALL LINT02(-125.,-125.)
695) CALL M0VT02(125.,-125.)
696) CALL LINT02(125.,154.)
697) CALL M0VT02(-125.,125.)
698) CALL LINT02(125.,125.)
699) *
700) POS=147.
701) DO 10 1=1,12
702) CALL M0VT02(150.,POS) *
703) CALL CHAINT(I,2)
704) CALL CHAARR(MENU(4*I-3),4,2)
705) P0S=P0S-20.
706) 10 CONTINUE
707) RETURN
708) END
709) *
710) •»«#«»*•»««•»•*»•#«
711) *
712) SUBROUTINE PUTZM(SCA,NAME,TITLE)
713) *
CHARACTERS TITLE(20),N0TE(7),NAME(2,100),NOTE1(16) 
CHARACTER*32 OUTFIL
DIMENSION X(100),Y(100),Z(!00),IC0N(100,4),ITYPE(100) 
COMMON/INFO/ X,Y,Z,NATOMS 
COMMON/SZ/DIX,DIY,FAC 
COMMON/ZM/ICON,ITYPE
DATA (NOTE(I),I=1,7)/'EN','TE','R ','FI','LE','NA','ME'/
CALL PRINT(147.,NOTE,2,7)
READ(*,'(A)') OUTFIL 
0PEN(6,FILE=OUTFIL)
2 3 7
715
716
717
718
719
720
721
722
723
724
725
726
730) WRITE(6,100)(TITLE(I),1=1,20)
73'.) 100 FORMAT(20A2)
732) WRITE(6,101)NATOMS,NATOMS
733) 101 FORMAT (21*1)
73*0 DO 10 1=1,NATOMS
735) X(I)=X(I)/(SCA*FAC)+DIX
736) Y(I)=Y(I)/(SCA*FAC)+DIY
737) C PRINT*,DIX,DIY
733) Z(I)=Z(I)/(SCA*FAC)'
739) WRITE(6,102) I,(NAME(J,I),J=1,2),X(I),Y(I),Z(I),
7*10) + (IC0N(I,J),J=1,4),ITYPE(I)
741) 10 CONTINUE
712) 102 FORMAT(14,2X,1»1 * ,2A2, • • "  ,3F10.5,4I4,2X,I4)
713) «
711) CLOSE(6)
715) ft
716 ) • CONVERT FROM ANGSTROMS BACK TO SCREEN COORDINATES
7 1 7 ) ft
7 1 6 ) DO 20 1=1,NATOMS
7 1 9 ) X(I)=X(I)*SCA*FAC+DIX
750) Y(I)=Y(I)*SCA*FAC+DIY
75)) Z(I)=Z(I)*SCA*FAC
752) 20 CONTINUE
753) CALL PRINT(147.,NOTE,1,7)
7 51 ) CALL PRINT(139.,N0TE1,1,16)
755) RETURN
756) END
757)
758) ft
759) SUBROUTINE ORIENT(LABS,NAME)
760) ft ---
761)
762) ft'
763) DIMENSION X(100),Y(100),Z(100),X1(100),Y1(100),Z1(100)
764) INTEGER I,J,III,K,JJJ,NATOMS,KKK
765) CHARACTER*2 NOTE(16),NOTE1(16),N0TE2(17),N0TE3(11),NAME(2,100)
766) LOGICAL LABS
767) COMMON/INFO/ X,Y,Z,NATOMS
768) COMMON/NI/NI(100) -
769) DATA (N0TE(I),I = 1,16)/'AT V O M V  T*,»0 *, ’BE1, * P’/LA*,
770) + *CE*,*D ’,’ON*,* T*,*HE*,1 0*,'RI',*GI*,*N */
77!) DATA (N0TE1 (I),1 = 1,16)/'AT'^OM',* T','0 \ ' B E V  P'/LA',
772) + 'CE1,*D ',1ON',' T*, •HE*, * X*, * A',»XIVS »/
773) DATA (N0TE2(I),1=1,17)/'AT',*0M',* T','0 ','BEV P','LA',
771 ) + 1CE1,' D V I N V  T \ ’H E V  X*,'Y *,'PL*,»ANVE »/
775) DATA (N0TE3(I),1=1,11)/*N0','T 1,'FO','UN','D 'TR ',
776) + *Y ','AG','AI','N •/
777) ft
778) IF(LABS)CALL LABELS(1,NAME)
779) CALL NUMBS(3)
780) 11 CALL PRINT(147.,N0TE,2,16)
781) READ(1,1)III
782) IF(III.GT.NATOMS)THEN
783) CALL PRINT(W.,NOTE, 1,16)
784) CALL PRINT(147.,N0TE3,2,11)
735) DO 1 1=1,1000
786) 1 CONTINUE
787) CALL PRINT(147.,N0TE3,1,11)
788) CALL SCRUB
789) GOTO 11
790) ENDIF
791) TRANSX=X(III)
792) TRANSY=Y(III)' «< ~ /  . " 2 3  8
796) 50 CONTINUE
797) DO 60 J=1,NATOMS
793) Y1(J)=Y(J)-TRANSY
799) 60 CONTINUE
800) DO 70 K=1,NATOMS
801) Z1(K)=Z(K)-TRANSZ
802) 70 CONTINUE
8 0 3 ) CALL SCRUB
804) CALL PRINT(147.,NOTE,1,16)
805) 12 CALL PRINT(147.,N0TE1,2,16)
806) READ(1,*)JJJ
307) IF(JJJ.GT.NATOMS)THEN
808) CALL PRINT(147.,N0TE1,1,16)
809) CALL PRINT(147.,N0TE3,2,11)
810) DO 2 1=1,1000
811) 2 CONTINUE
812) CALL PRINTC147.,N0TE3,1,11)
8 1 3 ) CALL SCRUB
814) GOTO 12
315) ENDIF
816) CALL SCRUB
817) CALL PRINTC147.,N0TE1,1,16)
818) 13 CALL PRINT(147.,N0TE2,2,17)
819) READ(1,*)KKK
820) IF(KKK.GT.NATOMS)THEN
821) CALL PRINT(147•,N0TE2,1,17)
322) CALL PRINT(147.,N0TE3,2,11)
823) DO 3 1=1,1000
824) 3 CONTINUE
825) CALL PRINT(147.,N0TE3,1,11)
826) CALL SCRUB
827) GOTO 13
828) END IF
829) CALL NUMBS(1)
830) DIST2=X1(JJJ)*X1(JJJ) + Y1(JJJ)#Y1(JJJ)
331) DIST=SQRT(DIST2)
332) 3INTH=Y1(JJJ)/DIST
833) C0STH=X1(JJJ)/DIST
334) DO 100 J=1,NATOMS
835) X(J)=X1(J)*COSTH + Y1(J)*SINTH
336) 100 CONTINUE
837) DO 101 J=1,NATOMS
8 3 8 ) Y(J)=Y1(J)*COSTH - X1(J)fSINTH
839) 101 CONTINUE
840) DO 102 J=1,NATOMS
841) Z(J)=Z1(J)
842) 102 CONTINUE
843) DIST2=X(JJJ)«X(JJJ) + Z(JJJ)»Z(JJJ)
844) DIST=SQRT(DIST2)
845) SINPHI=Z(JJJ)/DIST
346) COSPHI=X(JJJ)/DIST
847) DO 110 1=1,NATOMS
848) X1(I)=X(I)»C0SPHI + Z(I)*SINPHI
849) 110 CONTINUE
850) DO 111 1=1,NATOMS
851) Z1(I)=Z(I)*C0SPHI - X(I)*SINPHI
352) 111* i 4 CONTINUE
853) DO 112 1=1,NATOMS
854) Y1 (I)=Y(I)
855) 112 CONTINUE
356) DIST2=Y1(KKK)*Y1(KKK) + Z1(KKK)*Z1(KKK)
857) DIST=SQRT(DIST2)
358) * 1 SINPSI=Z1(KKK)/DIST
862) 140 CONTINUE
863) DO 150 1=1,NATOMS
864) Z(I)=Z1(I)*C0SP5I - Y1(I)*SINPSI
865) 150 CONTINUE
8 6 6 ) DO 151 1=1,NATOMS
867) X(I)=X1(I)
863) 151 CONTINUE
869) CALL SCRUB
870) CALL PRINT(147.,N0TE2,1,17)
871) RETURN
872) END
873) *
8 7 4 )
875) *
876) SUBROUTINE NUMBS(IT)
877) *
878)
879) *
880) DIMENSION X(100),Y(100),Z(100)
881) COMMON/INFO/ X,Y,Z,NATOMS
882) COMMON/NI/NI(100)
883) *
884) CALL WIND02(0.,250.,0.,250.)
885) CALL PENSEL(0,0•,IT)
8 8 6 ) DO 10 1=1,NATOMS
887) IF(NI(I).EQ.O)GOTO 10
8 8 8 ) CALL M0VT02(X(I),Y(I))
889) CALL CHAINT(NI(I),2)
890) 10 CONTINUE
391) CALL WINDOW(O)
892) RETURN
893) END
894) »
895) •»*«•««•»»••«***«»»**»••
896) «
897) SUBROUTINE DELETE(IBOND,NAME,LABS)
893) *
8 9 9 ) »»*««•«•«*•««»»««*»•*«•*
900) * -
901) DIMENSION X(100),Y(100),Z(100),IBOND(100,100)
902) CHARACTER NOTE*28,NOTE 1*28,ANS,NAME(2,100)*2
903) LOGICAL LABS
904) COMMON/INFO/ X,Y,Z,NATOMS
9053 COMMON/NI/NI(100)
906) *
907) DATA NOTE/'ENTER ATOM NO. TO BE DELETED*/
903) DATA N0TE1/'DELETE ANOTHER ATOM [Y/N] »/
909) *
910) IF(LABS)CALL LABELS(1,NAME)
911) CALL NUMBS(2)
912) 1 CALL PRINT(147.,NOTE,2,14)
913) READ*,N
914) CALL DRAW(IBOND,0,1,X,Y,Z,NATOMS)
915) CALL NUM33(1)
916) NAME(1,N) = * '
917) NAME(2,N) = * *
913) NI(N)=0
919) DO 10 1=1,NATOMS
920) IBOND(I,N)=0
921) IB0ND(N,I)=0
922) 10 CONTINUE
923) CALL DRAW(IBOND,0,2,X,Y,Z,NATOMS)
924) CALL NUMBS (2)
927 ) L>AL*u rnxwi v i*t i . f nwj-t. • /
928) CALL SCRUB
929) READC*,'(A)')ANS
930) CALL PRINT(147.,N0TE1,1,14)
931) IFCANS.EQ.'YOGOTO 1
932) RETURN
933) END
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A5.3 FILES
This program converts the file formats between the 
different types required by the various programs used in 
this study. It was written by myself, with the
exception of the routines to input a W D  (Video Vector 
Dynamics) file type, which is from the White molecular 
mechanics program [65], and the routines to input an 
internal coordinate file and a crystal coordinate file, 
which were written by Dr. Martin Saunders.
The input file types can be:-
Z-MATRIX: unformatted internal coordinate file which may 
also consist partially or entirely of cartesian 
coordinates.
VVD: Output from the White M.M. program [65],
CNINDO: Output from a CNDO/INDO molecular orbital
program.
TRICLINIC: Crysta11ographic triclinc coordinate which
also included unit cell information.
The output file types may be:_
Z-MATRIX: Formatted internal coordinates.
Z-MATRIX (Coords.): Formatted cartesian coordinates.
VVD: Input to the White M.M. program.
CNINDO: Input to the CNDO/INDO molecular orbital
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program.
PLUTO: Input for the PLUTO [153] molecular display package.
CSSR: Used as input for the ORBIT [99] eigenvector display 
program.
The input and output file type is deduced by the program 
from the filename extension. If a valid extension is not 
given, the user is prompted for the file type.
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5)
6) »
7) «
8) IMPLICIT REAL*8(A-H,0-Z)
9) CHARACTERS T ITLE(80), NAMES(100,3)
10) CHARACTERS C0NN( 100,4)
11) DIMENSION C (3 ,100 ), ICONC100,4) ,IT Y P E (100)
12) COMMON/MOL/C, ICON, IT YPE, NATOMS, QERR
13) COMMON/CHAR/CONN,TITLE,NAMES
14) COMMON/LOG/QCOOR
15) CHARACTER IN F IL*32 , 0UTFIL*32, FTYPE*8
16) CHARACTER CHAR,CHAR2*2,CHARS*4
17) LOGICAL QCOOR, QERR,QEXST
18) INTEGERS I
19) «
20) QCOOR=.TRUE.
21) QERR=.FALSE.
22)
23) I= Z ' 1A00 *
24) WRITE(*,1(A1 ) * ) I
25) DO 10 1=1,5
26) 10 PRINT V  *
27) *
28) 1 IN=0
29) WRITE(*,' (A31, $ ) * ) 'Enter input filename /  QUIT
30) READ(# , ' (A ) ' )INFIL
31) PRINT*,' *
32) CHARS=INFIL(1:4)
33) IF(CHARS.EQ.'QUIT')STOP'BYE BYE!'
34) 0PEN(5,STATUS='OLD*,ERR=1000,FILE=INFIL)
35) I=INDEX(INFIL,* . * )
36) 2 IF(I.NE.O)THEN
37) IF ( I .N E .999) CHAR=INFIL(I+1:I+1)
38) IF(CHAR. EQ. 1Z ' )THEN
39) IN=1
40) ELSE IF(CHAR.EQ.*V' )THEN
41) IN=2
42) ELSE IF(CHAR.EQ.'OTHEN
43) IN=3 -
44) ELSE IF(CHAR.EQ.'T')THEN
45) IN=4
46) END IF
47) ELSE
48) PRINT*,*Input f i l e s  can be the follow ing
49) PRINT*,1 *
50) PRINT*,' Z MATRIX'
51) PRINT*,' V .V .D . '
52) PRINT*,' CINDO'
53) PRINT*,' TRICLINIC'
54) PRINT*,' '
55) WRITE(*,' (A21 ,$ )  *) 'Se lec t Z /  V /  C /  T— >'
56) READ(*,' (A ) ' )CHAR
57) PRINT*,’ '
58) 1=999
59) GOTO 2
60) END IF
61) •
62) IF ( IN .E Q .1)THEN
63) CALL GETZM
64) ELSE IF(IN.EQ.2)THEN
65) CALL GETVVD
66) ELSE IF(IN.EQ.3)THEN
2 L 3/)
O OJ CLiOCt ir un>byiT/AiibH
69) CALL GETTRI
70) ELSE
71) PRINT*,’SOMETHING''3 WRONG ! '
72) GOTO 1
73) END IF
74) *
75) CLOSE(5)
76) IF(QERR)THEN
77) PRINT*,’ '
78) P R IN T * , '* * * * *  ERROR IN READING INPUT FILE *« * * * •
79) PRINT*,' '
80) GOTO 1
81) END IF
82) *
83) 3 I0UT=0
84) WRITE( * , ' (A 25 ,$ )* ) 'Enter output filename — >'
85) READ(*,»(A)’ )OUTFIL
86) PRINT*,' '
87) INQUIRE(FILE=OUTFIL,EXIST=QEXST)
88) IF(QEXST)THEN
89) WRITE( * , ' (A21, $ ) ' )  'OK to overw rite  [ Y /N ] '
90) READ(*,' (A ) ' )CHAR
91) PRINT*,' '
92) IF(CHAR.EQ.'N')GOTO 3
93) END IF
94) 0PEN(6,FILE=OUTFIL)
95) I=INDEX(OUTFIL,' . ' )
96) 4 IF(I.NE.O)THEN
97) IF(I.NE.999)THEN
98) CHAR=0UTFIL(I+1:1+1)
99) CHAR2=0UTFIL(I+1:I+2)
100) END IF
101) IF(CHAR2.EQ.'ZM')THEN
102) IF(QCOOR)THEN
103) PR INT*,'I  cannot convert coordinates to Z MATRIX*
104) PRINT*,' ’
105) GOTO 3
106) END IF
107) I0UT=1
109) ELSE IF(CHAR2.EQ.'ZC')THEN
109) I0UT=2
110) ELSE IF(CHAR.EQ.' V' )THEN
111) I0UT=3
112) ELSE IF(CHAR.EQ.'C')THEN
113) I0UT=4
114) ELSE IF(CHAR.EQ.*P’ )THEN
115) I0UT=5
116) ELSE IF(CHAR.EQ.'X')THEN
117) I0UT=6
118) END IF
119) ELSE
Output f i l e s  can be
i
Z MATRIX'
Z MATRIX (COORDS)'
V.V.D. ’
CINDO '
PLUTO ’
CSSR (XR) '
120) PRINT*
121) PRINT*
122) PRINT*
123) PRINT*
124) PRINT*
125) PRINT*
126) PRINT*
127) PRINT*
128) PRINT*
129) WRITE(
130) READ(*
131) PRINT*,
' (A 3 5 ,$ ) ' ) 'S e le c t  ZM /  ZC /  V /  C /  P /  X — > 
(A ) ' )CHAR2
i
132) CHAR=CHAR2(1:1)
i
2 LU
0 3 /
136) »
k l l f i /  X i
137) IF (I0U T.EQ .1)THEN
136) CALL PUTZM
139) ELSE IF(IOUT.EQ.2)THEN
140) CALL PUTZMC
141) ELSE IF(IQUT.EQ.i)THEN
142) CALL PUTVVD
143) ELSE IF(I0UT.EQ.4)THEN
144) CALL PUTCIN
145) ELSE IFdOUT.EQ. 5) THEN
146) CALL PUTPLU
147) ELSE IFdOUT.EQ. 6 )THEN
148) CALL PUTCSR
149) ELSE.
150) PRINT*,'SOMETHING*'S WRONG ! '
151) GOTO 3
152) END IF
153) «
154) CLOSE(6)
155) GOTO 1
156) «
157) 1000 P R IN T * , '* * * * *  ERROR IN OPENING FILE * * * * * *
153) PRINT*,' •
159) GOTO 1
160) ft
161) END
162)
163)
ft
164) ft
165) SUBROUTINE GETZM
166)
167)
ft
163) \
169) IMPLICIT REAL*8(A-H,0-Z)
170) CHARACTER*1 TITLE( 8 0 ) ,NAMES(100,3)
171) CHARACTER*3 C0NN(100,4)
172) DIMENSION C(3 ,1 0 0 ) ,ICON(100 ,4 ) ,ITYPE(100)
173) DIMENSION IREF(3 ,1 0 0 ) ,BOND(100 ) , ANG( 100) , TOR( 100)
174) COMMON/MOL./C,  ICON,  ITYPE, NATOMS,  QERR
175) COMMON/CHAR/CONN, TITLE , NAMES
176) COMMON/ZM/IREF, BOND, ANG, TOR
177) COMMON/LOG/QCOOR
173) LOGICAL QCOOR,QERR
179) CHARACTER«3 ATN(100)
130) DIMENSION N I(1 0 0 ) , IN (1 0 0 ) ,V (3 ) ,E X (3 ) ,E Y (3 ) ,E Z (3 )
131) READ( 5 , 120,ERR=1000) (T IT L E ( I ) ,1=1,80)
182) READ(5,*,ERR=1000) IOPT,NATOMS
183) IF(IOPT. NE. NATOMS)QCOOR = .FALSE.
184) 120 F0RMAT(80A1)
185) IX=1+I0PT
136) DO 2 M=1,NATOMS
137) 2 READ(5,*,ERR=1000 ) NI(M)
133) REWIND(5)
139) READ(5,120,£RR=1000)(T IT L E ( I ) ,1 = 1,80)
190) READ( 5 , * , ERR=1000 ) IOPT,NATOMS
191) DO 1 M=1,IOPT
192) NO=NI(M)
193) READ( 5 , * ,ERR=1000)N,ATN(NO),(C(J,N0),J = 1,3 )  , (ICON (NO, K)
194) ♦ITYPE(NO)
195) 1 IN(N)=NO
196) DO 15 M=IX,NATOMS
197) NO=NI(M)
198) READ(5,*,ERR=1000)N,ATN(N0),K1,K2,K3,BD,BA,DA,(IC0N(N0,
2 U  5
4 J 
202)
A i l U i  \ « 1
IREF(2,N0)=K2
203) IREF(3,N0)=K3
204) BOND(NO)=3D
205) ANG(N0)=BA
206) TOR(NO)=DA
207) THT = (130 .0-8A)*0.0174 532 9252
208) PHI= DA *0.01745329252
209) IF(M.LT.3)THEM
210) DO 4 1=1,3
211) 4 C (I,N 0 )= 0 .0
212) IFCM.EQ.2) C (1,N0)=8D
213) ELSE IF  (M.EQ.3) THEN
214) C( 1 , NO) =C( 1 ,2 )+BD*COS(THT)
215) C(2,N0)=BD*SIN(THT)
216) C(3»N0)=0.0
217) ELSE
218) K1=IN(K1)
219) K2=IN(K2)
220) DO 7 1=1,3
221) 7 E Z ( I )= C ( I ,K 1 ) -C ( I ,K 2 )
222) R=SQRT(EZ(1)**2+£Z(2)**2+EZ(3)#*2)
223) DO 8 1=1,3
224) 8 E Z (I)= E Z (I) /R
225) IF(AB3(BA-180.0) .LT. 0.001) THEN
226) DO 9 1=1,3
227) 9 C(I,NO)=C(I,K1)+3D*EZ(I)
228) ELSE
229) K3=IN(K3)
230) DO 11 1=1,3
231) 11 V ( I )= C ( I ,K 2 ) -C ( I ,K 3 )
232) EY(1 )=V (2 )*EZ (3)-V (3 )*E Z(2 )
233) EY(2)=V(3)*EZ(1)—V C1)*E Z (3 )
234) EY(3 )=V(1 )*£ Z (2 )-V (2 )*E Z (1 )
235) R=SQRT(EY( 1 ) **2+EY( 2 ) **2+EY( 3 ) #* 2 )
236) DO 12 1=1,3
237) 12 E Y (I)=E Y(I) /R
238) EX(1)=EY(2)*EZ(3)-EY(3)#EZ(2)
239) EX(2)=E7(3)*EZ(1)-EY(1)*EZ(3)
240) EX(3)=EY(1)«EZ(2)-EY(2)*EZ(1)
241) DO 13 1=1,3
242) V ( I )=  3D*(SIN(THT)*C0S(PHI)*EX(I) +
243) * SIN(THT)*SIN(PHI)*EY(I)+
244) » COS(THT)*EZ(D)
245) 13 C (I ,N 0 )= C (I ,K 1 )+ V (I)
246) END IF
247) END IF
243) 15 CONTINUE
249) C
250) C SET UP CONN ( ECTIVITY MATRIX OF CHARACTERS
251) nO
252) DO 16 1=1,NATOMS
253) DO 16 J = 1,4
254) ITEMP=ICON(I, J )
255) IF(ITEMP.NE.O)THEN
256) CONN(I, J)=ATN(ITEMP)
257) ELSE
258) CONN(I,J )= 1 1
259) END IF
260) 16 CONTINUE
261) c
262) c SET UP NAMES ( CHAR*1 ) FROM ATN ( CHAR*3 )
263) c
264) DO 17 1=1.NATOMS
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268 RETURN
269 1000 QERR=.TRUE.
270 RETURN
271 END
272 C
273 C
274 SUBROUTINE GETVVD
275 c
276 c
277 c
278 c READS IN V.V.D. FILE AND RETURNS C,NAMES,
279 c TITLE AND NATOMS IN COMMON BLOCK MOL
280 c
281 IMPLICIT REAL*8 (A-H,0-Z)
232 DIMENSION C ( 3 ,100 ) , ICON( 1 0 0 ,4 ) , ITYPE(IOO)
233 CHARACTERS CONN (100,4)
284 CHARACTER * 1 TITLE( 3 0 ) , INP3UF( 8 0 ) ,NAMES(100
285 COMMON/MOL/C, ICON, ITYPE, NATOMS, QERR
236 COMMON/CHAR/CONN, TITLE, NAMES
287 COMMON/INPUT/INPNTR, ERROR, ENDSEC
238 COMMON/INP/INP3UF
289 LOGICAL ERROR,ENDSEC,QERR
290 c TITLE
291 c
292 CALL POSN(*TITL')
293 IF(ERROR)STOP'NO TITLE IN FILE'
294 c
295 c USE ONLY FIRST LINE OF TITLE
296 c
297 100 CALL NXLINE
293 c IF(.NOT.ENDSEC)G0T0 100
299 DO 110 1=1,80
300 110 TITLE(I)=INPBUF(I)
301 Is P R IN T * ,(T IT L E (I) ,1=1,80)
302 C
303 c ATOM NAMES AND COORDINATES
304 c
305 CALL COORDS
306 IF(ERROR)STOP'NO COODINATES IN FILE*
307 c DO 99 1=1,NATOMS
308 c 99 WRITE(*,98)(NAMES(I,J),J=1,3 )
309 c 98 F0RMAT(3A1)
310 c
311 c CONNECTIVITY
312 c
313 CALL CONECT
314 IF(ERROR)STOP'NO CONNECTIVITIES IN FILE'
315 • •
316 * ATOM TYPES
317 *
313 CALL GTYPES
319 IF(ERROR)STOP'NO ATOM TYPES IN FILE'
320 c
321 c ALL INFO READ IN
322 c
3 23 RETURN
324 END
325 c
326 c
327 SUBROUTINE COORDS
328 c
329 c
330 c
J J J J  1;
334) IMPLICIT REAL* 8 (A-H, 0 -Z )
335) CHARACTER * 1 NAMES( 1 0 0 ,3 ) ,NAMT1,NAMT2, NAMT3, TITLE(30)
336) CHARACTER*3 C0NN(100,4)
337) DIMENSION C(3,1 0 0 ) ,ICON(100,4) ,0 0 ( 3 ) ,ITYPE(100)
333) COMMON/MOL/C, ICON, ITYPE, NATOMS,QERR
339) LOGICAL QERR
340) COMMON/CHAR/CONN, TITLE, NAMES
341) COMMON/INPUT/INPNTR,ERROR,ENDSEC
342) LOGICAL ERROR,ENDSEC
343) C
344) CALL POSN('COOR')
345) IF(ERROR)RETURN
346) C
347) NATOMS=0 
343) C
349) 10 CALL NXLINE
350) IF(ENDSEC)GOTO 80
351) IF(NATOMS.GE.100)THEN
352) PRINT*,'TOO MANY ATOMS, ONLY FIRST 100 ACCEPTED1
353) PRINT*,' ’
354) ERROR=.FALSE.
355) RETURN
356) END IF
357) NATOMS=NAT0MS+1 
353) C
359) C GET NAME FROM INPBUF
360) C
361) CALL GETNAM(NAMT1,NAMT2,NAMT3)
362) IF(ERROR)STOP' FORMAT ERROR IN COORDINATE SECTION'
363) C
364) C # CHECK IF  NAME USED MORE THAN ONCE
365) C
366) CALL NAMNUM(NAT0MS-1, NAMES,NAMT1,NAMT2,NAMT3,INDEX)
367) NAMES(NATOMS,1)=NAMT1
368) NAMES(NATOMS,2 )=NAMT2
369) NAMES(NATOMS,3 )=NAMT3
370) C
371) C
372) C IF NAME NOT USED BEFORE I . E .  INDEX = -1 CARRY ON
373) C ELSE GIVE ERROR MASSAGE AND STOP
374) C
375) I F ( INDEX. GT. 0 )THEN
376) WRITE(* ,1 0 0 )NAMT1,NAMT2,NAMT3
377) 100 FORMAT('ATOM NAME * ,3 A 1 , '  IS USED MORE THAN ONCE')
373) STOP
379) END IF
380) C
331) C READ COORDINATES FROM INPBUF ( VIA NUMBER )
382) C
383) DO 110 1=1,3
384) CALL NUMBER(CO(I) ) .
335) IF(ERROR)STOP'FORMAT ERROR IN COORDINATES'
386) 110 CONTINUE
337) C(1 ,NATOMS)=C0(1)
383) C(2,NAT0MS)=C0(2)
389) C(3,NAT0MS)=C0(3)
390) C
391) GOTO 10
392) 30 ERROR=.FALSE.,
393) IF(NATOMS.EQ.O)ERROR=.TRUE.
394) RETURN
395) END
396) C 9 US
j??;
400) C
j u o n o u  w n b w  a
401) C
402) C
403) c READS IN CONNECTIVITY AND SETS UP
404) c CONNECTIVITY MATRIX ICON
405) c
406) c ERROR SET .TRUE. IF 'CONN' MISSING FROM FILE
407) c FORMAT ERRORS DO NOT STOP PROGRAM BUT GIVE ERROR
403) c MESSAGE ON TTY
409) c
410) IMPLICIT REAL*8(A-H,0-Z)
411) CHARACTER * 1 NAMES(100,3),N1,N2,N3,NA,NB,NC
412) CHARACTER*3 CONN(100,4)
413) CHARACTER *1 TITLE(80),INPBUF(80)
414) DIMENSION C(3,100),ICON(100,4),INDXS(4),ITYPE(100)
415) COMMON/MOL/C,ICON,ITYPE,NATOMS,QERR
416) LOGICAL QERR
417) COMMON/CHAR/CONN,TITLE,NAMES
418) COMMON/INPUT/INPNTR,ERROR.ENDSEC
419) COMMOM/INP/INPBUF
420) LOGICAL ERROR,ENDSEC
421) c
422) c ZERO ICON
423) n
424) DO 10 1=1,4
425) DO 10 J=1.NATOMS ,
426) 10 ICON(J,I)=0
427) c
428) CALL POSN('CONN’)
429) IF(ERROR)RETURN
430) c READ NEXT NON BLANK LINE INTO INBUF VIA NXLINE
431) c
432) 30 ERROR=.FALSE.
433) CALL NXLINE
434) IF(ENDSEC)RETURN
435) CALL GETNAM(N1,N2,N3)
436) c •••••IGNORE BLANK LINES*"*
437) IF(ERROR)GOTO 30
438) c
439) CALL NAMNUM(NATOMS,NAMES,N1,N2,N3,INDEX)
440) IF(INDEX.LT.O)GOTO 100
441) c
442) c ZERO INDXS
443) c
444) DO 20 1=1,4
445) 20 INDXS(I)=0
446) c
447) c READ UP TO 4 MORE NAMES FROM CONNECTIVITY IN FILE
448) c
449) DO 50 1=1,4
450) CALL GETNAM(NA,NB,NC)
451) c
452) c IF ERROR, THEN HAVE FOUND END OF LINE
453) <1
454) IF(.NOT.ERROR)THEN
455) c
456) c CHECK FOR MATCH IN NAMES ARRAY
457) c
458) CALL NAMNUM(NATOMS,NAMES,NA,NB,NC,INDXS(I) )
459) IF(INDXS(I).LT.O)GOTO 100
460) END IF
461) 50 CONTINUE
462) c 1
466 DO 16 1=1.NATOMS
467 DO 16 J=1,4
453 ITEMP=ICON(I,J)
469 IF(ITEMP.NE.O)THEN
470 CONN(I,J)(1:1)=NAME3(ITEMP,1)
471 CONN(I,J)(2:2)=MAME3(ITEMP,2)
472 CONN(I,J)(3:3)=NAME3(ITEMP,3)
473 ELSE
474 CONN(I.J) = 1 '
475 END IF
476 16 CONTINUE
477 C
478 GOTO 30
479 C
480 C COME HERE IF ATOM NAME NOT FOUND IN 'NAMES'
481 C
482 100 NRITE(*,40)(INP8UF(I),1=1,80)
483 40 FORMAT('FORMAT ERROR IN CONNECTIVITY SECTION',//
484 *,80A1,/)
435 GOTO 30
48o END
487 C
483 c #»***«**«***»»**#*»***«*«**«#»«»
439 c
490 SUBROUTINE NXLINE
491 c
492 c
493 c
494 c READS THE NEXT LINE INTO INPBUF AND GIVES
495 c ENDSEC=.TRUE. IF *» IS FOUND
496 c
497 IMPLICIT REAL*3 (A-H.O-Z)
498 CHARACTER" INPBUF(80),ISTAR
499 LOGICAL ENDSEC,ERROR
500 COMMON/INPUT/INPNTR,ERROR,ENDSEC
501 COMMON/INP/INPBUF
502 DATA ISTAR/'*'/
503 c
504 READ(5,100)(INPBUF(I),1=1,80)
505 100 FORMAT(80A1)
506 INPNTR=0
507 IF(INPBUF(1).EQ.ISTAR.AND.INPBUF(2).EQ,ISTAR)THEN
503 ENDSEC=.TRUE.
509 ELSE
510 ENDSEC=.FALSE.
511 END IF
512 RETURN
513 END
514 c
515 c
516 c
517 SUBROUTINE NUMBER(X)
513 c
519 c
520 c
521 .'*1u READS INPBUF FROM INPNTR TO THE NEXT BLANK SPACE
522 c AND RETURNS A NUMBER FROM THE INPUT DIGITS. GIVES
523 c ERROR=.TRUE. IF A CHARACTER OTHER THAN 1,2,3,4,5,1
524 c ,7,8,9,0,+,-,., ,13 FOUND
525 c
526 IMPLICIT REAL*8 (A-H.O-Z)
527 CHARACTER* 1 INPBUF(30) ,I3LANK,IPOINT,IPLUS,IiMINUS
528 CHARACTER*1 11,12,13,14.15.16,17.I8.I9.I0.ICHAR 2 50
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
543
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
573
579
580
581
582
583
584
535
586
537
533
539
590
591
592
593
594
DATA IBLANK, IPLUS, IMINUS, IPOINT,1 0 ,1 1 / '  ' O ' , '1  • /
DATA I 2 , I 3 , l 4 , I 5 , I 6 f I 7 l I 3 , I 9 / ' 2 ' , ' 3 , , t 4 , , ’ 5 ' , ' 6 ' , ' 7 ' , ' 8 ' l ' 9 ' /
C
EMPTY=.TRUE.
ERROR=.TRUE.
POINT=.FALSE.
SIGN=+1.0
VAL=0.0
K=0
C
1 IF(INPNTR.GE.80)GOTO 50 
INPNTR=INPNTR+1 
ICHAR=INPBUF(INPNTR)
I F ( EMPTY. AND. ICHAR. EQ. IBLANK)GOTO 1 
I F ( ICHAR. EQ. IMINUS)G0T0 20 
IF  ( ICHAR. EQ. IPL.US )GOTO 30 
I F ( ICHAR.EQ.IPOINT)GOTO 40 
IF(ICHAR.EQ.IBLANK)GOTO 50
nU
INTCAR=99
IFClCHAR.EQ.il)THEN 
INTCAR=1 
ELSE IF(ICHAR.EQ.I2)THEN 
INTCAR=2 
ELSE IF(ICHAR.EQ.I3)THEN 
INTCAR=3 
ELSE I F ( ICHAR.EQ.14)THEN 
INTCAR=4 
ELSE IF(ICHAR.EQ.I5)THEN 
INTCAR=5 
ELSE IF(ICHAR.EQ.I6)THEN 
INTCAR=6 
ELSE IF(ICHAR. EQ.1 7 )THEN 
INTCAR=7 
ELSE I F ( ICHAR.EQ.I3')THEN 
INTCAR=8 
ELSE IF(ICHAR.EQ.I9)THEN 
INTCAR=9 
ELSE I F ( ICHAR. EQ.1 0 )THEN 
INTCAR=0 
END IF
C
IF(INTCAR.LT.10)THEN 
ERROR=.FALSE.
ELSE 
GOTO 999 
END IF
C
EMPTY=.FALSE.
IF(POINT)GOTO 60
VAL= 10.0*VAL+DBL.E ( INTCAR )
GOTO 1
r»
60 VAL=VAL+D3LE(INTCAR)/10#fK 
K=K+1 
GOTO 1
20 I F ( .NOT.EMPTY)GOTO 50 
EMPTY=.FALSE.
SIGN=-1.0 
GOTO 1
30 I F ( .NOT.EMPTY)GOTO 50 
EMPTYr.FALSE.
GOTO 1 2 5 1
593
599
600
60’
602
603
604
605
606
607
603
609
610
611
612
613
614
615
616
617
613
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
633
639
640
641
642
643
644
645
646
547
648
649
650
651
652
653
554
655
656
657
658
659
660
K=K+1 
GOTO 1 
50 IF(ERROR)GOTO 999 
X=VAL*3IGN 
999 RETURN 
END
c
SUBROUTINE G£TNAM(N1AND2,N3AND4,N5AND6)
C
c •>«•*««••«••««•«««•<«•«•««««
C READS THREE NON-BLANK CHARACTERS FROM INPBUF
C STARTING FROM COL. INPNTR
C AND ASSIGNS THEM TO N1AND2.N3AND4 AND N5AND6
C
IMPLICIT REAL*8(A-H,0-Z)
CHARACTER*1 INPBUF(80),ICHAR,IBLANK, N (3 )
+,N1AND2,N3AND4,N5AND6 
LOGICAL ERROR,EMPTY,ENDSEC 
COMMON/INPUT/INPNTR,ERROR,ENDSEC 
COMMON/INP/INPBUF 
DATA IBLANK/' '/
EMPTY=.TRU£.
N(1 )=IBLANK 
N(2)=IBLANK 
N(3)=IBLANK
C
IC0UNT=1 
1 IF(INPNTR.GE.80)GOTO 50 
INPNTR=INPNTR+1 
ICHAR=INPBUF(INPNTR)
IF(EMPTY.AND.ICHAR.EQ.IBLANK)GOTO 1 
N(ICOUNT)=ICHAR 
EMPTY=.FALSE.
ICOUN T=ICOUN T+1
IF(ICOUNT.LE•3)GOTO 1
N1AND2=N(1)
N3AND4=N(2)
N5AND6=N(3)
50 ERROR=EMPTY 
RETURN 
END
c
SUBROUTINE POSN(KEYTEX)
C
C I H M f H I I I M f H K I H I H H i l
c
C POSITIONS THE FILE AT 'KEYTEX'
C IF KEYTEX IS NOT FOUND I.E. IT FINDS 'END'
C INSTED, ERROR IS SET .TRUE.
C
IMPLICIT REAL*8 (A-H,0-Z)
CHARACTER*1. INPBUF(80) ,KEYTEX(4)
LOGICAL ERROR,ENDSEC 
COMMON/INPUT/INPNTR,ERROR,ENDSEC 
COMMON/INP/INPBUF
C
REWIND 5 
ERROR=.FALSE.
1 READ(5,10 )(INPBUF(I),1=1,4)
10 FORMAT(4A1)
DO 20 1=1,4
s2 52
~ % J / t by 9 U  ' J  JLI4UAV
664 ERR0R=.TRUE.
665 RET(JRN
666 ELSE
667 GOTO 1
663 END IF
669 END IF
670 20 CONTINUE
671 RETURN
672 END
673 C
674 C
675 SUBROUTINE NAMNUM(NATOMS,NAMES,N1AND2,N3AND4,N5AND6,INDEX)
676 C
677 C
678 C
679 C GIVES THE INDEX OF ATOM NAME N1AND2-N3AND4-N5AND6
680 C OR RETURNS INDEX=-1 IF IT IS NOT FOUND I.E. IF IT
681 C HAS NOT BEEN USED BEFORE (WHEN CALLED FROM COORDS)
682 C OR IT DOES NOT EXIST (WHEN CALLED FROM CONECT)
633 C
684 IMPLICIT REAL'S (A-H,0-Z)
685 CHARACTER*1 N1AND2,N3AND4,N5AND6,NAMES(100,3)
686 C
637 INDEX=0
688 1 INDEX=INDEX+1
689 IF(INDEX.GT.NATOMS)GOTO 90
590 IF(NAMES(INDEX,1).NE.N1AND2.OR.NAMES(INDEX,2).NE.N3AND4
691 + .OR.NAMES(INDEXf3).NE.N5AND6) G0T01
692 RETURN
693 90 INDEX=-1
694 RETURN
695 END
696
697 *
698 SUBROUTINE GTYPES
699 IMPLICIT REAL'S(A-H,0-Z)
700 CHARACTER*! TITLE(80),NAMES(100,3)
701 CHARACTER*3 C0NN(100,4)
702 DIMENSION C(3,100),ICON(100,4),ITYPE(100)
703 COMMON/MOL/C,ICON,ITYPE,NATOMS,QERR
704 LOGICAL QERR
705 COMMON/CHAR/CONN,TITLE,NAMES
706 CHARACTER*! N1,N2,N3
707 COMMON/INPUT/INPNTR,ERROR,ENDSEC
708 LOGICAL ERROR,ENDSEC
709 c
710 DO 10 1=1,NATOMS
711 10 ITYPE(I)=0
712 CALL POSNCATOM')
713 IF(ERROR)RETURN
714 20 ERROR=.FALSE.
715 END3EC=.TRUE.
716 CALL NXLINE
717 IF(ENDSEC)RETURN
718 CALL NUM3ER(TYPE)
719 IF(ERROR)RETURN
720 IT=INT(TYPE)
721 30 CALL GETNAM(N1,N2,N3)
722 IF(ERROR.AND.INPNTR.GE.80)GOTO 20
723 CALL NAMNUM(NATOMS,NAMES,N1,N2,N3,INDEX)
724 IF(INDEX.LT.O)THEN
725 ERROR=.TRUE.
726 RETURN 2 5 3
730) GOTO 30
731) END
732)  .... ..
733) *
734) SUBROUTINE PUTZM
735) *
736)
737) *
736) IMPLICIT REAL'S(A-H,0-Z)
739) CHARACTER'1 TITLE(80),NAMES(100,3)
740) CHARACTER'3 C0NN(100,4)
741) DIMENSION C(3,100),IC0N(100,4),ITYPE(100),IREF(3,100)
742) DIMENSION BOND(100),ANG(100),TOR(100)
743) COMMON/MOL/C,ICON,ITYPE,NATOMS,QERR
744) LOGICAL QERR
745) COMMON/CHAR/CONN,TITLE,NAMES
746) COMMON/ZM/IREF,BOND,ANG,TOR
747) »
748) WRITE(6,100)(TITLE(I),1=1,80)
749) 100 FORMAT(80A1)
750) WRITE(6,101)NATOMS
751) 101 F0RMAT(,0’,I4)
752) DO 10 1=1,NATOMS
753) 10 WRITE(6,102)1,(NAMES(I,J),J=1,3),(IREF(J,I),J=1,3),BOND(I),
754) + ANG(I),TOR(I), (ICON(I,J),J=1,4),ITYPE(I)
755) 102 F0RMAT(I4,2X,1’••,3A1,’111,3I4,2X,F6.4,2(2X,F6.1),4I4,2X,I4)
756) RETURN
757) END
758) •
759) H H i l f l H H H H H H I H i i H I I I
760) »
761) SUBROUTINE PUTZMC
762) »
763)
764) •
765) IMPLICIT REAL*8(A-H,0-Z)
766 ) CHARACTER'1 TITLE(80),NAMES(100,3)
767) CHARACTER'3 C0NN(100,4)
763) DIMENSION C(3,100),IC0N(100,4),ITYPE(100)
769) COMMON/MOL/C,ICON,ITYPE,NATOMS,QERR
770) LOGICAL QERR
771) COMMON/CHAR/CONN,TITLE,NAMES
772) »
773) WRITE(6,100)(TITLE(I),1=1,80)
774) WRITE(6,101)NATOMS,NATOMS
775) 100 FORMAT(80A1)
776) 101 FORMAT(214)
777) DO 10 1=1,NATOMS
773) 10 WRITE(6,102)1,(NAMES(I,J) ,J = 1,3),(C(J,I),J = 1,3),
779) + (ICONd, J),J = 1,4),ITYPE(I)
730) 102 FORMAT(14,2X,1 * * *,3A1,’’11,3F10.5,4I4,2X,I4)
781) RETURN
732) END
733) '
735) *
736) SUBROUTINE PUTCIN
737) »
738) Hi**#*****.*!*##..*#*#**.!###
789) *
790) IMPLICIT REAL*8(A-H,0-Z)
791) CHARACTER'1 TITLE(80),NAMES(100,3)
792) CHARACTER'3 C0NN(100,.4) 2 5
795 LOGICAL QERR,QADD
796 COMMON/CHAR/CONN,TITLE,NAMES
797 DIMENSION IATNO(100),JATNO(100)
793 *
799 DATA NUMAT,INPUT,ICHARG,MULTIP,IGAMMA,NDPArtT,ISCF,IVAB,ISBETA
800 + ,IONECE,IDELET,IKOOP,ISHIFT,ITRANS/
801 +0,1,0,1,1,0,25,2,1,0,0,0,0,0/
802 »
803 DO 10 1=1,NATOMS
804 t
805 IF(ITYPE(I).LE.4)THEN
306 IATN0(I)=6
807 ELSE IF (ITYPE(I).LE.9)THEN
803 IATN0(I)=7
809 ELSE IF (ITYPE(I).LE.12)THEN
810 IATN0(I)=8
811 ELSE IF (ITYPE(I).EQ.15.OR.ITYPE(I).EQ.19)THEN
312 IATN0(I)=1
313 ELSE IF (ITYPE(I).EQ.1o)THEN
3114 IATN0(I)=9
815 ELSE IF (ITYPE(I).EQ.17)THEN
316 IATNOCI)=17
317 ELSE IF (ITYPE(I).EQ.14)THEN
813 IATNO(I)=16
819 ELSE
320 PRINT1, •1 1 1 WARNING-ATOM TYPE NOT REGOGNISED 111*
821 PRINT1,' '
322 IATN0(I)=0
323 END IF
824 10 CONTINUE
825 * —
826 * FIND THE NUMBER OF ATOMIC SPECIES
827 «
828 NSPEC=1
329 JATN0(1)=IATN0(1)
830 DO 40 1=2,NATOMS
331 QADD=.TRUE.
332 DO 50 J=1,NSP£C
833 IF(JATNO(J).EQ.IATNO(I))TH£N
834 QADD=.FALSE.
835 END IF
836 50 CONTINUE
837 IF(QADD)THEN
338 NSPEC=NSPEC+1
839 JATNO(NSPEC)=1ATNO(I)
840 END IF
341 40 CONTINUE
842 *
843 WRITE(6,1(72A1,2X,A6)')(TITLE(I),1=1,72),'010000'
844 WRITE(o,100)(TITLE(I),1=1,76)
845
oo***• FORMAT('$',3X,76A1)
346 WRITE(6,102)
347 102 FORMATCINDO CLSD SOLV')
343 WRITE (6,103) NATOMS,ICHARG,MULTIP,NUMAT,NSPEC,INPUT,IGAMMA,NDPART
349 +,IVAB,ISBETA,IONECE,IDELET,IKOOP,ISHIFT,ITRANS
350 103 FORMAT(3I5,4X,'011111100',4X,1212)
651 PRINT1,1111 NOTE - INDO CALCULATION, CLOSED SHELL, CHARGE = 1 11
852 PRINT1,'111 MULTIP = 1, DEFAULT CALC AND PRINT OPTIONS 11
853 PRINT1,' '
854 *
355 DO 20 1=1,NATOMS
856 20 WRITE(6,104)IATNO(I),(C(J,I),J=1,3)
857 104 FORMAT(I4,3F15.7)
858 WRITE(6,'(A1,/,A1)')' ' 2 5 5
862)
363) I H 1 I H H I
864) •
365) SUBROUTINE PUTVVD
366) *
867) ......................
368) *
369) IMPLICIT REAL*3(A-H,0-Z)
370) CHARACTER*1 TITLE(80 ),NAMES(100,3)
871) CHARACTERS CONN(100,4)
872) DIMENSION C(3,100),IC0N(100,4),ITYPE(100)
373) C0MM0N/M0L/C,ICON,ITYPE,NAT0MS,QERR
874) LOGICAL QERR
875) COMMON/CHAR/CONN,TITLE,NAMES
876) *
877) WRITE(6,100)(TITLE(I),1=1,30)
378) 100 FORMAT(•— V.V.D. CHEMICAL GRAPHICS SYSTEM FILE— '/
879) + ’TITLE'/,80A1,/’**')
380) WRITE(6,101)
381) 101 FORMAT(’UNIT CELL’/' 1 1 1 90 90 90 '/•**’/
882) + 'COMMENTS’/'R.M.S. VALUE UNSET'/'**'/’COORDINATES’)
883) DO 10 1=1,NATOMS
884) 10 WRITE(6,103)(NAMES(I,J),J=1,3),(C(J,I),J=1,3)
885) 103 FORMAT(3A1,4X,3F10.5,’ 1’)
886) WRITE(6,104)
887) 104 FORMAT('**'/» CONNECTIVITY»)
838) DO 20 1=1,NATOMS
889) 20 WRITE(6,105)(NAME3(I,J),J=1,3),(CONN(I,J),J=1,4)
890) 105 FORMAT(3A1,4(5X,A3))
891) WRITE(6,106)
892) 106 FORMAT('**'/'ATOM TYPES')
393) DO 30 1=1,NAT0M3
894) 30 WRITE(6,107)ITYPE(I),(NAMES(I,J),J=1,3>
395) 107 FORMAT(12,4X,3A1)
895) WRITS(6,103)
897) 108 FORMAT('**'/'CHARGED ATOMS'/'«*'/'MINI')
893) PRINT*,’*** PRINT OPTIONS SET TO DEFAULT VALUES ***'
399) PRINT*,' •
900) WRITE(6,109)
901) 109 FORMAT(' 9999.90'/* 0.000010’/' 4.00000'/’ 0.05000'/
902) + ,8X,'0.0000010000')
903) WRITE(6,110)
904) 110 FORMAT('T/'0'/'0'/'1'/'1'/'1'/'1'/' 100'/'**’/’END’)
905) *
905) RETURN
907) END
903) »
909) I f M H f f i m U H H I I I H H M i l l H
910) *
911) SUBROUTINE PUTPL.U
912) *
9 1 3 ) »•**«*»•«•«•
914) *
915) IMPLICIT REAL*8(A-H,0-Z)
916) CHARACTER* 1 TITLE(80),NAMES(100,3)
917) CHARACTER*3 CONN(100,4)
918) DIMENSION C(3,100),IC0N(100,4),ITYPE(100),I30ND(100,100)
919) COMMON/MOL/C,ICON,ITYPE,NATOMS,QERR
920) LOGICAL QERR
921) COMMON/CHAR/CONN,TITLE,NAMES
922) *
923) WRITE(6,100)(TITLE(I),1=1,30)
924) 100 FORMATCDATA ' .80A1,/,'CELL 1., 1., 1. ,90. .90. ,90., •/,
2 56
/929)
i V J 4 wilt i n  a \ j n  j | i a } j \ & ; 1 V f J A  / /
WRITE(6 ,1 0 2 ) (T IT L E ( I ) ,1=1,30)
930) DO 5 1=1,100
931) DO 5 J=1,100
932) 5 IB0ND(I, J)=0
933) 102 F0RMAT('TITLE' ,80A1, / , 'SOLID1)
934) DO 11 1=1,NATOMS
935) DO 12 J=1,4
936) IF ( IC 0 N ( I , J).NE.0)THEN
937) I30ND( I , ICON(I, J ))=1
938) END IF
939) 12 CONTINUE
940) 11 CONTINUE
941) DO 20 1=1,NATOMS .
942) DO 30 J= 1 ,I
943) IF ( IB 0 N D ( I ,J ) . EQ. 0 )GOTO 30
944) WRITE(6 ,1 0 3 ) (NAMES(I,K),K=1 , 3 ) , (NAMES(J,L),L=1,3 )
945) 30 CONTINUE
946) 20 CONTINUE
947) 103 FORMAT( 'JO IN ', 1X,3A1, 1X.3A1)
948) WRITE(6,104)
949) 104 FORMAT('RADII ATOMS C 0 . 4 ' / 'R A D II  ATOMS N 0 .3 7 5 ' /
950) + 'RADII ATOMS 0 0 .3 5 ' / 'R A D I I  ATOMS CL 0 .6 ' / 'R A D II  ATOMS
951) + / 'R ADII ATOMS F 0 . 3 ' / 'R A D II  ATOMS H 0 . 2 ' / ’ RADII ATOMS P
952) + 'RADII ATOMS BR 0 .7 * / 'R A D II ATOMS I  0 . 8 ' /
953) + 'RADII BONDS INTER 0.1 LINES 2 ' , / ,
954) + 'RADII BONDS TAPER 1 0 0 ' , / , 'SIZE 200 ')
955) «
956) RETURN
957) END
958)
959)
•
—
960) « \
961) SUBROUTINE GETCIN
962) •
963)
964) *
965) IMPLICIT REAL*3( A-H, 0 -Z )
966) CHARACTERS JUNK
967) CHARACTER*3 CONN(100,4)
968) CHARACTER NUMCHA(2 0 0 ) ,TITLE( 8 0 ) ,NAMES(100,3)
969) COMMON/MOL/COORD, ICON, ITYPE, NATOMS, QERR
970) COMMON/CHAR/CONN, TITLE, NAMES
971) DIMENSION IATNO(1 0 0 ) ,COORD( 3 ,1 0 0 ) , ICON(1 0 0 ,4 ) , ITYPE(100)
972) LOGICAL QERR
973) DATA INDAT/5/
974) «
975) READ(INDAT,'(A)')JUNK
976) READ(INDAT,’ (1X,80A1)» ) ( T IT L E ( I ) ,1=1,80j
977) READ(INDAT,' (A ) ' )JUNK
978) READ(INDAT, * , ERR=101)NATOMS
979) DO 10 1=1,NATOMS
930) READ(INDAT,*,ERR=102)IATN O (I) , ( COORD(J,I), J=1,3 )
981) 10 CONTINUE
982) *
983) *
984) « CrET CONNECTIVITY AND ATOM NAMES
935) «
986) CALL CONNAM( IATNO)
987) *
988) RETURN
989) 101 QERR=.TRUE.
990) RETURN , .
1 5 1
996) SUBROUTINE PUTCSR
997 
993 
999
1000) IMPLICIT REAL*8(A-H,0-Z)
1001) CHARACTER * 1 TITLE(80 ) ,NAMES(100,3)
1002) CHARACT£R*3 C0NN(100,4)
1003) DIMENSION C(3,100),ICON(100,4),ITYPE(100)
1004) COMMON/MOL/C,ICON,ITYPE,NATOMS,QERR
1005) COMMON/CHAR/CONN,TITLE,NAMES
1006) LOGICAL QERR
1007 ) DIMENSION IJUNK(100,4),CHARGE(100),LABEL(100)
1008) CHARACTERS JUNK
1009;
1010) JUNKs * •
1011) WRITE(6,’(20A1)1)(TITLE(I),1=1,20)
1012) WRITE(6,*(A4)1)JUNK
1013) WRITE(6,'(14)')NATOMS
1014) WRITE(6,*(A4)»)JUNK
1015) DO 10 1=1,NATOMS
1016) 6 CHARGE(I)=0.0
1017) LABEL(I)=1
1018) DO 10 J=1,4
1019) IJUNK(I,J)=0
1020) 10 CONTINUE
1021) DO 20 1=1,NATOMS
1022) WRITE(6,'(14,1X,3A1,3X,3(F9.5,1X),8I4,1X,F7.3,1X,I3)')
1023) +1,(NAMES(I,J),J=1,3),(C(J,I),J=1,3),(ICON(I,J),J = 1,4),
1024) +(IJUNK(I,J),J=1,4),CHARGE(I),LABEL(I)
1025) - 20 CONTINUE
1026) RETURN
1027) END 
1028!
1029!
1030) SUBROUTINE CONNAM(IATNO)
1031
1032
1033) IMPLICIT REALS (A-H, 0 -Z )
1034) DIMExJSION C00RD(3,100) ,IATN0(100) ,IC0N(1t)0,4),VDWR(35)
1035) DIMENSION ICP(1 0 0 ) , ITYPE(100)
1036) CHARACTERS JUNK
1037) CHARACTER*200 NUMS
1038) CHARACTER*3 CONN(100 ,4 )
1039) CHARACTER NUHCHA(200) , TITLE(80) ,NAMES(100,3)
1040) COMMON/MOL/COORD,ICON,ITYPE,NATOMS,QERR
1041) LOGICAL QERR
1042) COMMON/CHAR/CONN,TITLE,NAMES 
1043
1044) DATA ( V D W R ( I ) , I= 1 ,3 5 ) /0 .5 ,1 ,1 ,1 ,1 ,1 ,1 ,1 ,1 , ! , 1 ,1 ,1 ,1 .5 ,
1045) + 1 .5 ,1 .5 ,1 . 5 , 1 . 5 ,1 .5 , 1 . 5 , 1 .5 ,1 . 5 , 1 . 5 ,1 .5 , 1 . 5 , 1 .5 ,1 . 5 ,
1046) + 2 . 0 , 2 .0 ,2 . 0 , 2 . 0 ,2 .0 , 2 . 0 , 2 .0 ,2 . 0 /
1047) DATA INDAT/5/
1048) DATA MUMS/M 2 3 4 5 6 7 8 9  10! 112131*1151617131920212223242526272
1049) +829303132333435363738394041424344454647484950515253545556575359506
1050) +162636465656763697071727374757677737930818283343586878889909192939
1051) +49595979399**'/
1052) *
1053) * ZEROISE ICON 1
1054
1055) DO 20 1=1,NATOMS
1056) ICP(I)=1
2 58
1060) 20 IC 0N (I,J )=0
1061) •
1062) • FILL ICON
1063) «
1064) DO 50 1=1,NATOMS
1065) XI=COORD(1,1)
1066) YI=C00RD(2, 1 )
1067) ZI=C00RD(3, I )
1063) DO 30 J=I+1,NATOMS
1069) XJ=COORD(1 ,J)
1070) YJ=C00RD(2,J)
1071) ZJ=C00RD(3,J)
1072) R IJ 2 = ( (X I -X J )* * 2 )+ ( (Y I -Y J ) * * 2 )+ ( (Z I -Z J )* * 2 )
1073) RIJ=SQRT(RIJ2)
1074) C WRITE(*,1( 2 I4 ,3 F 8 .2 ) ' ) I , J ,R IJ ,Z I ,Z J
1075) IF(RIJ.LT.VDWR(IATNO(I))+VDWR(IATNO(J) ) )THEN
1076) IC O N (I, IC P (I) )=J
1077) ICON(J,ICP(J) )= I
1073) IC P (I)= IC P (I)+1
1079) ICP(J)=ICP(J)+1
1080) IF(ICP(J).GT.5.0R.ICP(I).GT.5)PRINT*,'WARNING—CONNECTIVITY
1081) + , 'OVERLOAD---- 1C PCI) = ' , I C P ( I ) , '  ICP(J) = * ,ICP(J)
1082) END IF
1083) 30 CONTINUE
1084) f
1085) DO 40 1=1,NATOMS
1036) WRITE( * , ' ( 1 6 , 4 1 4 ) 1) I ,  ( IC O N (I ,J ) , J=1,4 )
1087) 40 CONTINUE
1088) •
1089) DO 50 1=1,200
1090) 50 NUMCHA(I)=NUMS(I:I)
1091) DO 60 1=1,NATOMS
1092) IF(IATNO(I).EQ. 1)THEN
1093) ITYPE(I)=15
1094) NAMES(I,1 ) = 'H '
1095) ELSE IF(IATNO(I).EQ.6)THEN
1096) ITYPE(I)=1
1097) NAMES(I,1 )= 'C '
1093) ELSE IF(IATNO(I).EQ.7)THEN
1099) ITYPE(I)=5
1100) NAMES(I,1 )= 'N'
1101) ELSE IF(IATNO(I).EQ.8)THEN
1102) ITYPE(I)=10
1103) NAMES(I,1 )= '0 '
1104) ELSE IF(IATN0(I).Sq.9)THEN
1105) ITYPE(I)=16
1106) NAMES(I,1 ) = 'F '
1107) ELSE IF(IATNO(I).EQ.16)THEN
110S) ITYPE(I)=14
1109) NAMESd, 1 ) = 'S'
1110) END IF
111!) NAMESd, 2)=NUMCNA(2*I-1)
1112) NaMES(I,3)=NUMCHA(2*I)
1113) IF (IA TN O (I).EQ .17)THEN
1114) NAMESd, 1)= ’ C'
1115) NAMES(I,2)='L'
l l l o ) NAMES( 1 ,3 ) =NUMCHA(2*1-1 )
1117) ITYPE(I)=17
1113) END IF
1119) IF(NAMES(1, 1 ) .EQ.1 • )THEN
1120) PRINT*,'UNIDENTIFIED ATOMIC NO.'
1121) NAME3(I,! ) = ' * '
1122) NAMES(I,2)=NUMCHA(2*I-1)
1126) 4
'■'.27) DO 70 1=1,NATOMS
1128) DO 70 J=1,3
' . ' .29) ITEMP=ICON(I,J)
1130) IF(ITEMP.EQ.O)GOTO 70
1131) CONN(I,J)=NAME3(ITEMP,1)//NAMES(ITEMP,2)//NA,
'■'■12) 70 CONTINUE
1)33) •
1131!) RETURN
1)35) END
1)36)
1)37) •
1138) SUBROUTINE GETTRI
)) 39)
4 4 ) | A \
«
i 140J
1141) IMPLICIT REAL*3(A-H,0-Z)
1142) CHARACTERS JUNK
1143) CHARACTERS CONN(100,4)
1144) CHARACTER NUMCHA(200),TITLE(80),NAMES(100,3)
1145) COMMON/MOL/COORD,ICON,ITYPE,NATOMS,QERR
1146) COMMON/CHAR/CONN,TITLE,NAMES
1147) DIMENSION IATNO(100),COORD(3,100),ICON(100,4),
1148) LOGICAL QERR
1149) DATA INDAT/5/
1150) •
1151) READ(INDAT,•( 80A1)1) (TITLE(I),1 = 1,80)
1152) READ(INDAT,*,ERR=101)NATOMS
1153) READ(INDAT,*,ERR=103)A,B,C,ALPHA,BETA,GAMMA
1154)
1155) R=0.01745329252
1156) COSA= COS (ALPHAS)
1157) COSB= COS (BETAS)
1158) COSG= COS (GAMMAS)
1159) SINB= SIN(BETAS)
1160) SING= SIN (GAMMAS)
1161) TRANSC=( COSA- COSB* C03G)/ SING
1162) TRANSQ= SQRT( SINB»»2-TRANSC**2)
1163) •
1164) DO 10 1=1,NATOMS
1165) READ(INDAT,«,ERR=102)IATNO(I),XF,YF,ZF
1166) XT=XF*A
1167) YT=YFS
1168) ZT=ZF«C
1169) COORD(1,I)=XT+ COSG*YT+ C03B*ZT
1170) C00RD(2,I)= SING#YT+TRANSC*ZT
1171) C00RD(3,I)=TRANSQ«ZT
1172) 10 CONTINUE
1173) «
1174) •
1175) # GET CONNECTIVITY AND ATOM NAMES
1176) *
1177) CALL CONNAM(IATNO)
1178) *
1179) RETURN
1180) 101 QERR=.TRUE.
1181) RETURN
1182) 102 QERR=.TRUE.
1183) RETURN
1184) 103 QERR=.TRUE.
1185) RETURN
1186) END
2 6 0
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